WO2006044497A2 - Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzhermer’s disease - Google Patents

Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzhermer’s disease Download PDF

Info

Publication number
WO2006044497A2
WO2006044497A2 PCT/US2005/036752 US2005036752W WO2006044497A2 WO 2006044497 A2 WO2006044497 A2 WO 2006044497A2 US 2005036752 W US2005036752 W US 2005036752W WO 2006044497 A2 WO2006044497 A2 WO 2006044497A2
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
optionally substituted
halogen
aryl
cyano
Prior art date
Application number
PCT/US2005/036752
Other languages
French (fr)
Other versions
WO2006044497A3 (en
Inventor
James C. Barrow
Craig A. Coburn
Melissa S. Egbertson
Georgia B. Mcgaughey
Melody A. Mcwherter
Lou Anne Neilson
Harold G. Selnick
Shaun R. Stauffer
Zhi-Qiang Yang
Wenjin Yang
Wanli Lu
Bruce Fahr
Kenneth E. Rittle
Original Assignee
Merck & Co., Inc.
Sunesis Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co., Inc., Sunesis Pharmaceuticals, Inc. filed Critical Merck & Co., Inc.
Priority to JP2007536860A priority Critical patent/JP2008515989A/en
Priority to EP05812233.4A priority patent/EP1804794B1/en
Priority to AU2005295814A priority patent/AU2005295814A1/en
Priority to CA002583342A priority patent/CA2583342A1/en
Priority to US11/663,388 priority patent/US8114887B2/en
Publication of WO2006044497A2 publication Critical patent/WO2006044497A2/en
Publication of WO2006044497A3 publication Critical patent/WO2006044497A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the invention is directed to compounds useful as inhibitors of the beta secretase enzyme, and useful in the treatment of diseases in which the beta secretase enzyme is involved, such as Alzheimer's Disease.
  • Alzheimer's disease is characterized by the abnormal deposition of amyloid in the brain in the form of extra-cellular plaques and intra-cellular neurofibrillary tangles.
  • the rate of amyloid accumulation is a combination of the rates of formation, aggregation and egress from the brain. It is generally accepted that the main constituent of amyloid plaques is the 4kD amyloid protein ( ⁇ A4, also referred to as A ⁇ , ⁇ -protein and ⁇ AP) which is a proteolytic product of a precursor protein of much larger size.
  • the amyloid precursor protein (APP or A ⁇ PP) has a receptor-like structure with a large ectodomain, a membrane spanning region and a short cytoplasmic tail.
  • the A ⁇ domain encompasses parts of both extra-cellular and transmembrane domains of APP, thus its release implies the existence of two distinct proteolytic events to generate its NH 2 - and COOH-termini. At least two secretory mechanisms exist which release APP from the membrane and generate soluble, COOH-truncated forms of APP (APP S ). Proteases that release APP and its fragments from the membrane are termed
  • secretases Most APP 8 is released by a putative ⁇ -secretase which cleaves within the A ⁇ protein to release ⁇ -APP s and precludes the release of intact A ⁇ . A minor portion of APP 5 is released by a ⁇ - secretase (“ ⁇ -secretase”), which cleaves near the NH 2 -terminus of APP and produces COOH-terminal fragments (CTFs) which contain the whole A ⁇ domain.
  • ⁇ -secretase ⁇ -secretase
  • CTFs COOH-terminal fragments
  • therapeutic agents that can inhibit ⁇ -secretase or BACE may be useful for the treatment of Alzheimer's disease.
  • the compounds of the present invention are useful for treating Alzheimer's disease by inhibiting the activity of ⁇ -secretase or BACE, thus preventing the formation of insoluble A ⁇ and arresting the production of A ⁇ .
  • the present invention is directed to novel spiropiperidine compounds represented by general formula (I)
  • the invention is also directed to pharmaceutical compositions which include an effective amount of a compound of formula (I), or pharmaceutically acceptable salts thereof, and a pharmaceutically acceptable carrier.
  • the invention is also directed to methods of treating mammals for diseases in which the ⁇ -secretase enzyme is involved, such as Alzheimer's disease, and the use of the compounds and pharmaceutical compositions of the invention in the treatment of such diseases.
  • the present invention is directed to methods of treating mammals for diseases in which the ⁇ -secretase enzyme is involved, such as Alzheimer's disease, by administering a compound of formula (I)
  • X 1 is CR5H or NH
  • Z is O or S
  • Rl is selected from the group consisting of
  • Rl aryl and heteroaryl moieties are optionally substituted with one or more (a) halogen, (b) -Ci -6 alkyl,
  • Q 1 and Q2 are selected from the group consisting of
  • n 0, 1 or 2;
  • R2 is selected from the group consisting of
  • R.2 cycloalkyl moiety is optionally substituted with one or more -C 1-6 alkyl
  • R.2 aryl or heteroaryl moiety is optionally substituted with one or more
  • Q3 and Q4 are selected from the same group as Ql and Q2;
  • R3 is selected from the group consisting of
  • R ⁇ alkyl moiety is optionally substituted with one or more
  • R.3 aryl and heteroaryl moiety is optionally substituted with one or more
  • Rl 2 is selected from the group consisting of (I) hydrogen, (U) -C 1.6 alkyl,
  • Rl 2 alkyl, alkenyl and alkynyl moiety is optionally substituted with one or more
  • RlO cycloalkyl moiety is optionally substituted with one or more (A) halogen, (B) hydroxyl,
  • Rl2 aryl moiety is optionally substituted with one or more
  • Q5 and Q6 are selected from the same group as Ql and Q2;
  • R4 and R4' are selected from the group consisting of (1) hydrogen, (2) -C 1-8 alkyl, wherein said alkyl is optionally substituted with
  • R5 is selected from the group csoonsisting of (1) hydrogen, (2) -C 1-6 alkyl,
  • R6, R7, R8 ; R9 ; RlO and Rl 1 are independently selected from the group consisting of: (1) hydrogen, (2) -Ci. 6 alkyl, (3) -C3-8 cycloalkyl,
  • the invention is also directed to pharmaceutical compositions which include an effective amount of a compound of formula (I), or pharmaceutically acceptable salts thereof, and a pharmaceutically acceptable carrier.
  • the present invention is further directed to a method for the manufacture of a medicament or a composition for inhibiting ⁇ -secretase enzyme activity in humans and animals.
  • the invention is also directed to a method for the manufacture of a medicament for the treatment of Alzheimer's Disease in humans, comprising combining a compound of the present invention with a pharmaceutical carrier or diluent.
  • the invention is directed to novel spiropiperidine compounds of formula (I) above, provided that when X is N; Z is O; Rl is unsubstituted cyclohexyl; and R.2 is unsubstituted phenyl, then R ⁇ is not unsubstituted benzyl.
  • Z is O.
  • the invention is directed to compounds of formula (I) wherein X is N and X 1 is NH .
  • X is CR ⁇ , wherein R5 is preferably hydrogen, and X' is CR ⁇ H, wherein R5 is preferably hydrogen.
  • Rl is -Ci-6 alkyl or -C ⁇ -3 alkyl-C3_i2 carbocyclic wherein said alkyl or carbocyclic is optionally substituted with one or more (a) -OR4,
  • Rl carbocyclic groups include-C ⁇ .g carbocyclic groups, including cyclobutyl, cyclopentyl, cyclohexyl, morpholinyl, tetrahydropyran and pyrrolidinyl.
  • Rl is -C ⁇ -3 alkyl -C6-10 ar yl > preferably phenyl or benzyl.
  • the Rl aryl moiety is optionally substituted with one or more
  • Rl is C ⁇ -3 alkyl-C5-i2 heteroaryl, wherein the heteroaryl moiety is optionally substituted with one or more
  • Rl heteroaryl groups include pyridinyl, thienyl, furanyl and imidazolyl.
  • R2 is selected from the group consisting of (1) -Ci_6 alkyl
  • R2 is selected from -Ci-6 alkyl, phenyl, benzyl, or -C ⁇ -3 alkyl-C3_8 carbocyclic, optionally substituted as described above.
  • R2 is -C ⁇ -3 alkyl-C6-lO aryl, preferably the aryl moiety is optionally substituted with one or more
  • Rl 5 is selected from the group consisting of (a) -ORlO, (b) halogen,
  • R ⁇ is preferably
  • R3 is -C ⁇ -3 alkyl-heteroaryl
  • the heteroaryl is selected from the group consisting of pyridyl, pyrrolyl, furanyl, thienyl, dihydrobenzofuran, indolyl, isoquinolinyl, imidazolyl, isoxazolyl, quinolinyl, tetrahydroquinolinyl, dihydroindolyl and pyridyl.
  • the heteroaryl is substituted with one or more (a) -ORl2,
  • X is N and Z is O.
  • alkyl by itself or as part of another substituent, means a saturated straight or branched chain hydrocarbon radical having the number of carbon atoms designated (e.g., C ⁇ . 10 alkyl means an alkyl group having from one to ten carbon atoms).
  • Preferred alkyl groups for use in the invention are Ci -6 alkyl groups, having from one to six carbon atoms.
  • Exemplary alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, pentyl, hexyl, and the like.Co alkyl means a bond.
  • alkoxy by itself or as part of another substituent, means the group - O- alkyl, wherein alkyl is defined above, having the number of carbon atoms designated (e.g., Ci-M) alkoxy means an alkoxy group having from one to ten carbon atoms.
  • Preferred alkoxy groups for use in the invention are C ⁇ .(, alkoxy groups, having from one to six carbon atoms.
  • Exemplary preferred alkoxy groups include methoxy, ethoxy, propoxy, butoxy, sec-butoxy and pentoxy.
  • Especially preferred alkoxy groups are Ci .3 alkoxy.
  • alkenyl by itself or as part of another substituent, means a straight or branched chain hydrocarbon radical having a single carbon-carbon double bond and the number of carbon atoms designated (e.g., C2-10 alkenyl means an alkenyl group having from two to ten carbon atoms).
  • Preferred alkenyl groups for use in the invention are C2-6 alkenyl groups, having from two to six carbon atoms.
  • Exemplary alkenyl groups include ethenyl and propenyl.
  • alkynyl by itself or as part of another substituent, means a straight or branched chain hydrocarbon radical having a single carbon-carbon triple bond and the number of carbon atoms designated (e.g., C2-10 alkynyl means an alkynyl group having from two to ten carbon atoms).
  • Preferred alkynyl groups for use in the invention are C2-6 alkynyl groups, having from two to six carbon atoms.
  • Exemplary alkynyl groups include ethynyl and propynyl.
  • cycloalkyl by itself or as part of another substituent, means a saturated cyclic hydrocarbon radical having the number of carbon atoms designated (e.g., C3-12 cycloalkyl means a cycloalkyl group having from three to twelve carbon atoms).
  • the term cycloalkyl as used herein includes mono-, bi- and tricyclic saturated carbocycles, as well as bridged and fused ring carbocycles, such as spiro fused ring systems.
  • Preferred cycloalkyl groups for use in the invention are monocyclic C3.8 cycloalkyl groups, having from three to eight carbon atoms.
  • Exemplary monocyclic cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and the like.
  • Exemplary bridged cycloalkyl groups include adamantly and norbornyl.
  • Exemplary fused cycloalkyl groups include decahydronaphthalene.
  • the term "carbocyclic,” by itself or as part of another substituent, means a cycloalkyl group as defined above, or a non-aromatic heterocyclic group.
  • a non-aromatic heterocyclic group, by itself or as part of another substituent means a cycloalkyl group as defined above in which one or more of the ring carbon atoms is replaced with a heteroatom (such as N, S or O).
  • Suitable non- aromatic heterocyclic groups for use in the invention include piperidinyl, piperazinyl, morpholinyl, tetrahydrofuranyl, tetrahydrothienyl, pyrrolidinyl, pyrazolidinyl, azetidinyl, tetrahydropyranyl and imidazolildinyl.
  • Preferred non-aromatic heterocyclic groups are piperidinyl, piperazinyl, tetrahydrofuranyl, tetrahydropyranyl, pyrrolidinyl, morpholinyl and azetidinyl.
  • the substituent When a non-aromatic heterocyclic group as defined herein is substituted, the substituent may be bonded to a ring carbon atom of the heterocyclic group, or on a ring heteroatom (i.e., a nitrogen, oxygen or sulfur), which has a valence which permits substitution. Preferably, the substituent is bonded to a ring carbon atom.
  • the point of attachment may be at a ring carbon atom of the heterocyclic group or on a ring heteroatom (i.e., a nitrogen, oxygen or sulfur), which has a valence which permits substitution.
  • the attachment is at a ring carbon atom.
  • aryl by itself or as part of another substituent, means an aromatic cyclic hydrocarbon radical having the number of carbon atoms designated (e.g., C ⁇ -lO aryl means an aryl group having from six to ten carbons atoms).
  • aryl includes multiple ring systems as well as single ring systems. Preferred aryl groups for use in the invention include phenyl and naphthyl.
  • aryl also includes fused cyclic hydrocarbon rings which are partially aromatic (i.e., one of the fused rings is aromatic and the other is non-aromatic).
  • An exemplary aryl group which is partially aromatic is indanyl.
  • halo or “halogen” includes fluoro, chloro, bromo and iodo.
  • heteroaryl by itself or as part of another substituent, means an aromatic cyclic group having at least one ring heteroatom (O, N or S). ).
  • heteroaryl includes multiple ring systems as well as single ring systems.
  • heteroaryl groups for use in the invention include furyl, pyranyl, benzofuranyl, isobenzofuranyl, chromenyl, thienyl, benzothiophenyl, pyrrolyl, pyrazolyl, imidazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolyl, benzimidazolyl, quinolinyl, isoquinolinyl, tetrazolyl, indazolyl, napthyridinyl, triazolyl, oxazolyl, oxadiazolyl, thiazolyl, thiadiazolyl, isoxazolyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl and dihydroindolyl.
  • heteroaryl also includes fused aromatic cyclic groups which are partially aromatic (i.e., one of the fused rings is aromatic and the other is non-aromatic).
  • exemplary heteroaryl groups which are partially aromatic include tetrahydroquinolyl, dihydrobenzofuran and dihydroindolyl.
  • the substituent When a heteroaryl group as defined herein is substituted, the substituent may be bonded to a ring carbon atom of the heteroaryl group, or on a ring heteroatom (i.e., a nitrogen, oxygen or sulfur), which has a valence which permits substitution. Preferably, the substituent is bonded to a ring carbon atom.
  • the point of attachment may be at a ring carbon atom of the heteroaryl group, or on a ring heteroatom (i.e., a nitrogen, oxygen or sulfur), which has a valence which permits attachment.
  • the attachment is at a ring carbon atom.
  • Some of the compounds of the instant invention have at least one asymmetric center. Additional asymmetric centers may be present depending upon the nature of the various substituents on the molecule. Compounds with asymmetric centers give rise to enantiomers (optical isomers), diastereomers (configurational isomers) or both, and it is intended that all of the possible enantiomers and diastereomers in mixtures and as pure or partially purified compounds are included within the scope of this invention. The present invention is meant to encompass all such isomeric forms of these compounds.
  • tautomer refers to a compound which exists in an equilibrium mixture and which can be isolated in either form and react through either form.
  • the tatutomers may differ in linkage, bond, or connections between atoms, and the position or distribution of the atoms in the molecule.
  • compounds of formula (I) may be present in the enamine form depicted above, or in the tautomeric imine form (F), as shown below:
  • compounds of formula (II) may be present in the enamine form depicted above, or in the tautomeric imine form (II'), as shown below:
  • Compounds described herein may contain one or more double bonds, and may thus give rise to cisltrans isomers as well as other conformational isomers.
  • the present invention includes all such possible isomers as well as mixtures of such isomers.
  • Formulas (I) to (HI) are shown above without a definite stereochemistry at certain positions.
  • the present invention includes all stereoisomers of Formulas (I) to (III) and pharmaceutically acceptable salts thereof.
  • the independent syntheses of the enantiomerically or diastereomerically enriched compounds, or their chromatographic separations, may be achieved as known in the art by appropriate modification of the methodology disclosed herein.
  • Their absolute stereochemistry may be determined by the x-ray crystallography of crystalline products or crystalline intermediates that are derivatized, if necessary, with a reagent containing an asymmetric center of known absolute configuration. If desired, racemic mixtures of the compounds may be separated so that the individual enantiomers are isolated.
  • the separation can be carried out by methods well known in the art, such as the coupling of a racemic mixture of compounds to an enantiomerically pure compound to form a diastereomeric mixture, followed by separation of the individual diastereomers by standard methods, such as fractional crystallization or chromatography.
  • the coupling reaction is often the formation of salts using an enantiomerically pure acid or base.
  • the diastereomeric derivatives may then be converted to the pure enantiomers by cleavage of the added chiral residue.
  • the racemic mixture of the compounds can also be separated directly by chromatographic methods using chiral stationary phases, which methods are well known in the art.
  • any enantiomer of a compound may be obtained by stereoselective synthesis using optically pure starting materials or reagents of known configuration by methods well known in the art.
  • Scheme 1 depicts an Ugi four-component coupling reaction between a piperidone derivative, amine, isonitrile, and cyanate, which assembles the core structure 1-1. Further elaboration of 1-1 is possible, for example, removal of a temporary R.3 group to give 1-2, followed by alkylation with a different R.3 to give new structures 1-3.
  • substantially pure means that the isolated material is at least 90% pure, and preferably 95% pure, and even more preferably 99% pure as assayed by analytical techniques known in the art.
  • salts refers to salts prepared from pharmaceutically acceptable non-toxic bases or acids including inorganic or organic bases and inorganic or organic acids.
  • the compounds of the invention may be mono, di or tris salts, depending on the number of acid functionalities present in the free base form of the compound.
  • Free bases and salts derived from inorganic bases include aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic salts, manganous, potassium, sodium, zinc, and the like. Particularly preferred are the ammonium, calcium, magnesium, potassium, and sodium salts. Salts in the solid form may exist in more than one crystal structure, and may also be in the form of hydrates.
  • Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, and basic ion exchange resins, such as arginine, betaine, caffeine, choline, N,N'-dibenzylethylene-diamine, diethylamine, 2- diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethyl-morpholine, N- ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, and the like.
  • basic ion exchange resins
  • salts may be prepared from pharmaceutically acceptable non-toxic acids, including inorganic and organic acids.
  • acids include acetic, trifluoroacetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethanesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, p-toluenesulfonic acid, and the like.
  • Particularly preferred are citric, hydrobromic, hydrochloric, trifluoroacetic, maleic, phosphoric, sulfuric, fumaric, and tartaric acids.
  • the present invention is directed to the use of the compounds of formulas (I) to (Hl) disclosed herein as inhibitors of ⁇ -secretase enzyme activity or ⁇ -site amyloid precursor protein-cleaving enzyme ("BACE") activity, in a patient or subject such as a mammal in need of such inhibition, comprising the administration of an effective amount of the compound.
  • BACE ⁇ -secretase enzyme
  • ⁇ -site amyloid precursor protein-cleaving enzyme and “BACE” are used interchangeably in this specification.
  • ⁇ -secretase enzyme ⁇ -site amyloid precursor protein-cleaving enzyme
  • BACE ⁇ -site amyloid precursor protein-cleaving enzyme
  • the compounds of the present invention have utility in treating, ameliorating, controlling or reducing the risk of Alzheimer's disease.
  • the compounds may be useful for the prevention of dementia of the Alzheimer's type, as well as for the treatment of early stage, intermediate stage or late stage dementia of the Alzheimer's type.
  • the compounds may also be useful in treating, ameliorating, controlling or reducing the risk of diseases mediated by abnormal cleavage of amyloid precursor protein (also referred to as APP), and other conditions that may be treated or prevented by inhibition of ⁇ - secretase.
  • APP amyloid precursor protein
  • Such conditions include mild cognitive impairment, Trisomy 21 (Down Syndrome), cerebral amyloid angiopathy, degenerative dementia, Hereditary Cerebral Hemorrhage with Amyloidosis of the Dutch-Type (HCHWA-D), Creutzfeld- Jakob disease, prion disorders, amyotrophic lateral sclerosis, progressive supranuclear palsy, head trauma, stroke, pancreatitis, inclusion body myositis, other peripheral amyloidoses, diabetes and atherosclerosis.
  • the subject or patient to whom the compounds of the present invention is administered is generally a human being, male or female, in whom inhibition of ⁇ -secretase enzyme activity is desired, but may also encompass other mammals, such as dogs, cats, mice, rats, cattle, horses, sheep, rabbits, monkeys, chimpanzees or other apes or primates, for which inhibition of ⁇ -secretase enzyme activity or treatment of the above noted disorders is desired.
  • the compounds of the present invention may be used in combination with one or more other drugs in the treatment of diseases or conditions for which the compounds of the present invention have utility, where the combination of the drugs together are safer or more effective than either drug alone. Additionally, the compounds of the present invention may be used in combination with one or more other drugs that treat, prevent, control, ameliorate, or reduce the risk of side effects or toxicity of the compounds of the present invention. Such other drugs may be administered, by a route and in an amount commonly used therefor, contemporaneously or sequentially with the compounds of the present invention. Accordingly, the pharmaceutical compositions of the present invention include those that contain one or more other active ingredients, in addition to the compounds of the present invention. The combinations may be administered as part of a unit dosage form combination product, or as a kit or treatment protocol wherein one or more additional drugs are administered in separate dosage forms as part of a treatment regimen.
  • combinations of the compounds of the present invention with other drugs in either unit dose or kit form include combinations with anti-Alzheimer's agents, for example other beta-secretase inhibitors or gamma-secretase inhibitors; tau phpsphorylation inhibitors; Ml receptor positive allosteric modulators; blockers of A ⁇ oligomer formation; 5-HT modulators, such as PRX-03140, GSK 742467, SGS-518, FK-962, SL-65.0155, SRA-333 and xaliproden; p25/CDK5 inhibitors; NK1/NK3 receptor antagonists; COX-2 inhibitors; HMG-CoA reductase inhibitors; NSAIDs including ibuprofen; vitamin E; anti-amyloid antibodies, including anti -amyloid humanized monoclonal antibodies; anti-inflammatory compounds such as (R)-flurbiprofen, nitroflurbiprofen, rosiglitazone, ND-1251, VP
  • composition as used herein is intended to encompass a product comprising specified ingredients in predetermined amounts or proportions, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts.
  • This term in relation to pharmaceutical compositions is intended to encompass a product comprising one or more active ingredients, and an optional carrier comprising inert ingredients, as well as any product which results, directly or indirectly, from combination, complexation or aggregation of any two or more of the ingredients, or from dissociation of one or more of the ingredients, or from other types of reactions or interactions of one or more of the ingredients.
  • compositions are prepared by uniformly and intimately bringing the active ingredient into association with a liquid carrier or a finely divided solid carrier or both, and then, if necessary, shaping the product into the desired formulation.
  • the active compound which is a compound of formulas (I) to (HI)
  • the pharmaceutical compositions of the present invention encompass any composition made by admixing a compound of the present invention and a pharmaceutically acceptable carrier.
  • the carrier may take a wide variety of forms depending on the form of preparation desired for administration, e.g., oral or parenteral (including intravenous).
  • compositions of the present invention can be presented as discrete units suitable for oral administration such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient. Further, the compositions can be presented as a powder, as granules, as a solution, as a suspension in an aqueous liquid, as a non-aqueous liquid, as an oil-in-water emulsion or as a water-in-oil liquid emulsion.
  • the compounds represented by Formulas (I) to (VII), or pharmaceutically acceptable salts thereof may also be administered by controlled release means and/or delivery devices.
  • compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations.
  • Tablets may contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets.
  • excipients may be, for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example magnesium stearate, stearic acid or talc.
  • the tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.
  • a tablet containing the composition of this invention may be prepared by compression or molding, optionally with one or more accessory ingredients or adjuvants.
  • Compressed tablets may be prepared by compressing, in a suitable machine, the active ingredient in a free-flowing form such as powder or granules, optionally mixed with a binder, lubricant, inert diluent, surface active or dispersing agent. Molded tablets may be made by molding in a suitable machine, a mixture of the powdered compound moistened with an inert liquid diluent.
  • Each tablet preferably contains from about 0.1 mg to about 500 mg of the active ingredient and each cachet or capsule preferably containing from about 0.1 mg to about 500 mg of the active ingredient.
  • compositions for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin, or olive oil.
  • an inert solid diluent for example, calcium carbonate, calcium phosphate or kaolin
  • water or an oil medium for example peanut oil, liquid paraffin, or olive oil.
  • compositions include aqueous suspensions, which contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions.
  • oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin. Oily suspensions may also contain various excipients.
  • the pharmaceutical compositions of the invention may also be in the form of oil-in-water emulsions, which may also contain excipients such as sweetening and flavoring agents.
  • the pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleaginous suspension, or in the form of sterile powders for the extemporaneous preparation of such sterile injectable solutions or dispersions.
  • the final injectable form must be sterile and must be effectively fluid for easy syringability.
  • the pharmaceutical compositions must be stable under the conditions of manufacture and storage; thus, preferably should be preserved against the contaminating action of microorganisms such as bacteria and fungi.
  • compositions of the present invention can be in a form suitable for topical use such as, for example, an aerosol, cream, ointment, lotion, dusting powder, or the like. Further, the compositions can be in a form suitable for use in transdermal devices. These formulations may be prepared via conventional processing methods. As an example, a cream or ointment is prepared by mixing hydrophilic material and water, together with about 5wt% to about 10wt% of the compound, to produce a cream or ointment having a desired consistency. Pharmaceutical compositions of this invention can also be in a form suitable for rectal administration wherein the carrier is a solid. It is preferable that the mixture forms unit dose suppositories. Suitable carriers include cocoa butter and other materials commonly used in the art.
  • administering a should be understood to mean providing a compound of the invention to the individual in need of treatment in a form that can be introduced into that individual's body in a therapeutically useful form and therapeutically useful amount, including, but not limited to: oral dosage forms, such as tablets, capsules, syrups, suspensions, and the like; injectable dosage forms, such as IV, IM, or IP, and the like; transdermal dosage forms, including creams, jellies, powders, or patches; buccal dosage forms; inhalation powders, sprays, suspensions, and the like; and rectal suppositories.
  • oral dosage forms such as tablets, capsules, syrups, suspensions, and the like
  • injectable dosage forms such as IV, IM, or IP, and the like
  • transdermal dosage forms including creams, jellies, powders, or patches
  • buccal dosage forms inhalation powders, sprays, suspensions, and the like
  • rectal suppositories rectal suppositories.
  • an effective amount or “therapeutically effective amount” means the amount of the subject compound that will elicit the biological or medical response of a tissue, system, animal or human that is being sought by the researcher, veterinarian, medical doctor or other clinician.
  • treatment or “treating” means any administration of a compound of the present invention and includes (1) inhibiting the disease in an animal that is experiencing or displaying the pathology or symptomatology of the diseased (i.e., arresting further development of the pathology and/or symptomatology), or (2) ameliorating the disease in an animal that is experiencing or displaying the pathology or symptomatology of the diseased (i.e., reversing the pathology and/or symptomatology).
  • controlling includes preventing treating, eradicating, ameliorating or otherwise reducing the severity of the condition being controlled.
  • compositions containing compounds of the present invention may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy.
  • unit dosage form is taken to mean a single dose wherein all active and inactive ingredients are combined in a suitable system, such that the patient or person administering the drug to the patient can open a single container or package with the entire dose contained therein, and does not have to mix any components together from two or more containers or packages.
  • Typical examples of unit dosage forms are tablets or capsules for oral administration, single dose vials for injection, or suppositories for rectal administration.
  • compositions containing compounds of the present invention may conveniently be presented as a kit, whereby two or more components, which may be active or inactive ingredients, carriers, diluents, and the like, are provided with instructions for preparation of the actual dosage form by the patient or person adminstering the drug to the patient.
  • kits may be provided with all necessary materials and ingredients contained therein, or they may contain instructions for using or making materials or components that must be obtained independently by the patient or person administering the drug to the patient.
  • the compounds of the present invention are administered at a daily dosage of from about 0.1 mg to about 100 mg per kg of animal body weight, preferably given as a single daily dose or in divided doses two to six times a day, or in sustained release form.
  • the total daily dosage is from about 1.0 mg to about 2000 mg, preferably from about 0.1 mg to about 20 mg per kg of body weight. In the case of a 70 kg adult human, the total daily dose will generally be from about 7 mg to about 1,400 mg. This dosage regimen may be adjusted to provide the optimal therapeutic response.
  • the compounds may be administered on a regimen of 1 to 4 times per day, preferably once or twice per day.
  • the amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration.
  • a formulation intended for the oral administration to humans may conveniently contain from about 0.005 mg to about 2.5 g of active agent, compounded with an appropriate and convenient amount of carrier materia.
  • Unit dosage forms will generally contain between from about 0.005 mg to about 1000 mg of the active ingredient, typically 0.005, 0.01 mg, 0.05 mg, 0.25 mg, 1 mg, 5 mg, 25 mg, 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 800 mg or 1000 mg, administered once, twice or three times a day.
  • ECL Assay A homogeneous end point electrochemiluminescence (ECL) assay is employed using a biotinylated BACE substrate.
  • the Km of the substrate is greater than 100 ⁇ M and can not be determined due to the limit of solubility of the substrate.
  • a typical reaction contains approximately 0.1 nM enzyme, 0.25 ⁇ M of the substrate, and buffer (50 mM NaOAc, pH 4.5 or 6.5, 0.1 mg/ml BSA, 0.2% CHAPS, 15 mM EDTA and 1 mM deferoxamine) in a total reaction volume of 100 ⁇ l. The reaction proceeds for 30 min and is then stopped by the addition of 25 ⁇ L of 1 M Tris-HCl, pH 8.0.
  • the resulting enzymatic product is assayed by adding a ruthenylated antibody which specifically recognizes the C- terminal residue of the product. Streptavidin coated magnetic beads are added into the solution and the samples are subjected to M-384 (Igen Inc., Gaithersburg, MD) analysis. Under these conditions, less than 10% of substrate is processed by BACE 1. The enzyme used in these studies is soluble
  • HPLC assay A homogeneous end point HPLC assay is used with the substrate (coumarin-CO- REVNFEVEFR), which is cleaved by BACE 1 to release the N-terminal fragment attached with coumarin.
  • the Km of the substrate is greater than 100 ⁇ M and can not be determined due to the limit of solubility of the substrate.
  • a typical reaction contains approximately 2 nM enzyme, 1.0 ⁇ M of the substrate, and buffer (50 mM NaOAc, pH 4.5 or 6.5, 0.1 mg/ml BSA, 0.2% CHAPS, 15 mM EDTA and 1 mM deferoxamine) in a total reaction volume of 100 ⁇ l.
  • the reaction is proceeded for 30 min and the reaction is stopped by the addition of 25 ⁇ L of 1 M Tris-HCl, pH 8.0.
  • the resulting reaction mixture is loaded on the HPLC and the product is separated from substrate with 5 min linear gradient. Under these conditions, less than 10% of substrate is processed by BACE 1.
  • the enzyme used in these studies is soluble (transmembrane domain and cytoplasmic extension excluded) human protein produced in a baculovirus expression system.
  • 12 concentrations of inhibitors are prepared, and the concentration rage is dependent on the potency predicted by ECL. Solutions of inhibitor in DMSO are included in the reaction mixture (final DMSO concentration is 10 %). All experiments are conducted at rt using the standard reaction conditions described above. To determine the IC50 of the compound, four parameters equation is employed for curve fitting. The errors in reproducing the dissociation constants are typically less than two-fold.
  • the compounds of the following examples had activity in inhibiting the beta- secretase enzyme in the aforementioned assays, generally with an IC50 from about 1 nM to 500 ⁇ M, preferably 1 nM to 100 ⁇ M. Such a result is indicative of the intrinsic activity of the compounds in use as inhibitors of beta-secretase enzyme activity.
  • BSA bovine serum albumin
  • TMSCN trimethylsilylnirrile
  • PS-DIEA N 5 N (diisopropyl) aminomethylpolystyrene
  • N-benzyl piperidinone (833 mg, 4.41 mmol) and benzyl isocyanide (500 mg, 4.2 mmol) were dissolved in MeOH (2.2mL).
  • Aniline hydrochloride was added in portions over 5 min. After stirring for Ih the crude product precipitated from solution.
  • the resulting solid was isolated via vacuum filtration, rinsed with H 2 O followed by Et 2 O, and dried in vacuo to give 150 mg of a white solid. A portion of this solid was further purified by RP-HPLC.
  • Step 1 l-benzyl-4-[(3-fluorophenyl)amino]piperidine-4-carbonitrile (4A-1)
  • Step 2 ethyl l-benzyl-4-[(3-fluorophenyl)amino]piperidine-4-carboxylate (4A-2)
  • a solution of 5g (16 mmol) l-benzyl-4-[(3-fluorophenyl)amino]piperidine-4-carbonitrile in 20 mL concentrated H 2 SO 4 was stirred vigorously for 18 hr, then cooled in an ice bath. The mixture was neutralized by slow addition of concentrated NaOH and ice chips, and the resulting heterogeneous mixture extracted with 500 mL CH 2 Cl 2 .
  • Step 3 ethyl 4-[acetyl(3-fluorophenyl)amino]-l-benzylpiperidrne-4-carboxylate (4A-3)
  • a solution of 0.2g (0.56 mmol) ethyl l-benzyl-4-[(3-fluorophenyl)amino]piperidine-4-carboxylate in 2.6 mL (28 mmol) acetic anhydride (neat) was heated to 120 0 C for 20 hr, then poured into 50 mL of a 1: 1 mixture of water and concentrated NH4OH, extracted with 100 mL EtOAc, washed with water then brine, dried over MgSO 4 , filtered, and concentrated.
  • Step 4 8-benzyl-l-(3-fluorophenyl)-l,8-diazaspiro[4.5]decane-2,4-dione (4A-4)
  • a 0 0 C solution of 0.86g (2.2 mmol) ethyl 4-[acetyl(3-fluorophenyl)amino]-l-benzylpiperidine-4- carboxylate in 1 mL THF was added 3.2 mL (6.5mmol, 2M solution in heptane, THF, ethylbenzene) lithium diisopropylamide solution and the reaction mixture was allowed to slowly warm to rt and stirred for an additional 14 hr.
  • Step 6 to give 8-benzyl-l-(3-fluorophenyl)-4-[(4-fluorophenyl)amino]-l,8-diazaspiro[4.5]dec-3-en-2-one.
  • Strecker adduct 4A-1 is first acylated to give 4B-2 and then cyclized to 4B-3 using a base such as NaOMe.
  • Structures of type 4B-3 and derivatives thereof are also of use for the intended invention described herein.
  • Decarboxylation of structures of type 4B-3 using a strong acid, such as aqueous 6N HCl gives initially structures of type 4B-4a, which are also claimed for use in the invention.
  • EXAMPLE 4B-7 8-Benzyl-4-[(2-ethylphenyl)amino]-l-(3-fluorophenyl)-l,8-diazaspiro[4.5]dec-3-en-2-one.
  • Step 1 Acylation to give Intermediate of type 4B-2.
  • ethyl 3-[(l- benzyl-4-cyanopiperidin-4-yl)(3-fluorophenyl)amino]-3-oxopropanoate (intermediate 4A-1 as describe above) in 150 niL CH 2 Cl 2 was added 4.9 mL (37.8 mmol) ethyl malonyl chloride and 5.1 mL (43.6 mmol) 2,6-lutidine. After 3 h, the reaction was diluted with 150 mL CH 2 Cl 2 and washed with water and brine.
  • Step 2 8-benzyl-l-(3-fluorophenyl)-l,8-diazaspiro[4.5]decane-2,4-dione
  • a rt solution of 14.9 g (35.2 mmol) ethyl 3-[(l-benzyl-4-cyanopiperidin-4-yl)(3-fluorophenyl)amino]- 3-oxopropanoate in 20 mL methanol was added 7.6 mL (42.2 mmol) 30% w/v sodium methoxide in methanol.
  • Step C Condensation with amine to give structures of type 4B-4. 8-benzyl-4-[(2-ethylphenyl)amino]-l- (3 -fluorophenyl)- 1 ,8-diazaspiro[4.5]dec-3-en-2-one (4B-7)
  • Scheme 5 depicts a method for synthesizing compounds with alternative R.3 groups, such as Example (5-3) below (Example (5-3) is depicted in enamine form, but may also exist in tautomeric imine form).
  • Stepl tert-Butyl 4-(cyclohexylamino)-l-(3-fluorophenyl)-2-oxo-l,3,8-triazaspiro[4.5]dec-3-ene-8- carboxylate (5-1)
  • Step 2 2: 4-(Cyclohexylamino)-l-(3-fluorophenyl)-2-oxo-l,3,8-triazaspiro[4.5]dec-3-ene dihydrochloride 5-2
  • Step 3 8-(3-Bromobenzyl)-4-(cyclohexylamino)-l-(3-fluorophenyl)-l,3,8-triazaspiro[4.5]dec-3-en-2-one (5-3)
  • Step 1 3-[(l-methylprop-2-enyl)oxy]benzaldehyde
  • Step 2 4-(cyclohexylamino)-l-(3-fluorophenyl)-8- ⁇ 3-[(l-methylprop-2-enyl)oxy]benzyl ⁇ -l,3,8- triazaspiro [4.5] dec-3 -en-2-one
  • Step 2 4-(cyclohexylamino)-l-(3-fluorophenyl)-8-(3-isopropoxybenzyl)-l,3,8-triazaspiro[4.5]dec-3-en- 2-one (5-6)
  • Scheme 6 depicts a method for preparing compounds wherein Rl is methyl, such as Examples (6-3) - (6-6) below.
  • Examples (6-3)-(6-6) are depicted in enamine form, but may also exist in tautomeric imine form as described above.
  • Scheme 7 demonstrates another method for preparing compounds with alternate R.3 groups (such as Example (7-2) and (7-3).
  • Example (7-2) and (7-3) are depicted in enamine form but may also exist in tautomeric imine form.
  • Step 1 3- ⁇ [4-(cyclohexylamino)-l-(3-fluorophenyl)-2 -oxo-1, 3,8-triazaspiro[4.5]dec-3-en-8- yl]methyl ⁇ phenylboronic acid (7-1)
  • Step 2 4-(cyclohexylamino)- 1 -(3 -fluorophenyl)-8-[3-(4-methylpyridin-3-yl)benzyl] -1,3,8- triazaspiro[4.5]dec-3-en-2-one (7-3)
  • Examples (7-4)- (7-109) listed below in Table 3 were prepared in a manner similar to that described in Schemes 3, 5 and 7.
  • Examples (7-4) - (7-109) and their pharmaceutically acceptable salts are depicted in enamine form, but may also exist in tautomeric imine form.
  • Table 3- Compounds (or salts thereof) Synthesized According to Schemes 5 and 7, using methods similar to that described for Examples (5-3) - (5-5) and (7-2) - (7-3).
  • Scheme 8 describes a method for preparation of compounds containing an aminopyridine R.3 substituent, such as Examples (8-1) - (8-4).
  • Examples (8-1) - (8-4) are depicted in enamine form, but may also exist in tautomeric imine form.
  • reaction vessel was capped and warmed to 110 0 C overnight.
  • the clear toluene layer was decanted and the residue extracted (2x hot toluene).
  • the combined organic extracts were concentrated to dryness in vacuo, the residue dissolved in 900 ⁇ L DMF and purified by preparative HPLC (5->95% CH 3 CN/H 2 O over 30m, 0.05% added TFA, C18 PRO YMC 20x150 mm)to afford, after lyophilization, 8- ⁇ [6- (benzylamino)pyridinium-3-yl]methyl ⁇ -4-(cyclohexylamino)-l-(3-fluorophenyl)-2 -oxo-1, 3-diaza-8- azoniaspiro[4.5]dec-3-ene bis(trifluoroacetate) as a white fluffy solid.
  • Example (8-5) - (8-25) listed below in Table 4 were prepared in a manner similar to that described in Scheme 8.
  • Examples (8-5) - (8-25) and their pharmaceutically acceptable salts are depicted in enamine form, but may also exist in tautomeric imine form.
  • Example (8-26) was prepared in the same manner as (8-5)-(8-25) starting with 8-[(6-bromophenyl)methyl]-4- (cyclohexylamino)-l-(3-fluorophenyl)-l,3,8-triazaspiro[4.5]dec-3-en-2-one.
  • Step 1 tert-Butyl 2-hydroxypropylcarbamate (9-2): tert-Butyl 2-hydroxypropylcarbamate (2): Biorg. Med Chem., 6, 1998 2405-2419 Added Boc anyhdride (8.19g, 37.4 mmole) in CH 2 Cl 2 (30mL)to a solution of l-amino-2-propanol in 77 mL of 10% Et3N in MeOH. Let stir at rt under Argon. After 6 hr, concentrated in vacuo. Purified on a 12Og redisep coumn eluting with 1-1 EtOAc Hex. Concentrated clean fractions in vacuo.
  • Step 2 t-Butyl 2,3-(formylphenoxy)propylcarbamate (9-3) t-Butyl 2,3-(formylphenoxy)propylcarbamate Dissolved triphenylphosphine (0.805g, 3.07 mmole), 3-hydroxybenzaldehyde (0.25g, 2.047 mmole) and t-butyl 2-hydroxypropylcarbamate(0.395g, 2.25 mmole, ) in dry toluene (5 mL) at rt. Added ADDP
  • Mass spec (m+1) 508 8-[3-(2-amino-l-(R)- methylethoxy)benzyl]-4-(cyclohexylamino)-l-(3-fluorophenyl)-l,3,8- triazaspiro[4.5]dec-3-en-2-one and 8-[3-(2-amino-l-(S)- methylethoxy)benzyl]-4-(cyclohexylamino)-l- (3-fluorophenyl)-l,3,8-triazaspiro[4.5]dec-3-en-2-one (9-5 and 9-5)
  • Methanesulfonyl chloride (.019 mL, 0.245 mmole) was added dropwise to a solution of 8- ⁇ 3-[(6- aminohexyl)oxy]benzyl ⁇ -4-(cyclohexylamino)-l-(3-fluorophenyl)-l,3,8-triazaspiro[4.5]dec-3-en-2-one (0.116 mg, 0.222 mmole)in 5 mL CH2CI2 at rt, and Et ⁇ N (0.034 mL, 0.245 mmole. After stirring for 0.5 hr at rt, the reaction was concentrated in vacuo.
  • Table 5 The following compounds (or salts thereof) of Table 5 were prepared by methods similar to that described for 9-4, 9-5, and 9-6, utilizing the appropriate reagents.
  • Method Z A 5ml dichloroethane suspension of 0.05g(0.1 lmmol) 4-(cyclohexylamino)-8-[3- aminobenzyl]-l-(3-fluorophenyl)-l,3,8-triazaspiro[4.5]dec-3-en-2-one (Example 11-2), 0.01mL(0.13mmol) 2-methylpentan-l-al, 0.05mL HOAc, and 0.05g (0.22mmol) sodium triacetoxyborohydride was allowed to stir at rt overnight. The reaction was quenched with saturated aqueous NaHCO 3 , diluted with CH 2 CI 2 and allowed to stir vigorously for 15 min.
  • Example (12-4) is depicted below in enamine form, but may also exist in tautomeric imine form, as described above Scheme 12
  • Step 1 3-(3-bromophenyl)-2-methylpropanenitrile (12-2).
  • Step 2 3-(3-formylphenyl)-2-methylpropanenitrile (12-3).
  • a 3-neck flask equipped with a condenser and 2 septa was flushed with N 2 , then the flask was charged with 0.6g(2.7mmol) 3-(3-bromophenyl)-2-methylpropionitrile(9-2), 0.275g(4mmol) sodium formate, 0.155g(0.13mmol) tetrakis(triphenylphospine)Palladium and flushed with CO from a balloon for 5 min.
  • the solids were suspended in 1OmL DMF and CO continued to bubble into the liquid.
  • the flask was heated in an oil bath at 100' for 20min then 110' while stirring.
  • Step 3 3-(3- ⁇ [4-(cyclohexylamino)-l-(3-fluorophenyl)-2-oxo-l,3,8-triazaspiro[4.5]dec-3-en-8- yl]methyl ⁇ phenyl)-2-methylpropanenitrile (12-4).
  • the compound was prepared in a manner similar to that described in WO 02/076983 (page 80). Dry isopropanol (25 mL, 42.2 mmole) was placed in an oven-dried 250 ml 3 necked flask under nitrogen, sodium spheres (0.5g, 21.1 mmol) were added and the reaction was heated to 80° C to dissolve the sodium. 2,6 dibromopyridine (1Og, 42.2 mmole) was added as a solid and the reaction was heated at 95 0 C . After heating for -2.5 hr the reaction was cooled and partitioned between ether and water.
  • ⁇ -isopropoxypyridine ⁇ -carbaldehyde was prepared in a manner similar to that described in D. L Comins, M.O. Killpack, J. Org. Chem. 1990 55 69-73 for the methoxy analog.
  • 2-bromo-6-isopropoxypyridine (Ig, 4.6 mmole) was dissolved in 10ml dry THF under argon, cooled to -78° C and treated with added 2.5 M n-Butyl lithium ( 1.9 mL, 4.8 mmole) keeping the temperature of the reaction below -65° C.
  • Step 3 4-(cyclohexylamino)-l-(3-fluorophenyl)-8-[(6-isopropoxypyridin-2-yl)methyl]-l,3,8- triazaspiro[4.5]dec-3-en-2-one.
  • This compound was prepare in a manner similar to that described for example (5-6) using the intermediate from scheme 13 step 2 and compound (5-2).
  • LCMS (m+l) 494.1
  • Scheme 14A depicts a method for preparing 8-Benzyl-l-phenyl-4-thioxo-l,3,8-triaza- spiro[4.5]decan-2-one 14A-5 intermediates useful for making compounds of the invention.
  • the commercially available 14A-1 may be alkylated with an appropriate alkyl halide like benzyl chloride using a suitable base like potassium carbonate in a suitable solvent like acetonitrile to afford 14A-2.
  • a similar method is described by M. E. Kopach et. al. J. Org .Chem. 2003 68 5739-5741.
  • 14A-3 A modified Strecker reaction of A-2 yields 14A-3; and followed by the treatment of chlorosulfonyl isocyanate in methylene chloride to afford 14A-4.
  • 14A-5 is obtained by the thiolation of 14A-4 by Na 2 S.
  • Step 2 l-(3-Isopropoxy-benzyl)-piperidin-4-one monohydrate (14-4)
  • Step 3 4-(3-Fluoro-phenyl)-l-(3-isopropoxy-benzyl)-piperidine-4-carbomtrile (14-5)
  • TMSCN 2.98g, 30 mmol
  • LCMS (MH+ 368.3)
  • Step 4 l-(3-Fluoro-phenyl)-8-(3-isopropoxy-benzyl)-4-thioxo-l,3,8-triaza-spiro[4.5]decan-2-one (14-7)
  • the 4-(3-Fluoro-phenyl)-l-(3-isopropoxy-benzyl)-piperidine-4-carbonitrile 14-5 (5.28 g, 15.0 mmole) was dissolved into chloroform (15 mL).
  • Step 6 l-(3-Fluorophenyl)-4-isobutylamino-8-(3-isopropoxy-benzyl)-l,3,8-triaza-spiro[4.5]dec-3-en-2- one (14-8).
  • SNS-I 21.4 mg, 0.05mmol
  • isobutyl amine 36.5 mg, 0.5 mmol
  • the reaction mixture was heated at 110 0 C for 12 hr.
  • the crude was purified by preparative HPLC to provide
  • Table 6 The following compounds (or salts thereof) of table 6 were prepared in a manner similar to that described for scheme 14.
  • R2 elaboration can be prepared by the methods described in Scheme 3, Scheme 14-A with various substituted aniline or by Suzuki coupling of 15-1 with a various of boronic acid or boronate ester.
  • a representative procedure for elaboration of the R.2 substituent, as depicted in Scheme 15 below, can be used in the synthesis of various compounds of the invention, including Examples (15-2) - (15-42) below.
  • the boronate ester can be prepared as describe in Scheme 15-A. Examples (15-2) - (15-42) are depicted below in enamine form, but may also exist in tautomeric imine form, as described above.
  • the crude 15-B-2 (0.05Og, 0.20 mmol ), potassium acetate (0.059g O. ⁇ Ommol), bis(pinacolato)diboron (0.046g, 0.18 mmol) and PdCl 2 (dppf) (0.016g 0.020mmol) were added to a round bottom flask. Dry DMF (3 ml) was then added, and the flask was flushed with nitrogen, then capped. The resultant mixture was stirred and placed into an 8O 0 C oil bath. The reaction was followed by LCMS. Upon consumption of starting material, the reaction mixture was extracted with ethyl acetate / water 3-4 times, then washed with brine twice.
  • Example 15-35 The Suzuki coupling was carried out using the standard conditions already described with the Boykin catalyst.
  • Step 1 Step 2: 2'-[4-Cyclohexylamino-8-(3-isopropoxy-benzyl)-2-oxo-l,3,8-triaza-spiro[4.5]dec-3-en-l-yl]-4'- fluoro-biphenyl-4-sulfonic acid dimethylamide (15-2)
  • the vial was capped, and placed to stir in a 90° C aluminum block over a hot plate.
  • the reaction showed black palladium precipitate (approximately 3 hr)
  • the reaction was cooled to rt.
  • the reaction was then filtered through celite, and the resulting solution was purified directly by reverse phase HPLC in acetonitrile: water with 0.1% TFA, to provide the desired diaryl product as the TFA salt.
  • N-(t-butyloxycarbonyl)-4-piperidone (10.13 g, 50.8 mmol, 1.0 eq) and the 2-bromo-5-fluoroaniline (11.6Og, 61.0 mmol, 1.2 eq.) were weighed into a flask.
  • Acetic acid 75 mL was added, followed by trimethylsilyl cyanide (7.75 mL, 58.1 mmol, 1.14 eq.). The mixture was stirred at rt for 24 hr, and was then added to a mixture of 200 mL ice and 200 mL saturated ammonium hydroxide solution.
  • the resulting solution was diluted with diethyl ether, and washed with 1 N hydrochloric acid, then dried over magnesium sulfate, filtered and concentrated.
  • the crude aminohydantoin was purified by filtration through a 600 mL silica plug in 2 L fritted funnel, using 70% ethyl acetate in hexanes, followed by 100% ethyl acetate, as the elution solvents. This procedure yielded (2.0971g, 23%)of the desired product as a dark green semi-solid.
  • a combined solution of A (6.54g, 30mmol), 50% w/w aqueous hydroxylamine (3.6mL, ⁇ Ommol), and 6OmL ethanol was refluxed for three hours. Ethanol was removed under high vacuum to yield B (7.3g, 96.9%) as a brittle foam.
  • the reaction mixture was stirred for another one hr at rt, then added to a 0° C aqueous solution Of H 2 S (622.5mg Na 2 S + 313.OmL H 2 O + 622.5-650.0 ⁇ L acetic acid), which was prepared immediately before use.
  • the resulting mixture was stirred at room temperature for 24 hr, then made alkaline with saturated sodium bicarbonate solution until pH>7, then extracted two times with ethyl acetate.
  • the combined extracts was washed with brine, dried over magnesium sulfate and concentrated.
  • the crude material was purified by preparative TLC (40% ethylacetate/60% hexane) to provide D (98.8mg, 38.0%) as an oil residue.
  • Boc removal of E (30mg, 0.43mmol) was carried out using 0.5 ml 25%TFA/DCM at rt for 10 min.
  • the TFA amine salt was dried in vacuo and redissolved in 0.5mL tetrahydrofuran.
  • Triethylamine (0.09mmol, 12.5 ⁇ L) was added to the reaction solution, followed by acetyl chloride ( ⁇ 4.0 ⁇ L, 0.052mmol), and the reaction was then stirred at rt for 15 min.
  • the crude reaction was purified by preparative reverse phase HPLC and lyophilized to provide 15-45 (6.4mg, 23.6%) MS (MH+) 633.3, as a fine yellow powder.

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The present invention is directed to spiropiperidine compounds of formula (I) which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.

Description

TITLE OF THE INVENTION
SPIROPIPERIDINE COMPOUNDS USEFUL AS BETA-SECRETASE INHIBITORS FOR THE
TREATMENT OF ALZHEIMER'S DISEASE
CROSS-REFERENCE TO RELATED APPLICATIONS
This application claims priority under 35 U.S.C. § 119(e) of U.S. provisional application serial no. 60/618,420, filed October 13, 2004.
FIELD OF THE INVENTION The invention is directed to compounds useful as inhibitors of the beta secretase enzyme, and useful in the treatment of diseases in which the beta secretase enzyme is involved, such as Alzheimer's Disease.
BACKGROUND OF THE INVENTION Alzheimer's disease is characterized by the abnormal deposition of amyloid in the brain in the form of extra-cellular plaques and intra-cellular neurofibrillary tangles. The rate of amyloid accumulation is a combination of the rates of formation, aggregation and egress from the brain. It is generally accepted that the main constituent of amyloid plaques is the 4kD amyloid protein (βA4, also referred to as Aβ, β-protein and βAP) which is a proteolytic product of a precursor protein of much larger size. The amyloid precursor protein (APP or AβPP) has a receptor-like structure with a large ectodomain, a membrane spanning region and a short cytoplasmic tail. The Aβ domain encompasses parts of both extra-cellular and transmembrane domains of APP, thus its release implies the existence of two distinct proteolytic events to generate its NH2- and COOH-termini. At least two secretory mechanisms exist which release APP from the membrane and generate soluble, COOH-truncated forms of APP (APPS). Proteases that release APP and its fragments from the membrane are termed
"secretases." Most APP8 is released by a putative α-secretase which cleaves within the Aβ protein to release α-APPs and precludes the release of intact Aβ. A minor portion of APP5 is released by a β- secretase ("β-secretase"), which cleaves near the NH2-terminus of APP and produces COOH-terminal fragments (CTFs) which contain the whole Aβ domain. Thus, the activity of β-secretase or β-site amyloid precursor protein-cleaving enzyme ("BACE") leads to the cleavage of APP, production of Aβ, and accumulation of β amyloid plaques in the brain, which is characteristic of Alzheimer's disease (see R. N. Rosenberg, Arch. Neurol., vol. 59, Sep 2002, pp. 1367-1368; H. Fukumoto et al, Arch. Neurol., vol. 59, Sep 2002, pp. 1381-1389; J.T. Huse et al, J. Biol. Chem., vol 277, No. 18, issue of May 3, 2002, pp. 16278-16284; K.C. Chen and WJ. Howe, Biochem. Biophys. Res. Comm, vol. 292, pp 702-708, 2002). Therefore, therapeutic agents that can inhibit β-secretase or BACE may be useful for the treatment of Alzheimer's disease. The compounds of the present invention are useful for treating Alzheimer's disease by inhibiting the activity of β-secretase or BACE, thus preventing the formation of insoluble Aβ and arresting the production of Aβ.
SUMMARY OF THE INVENTION
The present invention is directed to novel spiropiperidine compounds represented by general formula (I)
Figure imgf000003_0001
(I)
or its tautomer (F)
Figure imgf000003_0002
(I1)
and pharmaceutically acceptable salts thereof, which are useful as inhibitors of the β-secretase enzyme.
The invention is also directed to pharmaceutical compositions which include an effective amount of a compound of formula (I), or pharmaceutically acceptable salts thereof, and a pharmaceutically acceptable carrier. The invention is also directed to methods of treating mammals for diseases in which the β-secretase enzyme is involved, such as Alzheimer's disease, and the use of the compounds and pharmaceutical compositions of the invention in the treatment of such diseases.
DETAILED DESCRIPTION OF THE INVENTION
In one embodiment, the present invention is directed to methods of treating mammals for diseases in which the β-secretase enzyme is involved, such as Alzheimer's disease, by administering a compound of formula (I)
Figure imgf000004_0001
or its tautomer (F)
Figure imgf000004_0002
(I1) and pharmaceutically acceptable salts thereof, and individual enantiomers and diastereomers thereof, wherein:
XisCR5orN;
X1 is CR5H or NH;
Z is O or S;
Rl is selected from the group consisting of
(1) hydrogen, (2)-Ci-6alkyl,
(3)-Co-6alkyl-C6-lOaryl,
(4) -Cθ-6 alkyl-C5-i2 heteroaryl,
(5) - Cθ-6 alkyl-C3-i2 carbocyclic, wherein the carbocyclic group optionally has from one to three ring heteroatoms selected from the group consisting of S, N and O,
(6) - O-R6 , and (7)-Co-6alkyl-Ql-R6, wherein said Rl alkyl moiety is optionally substituted with one or more
(a) -OR4
(b) halogen, (c) cyano, and
(d) -NR4R4\
said Rl carbocyclic moiety is optionally substituted with one or more (a) -OR4 (b) =O,
(c) halogen,
(d) cyano,
(e) -C(=O)-NR4R4',
(f) -C 1-6 alkyl, wherein said alkyl is optionally substituted with one or more
(I) halogen,
(II) -OH, and (III) -C6-IO aryl,
(g) -NR4-SO2-R4\
Figure imgf000005_0001
(i) -NR4-C(=O)-R4', (J) -C(=O)-OR4, (k) -NR4R4',
(1) -C(=O)-R4, and
Figure imgf000005_0002
and said Rl aryl and heteroaryl moieties are optionally substituted with one or more (a) halogen, (b) -Ci -6 alkyl,
(c) -C2-6 alkenyl,
(d) -C2-6 alkynyl,
(e) -Co-3 alkyl-C6-lO aryl,
(f) cyano, (g) -O-Co-3 alkyl-C6-lθ aryl,
(h) -O-R4, (i) -C(=O)-NR4R4', G) -NR4R4',
(k) -Q2.R7, and
(1) -Co-3 alkyl-C5-i2 heteroaryl,
Q 1 and Q2 are selected from the group consisting of
(a)_C(=o)-, (b)-C(=O)-O-,
(c) -C(=O)-NR8-,
(d) -NR8-C(=O)-, (e) -SC=O)n- ,
(I) -SI(R8R9)-; (g) -S(=O)2-R8-,
Figure imgf000006_0001
(0 -O-C(=O)-,
Figure imgf000006_0002
(k) -SO2-NR4-
Figure imgf000006_0003
(m) -NR4-
wherein n is 0, 1 or 2;
R2 is selected from the group consisting of
(1) hydrogen,
(2) -Ci-6 alkyl, (3) - Co-6 alkyl-C3_i2 carbocyclic, wherein the carbocyclic group optionally has from one to three ring heteroatoms selected from the group consisting of S,
N and O,
(^ -Co-ό alkyl-Cό-lO aryl,
(5) -Co-6 alkyl-Q3-Ci_6 alkyl, (6) -Co-6 alkyl-C5_i2 heteroaryl, wherein said R2 alkyl moiety is optionally substituted with one or more
(a) halogen
(b) cyano (c ) -C3-8 cycloalkyl
(d) -O-Cμ6 alkyl,
(e) OH, and said R.2 cycloalkyl moiety is optionally substituted with one or more -C 1-6 alkyl,
and said R.2 aryl or heteroaryl moiety is optionally substituted with one or more
(a) -ORlO,
(b) halogen,
(c) -cyano, (d) -NO2,
(e) -Q4-Ci-6 alkyl,
(f) - C 1-6 alkyl, wherein said alkyl is optionally substituted with one or more
(I) halogen, and (II) cyano,
(g) -Cθ-3 alkyl-C6-10 aryl, wherein said aryl is optionally substituted with one or more
(I) halogen, (U) -C 1.6 alkyl, (IE) -C2-6 alkenyl,
(IV) -C2-6 alkynyl, (V) -O-C 1-6 alkyl, (VI) -SO2 -Ci _6 alkyl,
(Vπ) cyano, (Vm) -C3.8 cycloalkyl,
(DC) -NO2,
(X) -SO2-NR4R4'
(h) -SO2 -CL6 alkyl, (i) -SO2 -NR4R4', (j) -NR4R4',
(k) -C3.8 cycloalkyl,
(1) -C2-6 alkenyl,
(m) -NHC(=O)-Ci-6 alkyl, wherein said alkyl is optionally substituted with one or more (I) -NR4R4'
(1I) OH
(m) -SO2R4, and (IV) -NHSO2R4, (n) -NHC(=0)-Cθ-3 alkyl-C6-10 aryl, wherein said aryl is optionally substituted with one or more (I) NR4R4', (II) OH,
(ffl) -SO2R4, and (F/)-NHSO2R4,
(o) -Cθ-3 alkyl-C5_i2 heteroaryl, wherein said heteroaryl is optionally substituted with one or more (I) halogen,
(II) -Ci-6 alkyl, and
(HI) =0,
(p) -S(=0)m-Co-6 alkyl-C6-lθ aryl, (q) -CO2-R4, (r) -C(=O)-NR4R4',
(s) -Co-6 alkyl-NR4 SO2-R4, (t) -O-C2-6 alkenyl,
and m is 0, 1 or 2;
and Q3 and Q4 are selected from the same group as Ql and Q2;
R3 is selected from the group consisting of
(1) hydrogen, (2) -Co-3 alkyl-C6-10 aryl,
(3) -Co-3 alkyl-C5-i2 heteroaryl,
(4) - Co-3 alkyl-C3_io carbocyclic, wherein the carbocyclic group optionally has from one to three ring heteroatoms selected from the group consisting of S, N and O,
wherein said R^ alkyl moiety is optionally substituted with one or more
(a) -ORl I,
(b) halogen,
(c) cyano,
(d) -C(=O)-NR4R4', (e) -Q5-C 1.6 alkyl,
(f) -Q5-H; and said R.3 cycloalkyl moiety is optionally substituted with one or more (a) -Ci_6 alkyl,
(b) -Co-3 alkyl-C6-10 aryl,
and said R.3 aryl and heteroaryl moiety is optionally substituted with one or more
(a) -ORl 2, (b) -NR4R4'; (c) halogen, (d) cyano, (f) -NO2,
(g) -Q6-R4, and
(h) -C 1-6 alkyl, wherein said alkyl is optionally substituted with one or more
(I) halogen,
(II) cyano, (TS) -Ci.6 alkyl,
(IV) -O-Ci-6 alkyl,
(V) -C3-8 cycloalkyl,
(VI) -C(=O)-Ci_6 alkyl, (i) -C2-6 alkenyl, (j) -C2-6 alkynyl,
(k) -Cθ-3 alkyl-C5-i2 heteroaryl,
(1) -O-C2-6 alkenyl,
(m) -Cθ-3 alkyl -Cβ- 10 aryl, wherein said aryl moiety is optionally substituted with one or more (I) -C 1-6 alkyl,
(II) -C2-6 alkenyl,
(IE) -C2-6 alkynyl,
(IV) halogen,
(V) cyano, (VI) -C3.8 cycloalkyl, and
(Vn) NO2,
and Rl 2 is selected from the group consisting of (I) hydrogen, (U) -C 1.6 alkyl,
(IE) -C2-6 alkenyl, (IV) -C2-6 alkynyl, (V) -C3-8 cycloalkyl, and (VI)-Co-3 alkyl-C6-10 aryl,
and said Rl 2 alkyl, alkenyl and alkynyl moiety is optionally substituted with one or more
(A) halogen,
(B) hydroxyl,
(C) cyano,
(D) -O-Ci-6 alkyl, wherein said alkyl is optionally substituted with one or more halogen,
(E) -NR4R4\
Figure imgf000010_0001
(G) -NR4-C(=O)-R4', (H) -NR4-C(=O)-OR4',
Figure imgf000010_0002
and said RlO cycloalkyl moiety is optionally substituted with one or more (A) halogen, (B) hydroxyl,
(C) -cyano,
(D) -O-Ci-6 alkyl, and
(E) -C 1-6 alkyl, wherein said alkyl is optionally substituted one or more halogen;
and said Rl2 aryl moiety is optionally substituted with one or more
(A) halogen,
(B) cyano, (C) -O-C 1-6 alkyl, and
(D) -C 1-6 alkyl, wherein said alkyl is optionally substituted one or more halogen;
Q5 and Q6 are selected from the same group as Ql and Q2;
R4 and R4' are selected from the group consisting of (1) hydrogen, (2) -C 1-8 alkyl, wherein said alkyl is optionally substituted with
(a) halogen,
(b) -C3-8 cycloalkyl (c) -CO2C 1-6 alkyl (d) -OC 1-6 alkyl, wherein said alkyl is optionally substituted with one or more
(I) halogen, or
(II) cyano,
(3) -C2-8 alkenyl, and (4) -Co-3 alkyl-C6-ioaryl;
R5 is selected from the group csoonsisting of (1) hydrogen, (2) -C 1-6 alkyl,
(3) halogen, and (4) -CO2-R4,
R6, R7, R8; R9; RlO and Rl 1 are independently selected from the group consisting of: (1) hydrogen, (2) -Ci.6 alkyl, (3) -C3-8 cycloalkyl,
(4) -Co-3 alkyl-C6-lO aryl, wherein said alkyl is optionally substituted with one or more
(A) halogen,
(B) hydroxyl, (C) cyano,
(D) -O-Ci-6 alkyl, wherein said alkyl is optionally substituted with one or more halogen, and said cycloalkyl and aryl are optionally substituted with one or more (A) halogen, (B) hydroxyl,
(C) cyano,
(D) -O-Ci-6 alkyl, and
(E) -C 1-6 alkyl, wherein said alkyl is optionally substituted one or more halogen. The invention is also directed to pharmaceutical compositions which include an effective amount of a compound of formula (I), or pharmaceutically acceptable salts thereof, and a pharmaceutically acceptable carrier. The present invention is further directed to a method for the manufacture of a medicament or a composition for inhibiting β-secretase enzyme activity in humans and animals. The invention is also directed to a method for the manufacture of a medicament for the treatment of Alzheimer's Disease in humans, comprising combining a compound of the present invention with a pharmaceutical carrier or diluent.
In another embodiment, the invention is directed to novel spiropiperidine compounds of formula (I) above, provided that when X is N; Z is O; Rl is unsubstituted cyclohexyl; and R.2 is unsubstituted phenyl, then R^ is not unsubstituted benzyl.
In a preferred embodiment, Z is O. In one sub-genus of this embodiment, the invention is directed to compounds of formula (I) wherein X is N and X1 is NH . In another embodiment, X is CR^, wherein R5 is preferably hydrogen, and X' is CR^H, wherein R5 is preferably hydrogen.
In another embodiment of the compounds of formula (I), Rl is -Ci-6 alkyl or -Cθ-3 alkyl-C3_i2 carbocyclic wherein said alkyl or carbocyclic is optionally substituted with one or more (a) -OR4,
(b) halogen,
(c) cyano, (d) -NR4R4', and (e) -C 1-6 alkyl. Preferred Rl carbocyclic groups include-Cβ.g carbocyclic groups, including cyclobutyl, cyclopentyl, cyclohexyl, morpholinyl, tetrahydropyran and pyrrolidinyl.
In another embodiment of the compounds of formula (I), Rl is -Cθ-3 alkyl -C6-10 aryl> preferably phenyl or benzyl. Preferably, the Rl aryl moiety is optionally substituted with one or more
(a) halogen, or (b) -C 1-6 alkyl.
In another embodiment, Rl is Cθ-3 alkyl-C5-i2 heteroaryl, wherein the heteroaryl moiety is optionally substituted with one or more
(a) halogen, or
(b) -C 1-6 alkyl. Preferred Rl heteroaryl groups include pyridinyl, thienyl, furanyl and imidazolyl.
In another embodiment, R2 is selected from the group consisting of (1) -Ci_6 alkyl,
(2) -Cθ-6 alkyl-C3-8 carbocyclic, and
(3) -Cθ-3 alkyl~Cό-10 aryl, which are optionally substituted as described above. Preferably, R2 is selected from -Ci-6 alkyl, phenyl, benzyl, or -Cθ-3 alkyl-C3_8 carbocyclic, optionally substituted as described above. When R2 is -Cθ-3 alkyl-C6-lO aryl, preferably the aryl moiety is optionally substituted with one or more
(a) -ORlO,
(b) halogen, (c) -C 1-6 alkyl, wherein said alkyl is optionally substituted with one or more
(I) halogen,
(II) cyano,
(ffl) -C 1.6 alkyl, (IV) -O-Ci-6 alkyl, (V) -C3-8 cycloalkyl,
(VI) -C(=O) -Ci-6 alkyl, (d) -Co-3 alkyl-C6-lO aryl, wherein said aryl moiety is optionally substituted with one or more
(I) -Ci-6 alkyl, (H) -C2-6 alkenyl,
(ffl) -C2-6 alkynyl, (IV) halogen, (V) cyano, (VI) -C3-8 cycloalkyl, (Vn) NO2,
(e) -S02-Ci_6 alkyl, and
(f) -NHC(=O) -C 1-6 alkyl, wherein said alkyl is optionally substituted withone or more
(I) -NR4R4', and (H) -OH.
Within this embodiment, there is a sub-genus of compounds of formula (II)
Figure imgf000013_0001
or its tautomer (II')
Figure imgf000014_0001
(M1)
and pharmaceutically acceptable salts thereof, and individual enantiomers and diasteromers thereof, wherein X, X', Z, Rl and R.3 are as defined above, and Rl 5 is selected from the group consisting of (a) -ORlO, (b) halogen,
(c) -cyano, (d) -Q4-Ci-6 alkyl,
(e) - C 1-6 alkyl, wherein said alkyl is optionally substituted with one or more (I) halogen, and
(II) cyano,
(f) -Cθ-3 alkyl-C6-io aryl> wherein said aryl is optionally substituted with one or more
(I) halogen, (U) -Ci.6 alkyl,
(V) -O-Ci-6 alkyl,
(VI) -SO2 -C 1.6 alkyl,
(VII) cyano,
(VIE) -C3.8 cycloalkyl, (X) -SO2-NR4R4'
(g) -SO2 -C 1-6 alkyl, (h) -SO2 -NR4R4', (i) -C3-8 cycloalkyl,
(j) -NHC(=O)-Ci-6 alkyl, wherein said alkyl is optionally substituted with one or more
(I) -NR4R4' (π) OH
(HI) -SO2R4, and (IV) -NHSO2R4, (k) -Co-3 alkyl-C5-i2 heteroaryl, wherein said heteroaryl is optionally substituted with one or more
(I) halogen,
(II) -Ci-6 alkyl, and (UI) =O,
(1) -S(=0)m-Co-6 alkyl-Cβ-10 aiyl,
(m) -CO2-R4,
(n) -C(=O)-NR4R4;,
(0) -Co-6 alkyl-NR4 SO2-R4. Within this sub-genus of compounds of formula (II), R^ is preferably
(1) -Co-3 alkyl-C6-10 aryl, or
(2) -CO-3 alkyl-C5_i2 heteroaryl, and said aryl and heteroaryl are optionally substituted with one or more (a) -ORl2 Cb) -NR4R4',
(c) halogen,
(d) cyano, (f) -NO2, (g) -Q6- R4 and (h) -C 1-6 alkyl, wherein said alkyl is optionally substituted with one or more
(1) halogen, (II) cyano,
(III) -C 1-6 alkyl, (IV) -O-C 1.6 alkyl, (V) -C3-8 cycloalkyl,
(VI) -CC=O)-C1-O alkyl, (i) -C2-6 alkenyl, (j) -C2-6 alkynyl, (k) -Cθ-3 alkyl-C5-i2 heteroaryl, (1) -CO-3 alkyl-Cβ-lO aryl, and said aryl moiety is optionally substituted with one or more
(I) -C 1-6 alkyl, (II) -C2-6 alkenyl, CO) -C2-6 alkynyl, (IV) halogen,
(V) cyano, (VI) -C3-8 cycloalkyl, and (VII) NO2. When R3 is -Cθ-3 alkyl-heteroaryl, preferably the heteroaryl is selected from the group consisting of pyridyl, pyrrolyl, furanyl, thienyl, dihydrobenzofuran, indolyl, isoquinolinyl, imidazolyl, isoxazolyl, quinolinyl, tetrahydroquinolinyl, dihydroindolyl and pyridyl. Preferably, when R.3 is -Cθ-3 alkyl- heteroaryl, the heteroaryl is substituted with one or more (a) -ORl2,
(b) halogen,
(c) cyano,
(d) -C(=O)-NR4R4',
(e) -Ci-6 alkyl, and (I) -NR4R4\
In preferred embodiments of compounds of formula (II), X is N and Z is O. In another sub-genus of the embodiment of compounds of formula (I), the invention is directed to compounds of formula (III):
Figure imgf000016_0001
(III)
or its tautomer (EI')
Figure imgf000016_0002
(IN1) and pharmaceutically acceptable salts thereof, and individual enantiomers and diastereomers thereof, wherein X, X1, Z, Rl, and R.2 are as defined above, and Rl 6 is selected from the group consisting of
(a) -ORl2, (b) NR4R4',
(c) halogen,
(d) cyano,
(f) -NO2,
(g) -Q6- R4 and (h) -C 1-6 alkyl, wherein said alkyl is optionally substituted with one or more
(I) halogen,
(II) cyano,
(HI) -Ci-6 alkyl, (IV) -O-C 1.6 alkyl, (V) -C3.8 cycloalkyl,
(VI) -C(=O) -C 1-6 alkyl, (i) -C2-6 alkenyl, 0) -C2-6 alkynyl,
(k) -Cθ-3 alkyl-C5-i2 heteroaryl, and (1) -Cθ-3 alkyl-C6-10 aryl> wherein said aryl moiety is optionally substituted with one or more (I) -Ci_6 alkyl, (U) -C2-6 alkenyl, (IH) -C2-6 alkynyl, (IV) halogen,
(V) cyano,
(VI) -C3-8 cycloalkyl, and (VU) Nθ2-
In preferred embodiments of compounds of formula (TS), X is N and Z is O. As used herein, the term "alkyl," by itself or as part of another substituent, means a saturated straight or branched chain hydrocarbon radical having the number of carbon atoms designated (e.g., C\. 10 alkyl means an alkyl group having from one to ten carbon atoms). Preferred alkyl groups for use in the invention are Ci -6 alkyl groups, having from one to six carbon atoms. Exemplary alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, pentyl, hexyl, and the like.Co alkyl means a bond.
As used herein, the term "alkoxy," by itself or as part of another substituent, means the group - O- alkyl, wherein alkyl is defined above, having the number of carbon atoms designated (e.g., Ci-M) alkoxy means an alkoxy group having from one to ten carbon atoms. Preferred alkoxy groups for use in the invention are C\.(, alkoxy groups, having from one to six carbon atoms. Exemplary preferred alkoxy groups include methoxy, ethoxy, propoxy, butoxy, sec-butoxy and pentoxy. Especially preferred alkoxy groups are Ci .3 alkoxy. As used herein, the term "alkenyl," by itself or as part of another substituent, means a straight or branched chain hydrocarbon radical having a single carbon-carbon double bond and the number of carbon atoms designated (e.g., C2-10 alkenyl means an alkenyl group having from two to ten carbon atoms). Preferred alkenyl groups for use in the invention are C2-6 alkenyl groups, having from two to six carbon atoms. Exemplary alkenyl groups include ethenyl and propenyl. As used herein, the term "alkynyl," by itself or as part of another substituent, means a straight or branched chain hydrocarbon radical having a single carbon-carbon triple bond and the number of carbon atoms designated (e.g., C2-10 alkynyl means an alkynyl group having from two to ten carbon atoms). Preferred alkynyl groups for use in the invention are C2-6 alkynyl groups, having from two to six carbon atoms. Exemplary alkynyl groups include ethynyl and propynyl. As used herein, the term "cycloalkyl," by itself or as part of another substituent, means a saturated cyclic hydrocarbon radical having the number of carbon atoms designated (e.g., C3-12 cycloalkyl means a cycloalkyl group having from three to twelve carbon atoms). The term cycloalkyl as used herein includes mono-, bi- and tricyclic saturated carbocycles, as well as bridged and fused ring carbocycles, such as spiro fused ring systems. Preferred cycloalkyl groups for use in the invention are monocyclic C3.8 cycloalkyl groups, having from three to eight carbon atoms. Exemplary monocyclic cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and the like. Exemplary bridged cycloalkyl groups include adamantly and norbornyl. Exemplary fused cycloalkyl groups include decahydronaphthalene.
As used herein, the term "carbocyclic," by itself or as part of another substituent, means a cycloalkyl group as defined above, or a non-aromatic heterocyclic group. A non-aromatic heterocyclic group, by itself or as part of another substituent, means a cycloalkyl group as defined above in which one or more of the ring carbon atoms is replaced with a heteroatom (such as N, S or O). Suitable non- aromatic heterocyclic groups for use in the invention include piperidinyl, piperazinyl, morpholinyl, tetrahydrofuranyl, tetrahydrothienyl, pyrrolidinyl, pyrazolidinyl, azetidinyl, tetrahydropyranyl and imidazolildinyl. Preferred non-aromatic heterocyclic groups are piperidinyl, piperazinyl, tetrahydrofuranyl, tetrahydropyranyl, pyrrolidinyl, morpholinyl and azetidinyl.
When a non-aromatic heterocyclic group as defined herein is substituted, the substituent may be bonded to a ring carbon atom of the heterocyclic group, or on a ring heteroatom (i.e., a nitrogen, oxygen or sulfur), which has a valence which permits substitution. Preferably, the substituent is bonded to a ring carbon atom. Similarly, when a non-aromatic heterocyclic group is defined as a substituent herein, the point of attachment may be at a ring carbon atom of the heterocyclic group or on a ring heteroatom (i.e., a nitrogen, oxygen or sulfur), which has a valence which permits substitution. Preferably, the attachment is at a ring carbon atom.
As used herein, the term "aryl," by itself or as part of another substituent, means an aromatic cyclic hydrocarbon radical having the number of carbon atoms designated (e.g., Cβ-lO aryl means an aryl group having from six to ten carbons atoms). The term "aryl" includes multiple ring systems as well as single ring systems. Preferred aryl groups for use in the invention include phenyl and naphthyl.
The term "aryl" also includes fused cyclic hydrocarbon rings which are partially aromatic (i.e., one of the fused rings is aromatic and the other is non-aromatic). An exemplary aryl group which is partially aromatic is indanyl. The term "halo" or "halogen" includes fluoro, chloro, bromo and iodo.
As used herein, the term "heteroaryl," by itself or as part of another substituent, means an aromatic cyclic group having at least one ring heteroatom (O, N or S). ). The term "heteroaryl" includes multiple ring systems as well as single ring systems. Exemplary heteroaryl groups for use in the invention include furyl, pyranyl, benzofuranyl, isobenzofuranyl, chromenyl, thienyl, benzothiophenyl, pyrrolyl, pyrazolyl, imidazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolyl, benzimidazolyl, quinolinyl, isoquinolinyl, tetrazolyl, indazolyl, napthyridinyl, triazolyl, oxazolyl, oxadiazolyl, thiazolyl, thiadiazolyl, isoxazolyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl and dihydroindolyl.
The term "heteroaryl" also includes fused aromatic cyclic groups which are partially aromatic (i.e., one of the fused rings is aromatic and the other is non-aromatic). Exemplary heteroaryl groups which are partially aromatic include tetrahydroquinolyl, dihydrobenzofuran and dihydroindolyl.
When a heteroaryl group as defined herein is substituted, the substituent may be bonded to a ring carbon atom of the heteroaryl group, or on a ring heteroatom (i.e., a nitrogen, oxygen or sulfur), which has a valence which permits substitution. Preferably, the substituent is bonded to a ring carbon atom. Similarly, when a heteroaryl group is defined as a substituent herein, the point of attachment may be at a ring carbon atom of the heteroaryl group, or on a ring heteroatom (i.e., a nitrogen, oxygen or sulfur), which has a valence which permits attachment. Preferably, the attachment is at a ring carbon atom.
Some of the compounds of the instant invention have at least one asymmetric center. Additional asymmetric centers may be present depending upon the nature of the various substituents on the molecule. Compounds with asymmetric centers give rise to enantiomers (optical isomers), diastereomers (configurational isomers) or both, and it is intended that all of the possible enantiomers and diastereomers in mixtures and as pure or partially purified compounds are included within the scope of this invention. The present invention is meant to encompass all such isomeric forms of these compounds.
As used herein, the term "tautomer" refers to a compound which exists in an equilibrium mixture and which can be isolated in either form and react through either form. The tatutomers may differ in linkage, bond, or connections between atoms, and the position or distribution of the atoms in the molecule. One common form of tautomerism occurs when an enamine group, for example a group R2C=CR-NHR, exists in equilibrium with its tautomeric imine form, for example R2CH-CR=NR. In the context of this invention, compounds of formula (I) may be present in the enamine form depicted above, or in the tautomeric imine form (F), as shown below:
Figure imgf000020_0001
(I1) and pharmaceutically acceptable salts thereof, and individual enantiomers and diastereomers thereof, wherein X', Z, Rl, R2 and R^ are as defined above.
Additionally, compounds of formula (II) may be present in the enamine form depicted above, or in the tautomeric imine form (II'), as shown below:
Figure imgf000020_0002
(H1) and pharmaceutically acceptable salts thereof, and individual enantiomers and diastereomers thereof, wherein X', Z, Rl, R^ and Rl5 are as defined above.
Compounds of formula (HI) may be present in the enamine form depicted above, or in the tautomeric imine form (HI'), as shown below:
Figure imgf000021_0001
(III1)
and pharmaceutically acceptable salts thereof, and individual enantiomers and diastereomers thereof, wherein X', Z, Rl, R2 and Rl6 are as defined above.
Compounds described herein may contain one or more double bonds, and may thus give rise to cisltrans isomers as well as other conformational isomers. The present invention includes all such possible isomers as well as mixtures of such isomers.
Formulas (I) to (HI) are shown above without a definite stereochemistry at certain positions. The present invention includes all stereoisomers of Formulas (I) to (III) and pharmaceutically acceptable salts thereof. The independent syntheses of the enantiomerically or diastereomerically enriched compounds, or their chromatographic separations, may be achieved as known in the art by appropriate modification of the methodology disclosed herein. Their absolute stereochemistry may be determined by the x-ray crystallography of crystalline products or crystalline intermediates that are derivatized, if necessary, with a reagent containing an asymmetric center of known absolute configuration. If desired, racemic mixtures of the compounds may be separated so that the individual enantiomers are isolated. The separation can be carried out by methods well known in the art, such as the coupling of a racemic mixture of compounds to an enantiomerically pure compound to form a diastereomeric mixture, followed by separation of the individual diastereomers by standard methods, such as fractional crystallization or chromatography. The coupling reaction is often the formation of salts using an enantiomerically pure acid or base. The diastereomeric derivatives may then be converted to the pure enantiomers by cleavage of the added chiral residue. The racemic mixture of the compounds can also be separated directly by chromatographic methods using chiral stationary phases, which methods are well known in the art.
Alternatively, any enantiomer of a compound may be obtained by stereoselective synthesis using optically pure starting materials or reagents of known configuration by methods well known in the art.
The compounds claimed in this invention can be prepared according to the following general procedure methods (Schemes 1 and 2). Scheme 1 below depicts an Ugi four-component coupling reaction between a piperidone derivative, amine, isonitrile, and cyanate, which assembles the core structure 1-1. Further elaboration of 1-1 is possible, for example, removal of a temporary R.3 group to give 1-2, followed by alkylation with a different R.3 to give new structures 1-3.
Scheme 1
Figure imgf000022_0001
Alternatively, compounds of the invention where X=C may be prepared as shown in Scheme 2, below. Strecker reaction on a suitably configured piperidone gives nitrile 2-1 which can be hydrolyzed and esterifϊed to 2-2. Acylation to 2-3 and ring closure to 2-4 followed by condensation with amines gives compounds 2-5.
Scheme 2
Figure imgf000023_0001
Figure imgf000023_0002
Specific embodiments of the compounds of the invention, and methods of making them, are described in Examples (3-1)- (15-45) herein, and in Schemes 3-15.
The term "substantially pure" means that the isolated material is at least 90% pure, and preferably 95% pure, and even more preferably 99% pure as assayed by analytical techniques known in the art.
The term "pharmaceutically acceptable salts" refers to salts prepared from pharmaceutically acceptable non-toxic bases or acids including inorganic or organic bases and inorganic or organic acids. The compounds of the invention may be mono, di or tris salts, depending on the number of acid functionalities present in the free base form of the compound. Free bases and salts derived from inorganic bases include aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic salts, manganous, potassium, sodium, zinc, and the like. Particularly preferred are the ammonium, calcium, magnesium, potassium, and sodium salts. Salts in the solid form may exist in more than one crystal structure, and may also be in the form of hydrates. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, and basic ion exchange resins, such as arginine, betaine, caffeine, choline, N,N'-dibenzylethylene-diamine, diethylamine, 2- diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethyl-morpholine, N- ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, and the like. When the compound of the present invention is basic, salts may be prepared from pharmaceutically acceptable non-toxic acids, including inorganic and organic acids. Such acids include acetic, trifluoroacetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethanesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, p-toluenesulfonic acid, and the like. Particularly preferred are citric, hydrobromic, hydrochloric, trifluoroacetic, maleic, phosphoric, sulfuric, fumaric, and tartaric acids.
The present invention is directed to the use of the compounds of formulas (I) to (Hl) disclosed herein as inhibitors of β-secretase enzyme activity or β-site amyloid precursor protein-cleaving enzyme ("BACE") activity, in a patient or subject such as a mammal in need of such inhibition, comprising the administration of an effective amount of the compound. The terms "β-secretase enzyme," "β-site amyloid precursor protein-cleaving enzyme," and "BACE" are used interchangeably in this specification. In addition to humans, a variety of other mammals can be treated according to the method of the present invention.
The compounds of the present invention have utility in treating, ameliorating, controlling or reducing the risk of Alzheimer's disease. For example, the compounds may be useful for the prevention of dementia of the Alzheimer's type, as well as for the treatment of early stage, intermediate stage or late stage dementia of the Alzheimer's type. The compounds may also be useful in treating, ameliorating, controlling or reducing the risk of diseases mediated by abnormal cleavage of amyloid precursor protein (also referred to as APP), and other conditions that may be treated or prevented by inhibition of β- secretase. Such conditions include mild cognitive impairment, Trisomy 21 (Down Syndrome), cerebral amyloid angiopathy, degenerative dementia, Hereditary Cerebral Hemorrhage with Amyloidosis of the Dutch-Type (HCHWA-D), Creutzfeld- Jakob disease, prion disorders, amyotrophic lateral sclerosis, progressive supranuclear palsy, head trauma, stroke, pancreatitis, inclusion body myositis, other peripheral amyloidoses, diabetes and atherosclerosis.
The subject or patient to whom the compounds of the present invention is administered is generally a human being, male or female, in whom inhibition of β-secretase enzyme activity is desired, but may also encompass other mammals, such as dogs, cats, mice, rats, cattle, horses, sheep, rabbits, monkeys, chimpanzees or other apes or primates, for which inhibition of β-secretase enzyme activity or treatment of the above noted disorders is desired.
The compounds of the present invention may be used in combination with one or more other drugs in the treatment of diseases or conditions for which the compounds of the present invention have utility, where the combination of the drugs together are safer or more effective than either drug alone. Additionally, the compounds of the present invention may be used in combination with one or more other drugs that treat, prevent, control, ameliorate, or reduce the risk of side effects or toxicity of the compounds of the present invention. Such other drugs may be administered, by a route and in an amount commonly used therefor, contemporaneously or sequentially with the compounds of the present invention. Accordingly, the pharmaceutical compositions of the present invention include those that contain one or more other active ingredients, in addition to the compounds of the present invention. The combinations may be administered as part of a unit dosage form combination product, or as a kit or treatment protocol wherein one or more additional drugs are administered in separate dosage forms as part of a treatment regimen.
Examples of combinations of the compounds of the present invention with other drugs in either unit dose or kit form include combinations with anti-Alzheimer's agents, for example other beta-secretase inhibitors or gamma-secretase inhibitors; tau phpsphorylation inhibitors; Ml receptor positive allosteric modulators; blockers of Aβ oligomer formation; 5-HT modulators, such as PRX-03140, GSK 742467, SGS-518, FK-962, SL-65.0155, SRA-333 and xaliproden; p25/CDK5 inhibitors; NK1/NK3 receptor antagonists; COX-2 inhibitors; HMG-CoA reductase inhibitors; NSAIDs including ibuprofen; vitamin E; anti-amyloid antibodies, including anti -amyloid humanized monoclonal antibodies; anti-inflammatory compounds such as (R)-flurbiprofen, nitroflurbiprofen, rosiglitazone, ND-1251, VP-025, HT-0712 and EHT-202; CB-I receptor antagonists or CB-I receptor inverse agonists; antibiotics such as doxycycline and rifampin; N-methyl-D-aspartate (NMDA) receptor antagonists, such as memantine and neramexane; cholinesterase inhibitors such as galantamine, rivastigmine, donepezil, tacrine, phenserine, ladostigil and ABT-089; growth hormone secretagogues such as ibutamoren, ibutamoren mesylate, and capromorelin; histamine H3 antagonists such as ABT-834, ABT 829 and GSK 189254; AMPA agonists or AMPA modulators, such as CX-717, LY 451395 and S-18986; PDE IV inhibitors; GABAA inverse agonists; neuronal nicotinic agonists; selective Ml agonists; microtobubule affinity regulating kinase (MARK) ligands; P-450 inhibitors, such as ritonavir, or other drugs that affect receptors or enzymes that either increase the efficacy, safety, convenience, or reduce unwanted side effects or toxicity of the compounds of the present invention. The foregoing list of combinations is illustrative only and not intended to be limiting in any way.
The term "composition" as used herein is intended to encompass a product comprising specified ingredients in predetermined amounts or proportions, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts. This term in relation to pharmaceutical compositions is intended to encompass a product comprising one or more active ingredients, and an optional carrier comprising inert ingredients, as well as any product which results, directly or indirectly, from combination, complexation or aggregation of any two or more of the ingredients, or from dissociation of one or more of the ingredients, or from other types of reactions or interactions of one or more of the ingredients.
In general, pharmaceutical compositions are prepared by uniformly and intimately bringing the active ingredient into association with a liquid carrier or a finely divided solid carrier or both, and then, if necessary, shaping the product into the desired formulation. In the pharmaceutical composition the active compound, which is a compound of formulas (I) to (HI), is included in an amount sufficient to produce the desired effect upon the process or condition of diseases. Accordingly, the pharmaceutical compositions of the present invention encompass any composition made by admixing a compound of the present invention and a pharmaceutically acceptable carrier. The carrier may take a wide variety of forms depending on the form of preparation desired for administration, e.g., oral or parenteral (including intravenous). Thus, the pharmaceutical compositions of the present invention can be presented as discrete units suitable for oral administration such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient. Further, the compositions can be presented as a powder, as granules, as a solution, as a suspension in an aqueous liquid, as a non-aqueous liquid, as an oil-in-water emulsion or as a water-in-oil liquid emulsion. In addition to the common dosage forms set out above, the compounds represented by Formulas (I) to (VII), or pharmaceutically acceptable salts thereof, may also be administered by controlled release means and/or delivery devices. Pharmaceutical compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets may contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets. These excipients may be, for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example magnesium stearate, stearic acid or talc. The tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.
A tablet containing the composition of this invention may be prepared by compression or molding, optionally with one or more accessory ingredients or adjuvants. Compressed tablets may be prepared by compressing, in a suitable machine, the active ingredient in a free-flowing form such as powder or granules, optionally mixed with a binder, lubricant, inert diluent, surface active or dispersing agent. Molded tablets may be made by molding in a suitable machine, a mixture of the powdered compound moistened with an inert liquid diluent. Each tablet preferably contains from about 0.1 mg to about 500 mg of the active ingredient and each cachet or capsule preferably containing from about 0.1 mg to about 500 mg of the active ingredient.
Compositions for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin, or olive oil.
Other pharmaceutical compositions include aqueous suspensions, which contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions. In addition, oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin. Oily suspensions may also contain various excipients. The pharmaceutical compositions of the invention may also be in the form of oil-in-water emulsions, which may also contain excipients such as sweetening and flavoring agents.
The pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleaginous suspension, or in the form of sterile powders for the extemporaneous preparation of such sterile injectable solutions or dispersions. In all cases, the final injectable form must be sterile and must be effectively fluid for easy syringability. The pharmaceutical compositions must be stable under the conditions of manufacture and storage; thus, preferably should be preserved against the contaminating action of microorganisms such as bacteria and fungi.
Pharmaceutical compositions of the present invention can be in a form suitable for topical use such as, for example, an aerosol, cream, ointment, lotion, dusting powder, or the like. Further, the compositions can be in a form suitable for use in transdermal devices. These formulations may be prepared via conventional processing methods. As an example, a cream or ointment is prepared by mixing hydrophilic material and water, together with about 5wt% to about 10wt% of the compound, to produce a cream or ointment having a desired consistency. Pharmaceutical compositions of this invention can also be in a form suitable for rectal administration wherein the carrier is a solid. It is preferable that the mixture forms unit dose suppositories. Suitable carriers include cocoa butter and other materials commonly used in the art.
By "pharmaceutically acceptable" it is meant the carrier, diluent or excipient must be compatible with the other ingredients of the formulation and not deleterious to the recipient thereof. The terms "administration of or "administering a" compound should be understood to mean providing a compound of the invention to the individual in need of treatment in a form that can be introduced into that individual's body in a therapeutically useful form and therapeutically useful amount, including, but not limited to: oral dosage forms, such as tablets, capsules, syrups, suspensions, and the like; injectable dosage forms, such as IV, IM, or IP, and the like; transdermal dosage forms, including creams, jellies, powders, or patches; buccal dosage forms; inhalation powders, sprays, suspensions, and the like; and rectal suppositories.
The terms "effective amount" or "therapeutically effective amount" means the amount of the subject compound that will elicit the biological or medical response of a tissue, system, animal or human that is being sought by the researcher, veterinarian, medical doctor or other clinician. As used herein, the term "treatment" or "treating" means any administration of a compound of the present invention and includes (1) inhibiting the disease in an animal that is experiencing or displaying the pathology or symptomatology of the diseased (i.e., arresting further development of the pathology and/or symptomatology), or (2) ameliorating the disease in an animal that is experiencing or displaying the pathology or symptomatology of the diseased (i.e., reversing the pathology and/or symptomatology). The term "controlling" includes preventing treating, eradicating, ameliorating or otherwise reducing the severity of the condition being controlled. The compositions containing compounds of the present invention may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. The term "unit dosage form" is taken to mean a single dose wherein all active and inactive ingredients are combined in a suitable system, such that the patient or person administering the drug to the patient can open a single container or package with the entire dose contained therein, and does not have to mix any components together from two or more containers or packages. Typical examples of unit dosage forms are tablets or capsules for oral administration, single dose vials for injection, or suppositories for rectal administration. This list of unit dosage forms is not intended to be limiting in any way, but merely to represent typical examples of unit dosage forms. The compositions containing compounds of the present invention may conveniently be presented as a kit, whereby two or more components, which may be active or inactive ingredients, carriers, diluents, and the like, are provided with instructions for preparation of the actual dosage form by the patient or person adminstering the drug to the patient. Such kits may be provided with all necessary materials and ingredients contained therein, or they may contain instructions for using or making materials or components that must be obtained independently by the patient or person administering the drug to the patient.
When treating, ameliorating, controlling or reducing the risk of Alzheimer's disease or other diseases for which compounds of the present invention are indicated, generally satisfactory results are obtained when the compounds of the present invention are administered at a daily dosage of from about 0.1 mg to about 100 mg per kg of animal body weight, preferably given as a single daily dose or in divided doses two to six times a day, or in sustained release form. The total daily dosage is from about 1.0 mg to about 2000 mg, preferably from about 0.1 mg to about 20 mg per kg of body weight. In the case of a 70 kg adult human, the total daily dose will generally be from about 7 mg to about 1,400 mg. This dosage regimen may be adjusted to provide the optimal therapeutic response. The compounds may be administered on a regimen of 1 to 4 times per day, preferably once or twice per day.
The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. For example, a formulation intended for the oral administration to humans may conveniently contain from about 0.005 mg to about 2.5 g of active agent, compounded with an appropriate and convenient amount of carrier materia. Unit dosage forms will generally contain between from about 0.005 mg to about 1000 mg of the active ingredient, typically 0.005, 0.01 mg, 0.05 mg, 0.25 mg, 1 mg, 5 mg, 25 mg, 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 800 mg or 1000 mg, administered once, twice or three times a day.
It will be understood, however, that the specific dose level and frequency of dosage for any particular patient may be varied and will depend upon a variety of factors including the activity of the specific compound employed, the metabolic stability and length of action of that compound, the age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular condition, and the host undergoing therapy.
The utility of the compounds in accordance with the present invention as inhibitors of β- secretase enzyme activity may be demonstrated by methodology known in the art. Enzyme inhibition is determined as follows.
ECL Assay: A homogeneous end point electrochemiluminescence (ECL) assay is employed using a biotinylated BACE substrate. The Km of the substrate is greater than 100 μM and can not be determined due to the limit of solubility of the substrate. A typical reaction contains approximately 0.1 nM enzyme, 0.25 μM of the substrate, and buffer (50 mM NaOAc, pH 4.5 or 6.5, 0.1 mg/ml BSA, 0.2% CHAPS, 15 mM EDTA and 1 mM deferoxamine) in a total reaction volume of 100 μl. The reaction proceeds for 30 min and is then stopped by the addition of 25 μL of 1 M Tris-HCl, pH 8.0. The resulting enzymatic product is assayed by adding a ruthenylated antibody which specifically recognizes the C- terminal residue of the product. Streptavidin coated magnetic beads are added into the solution and the samples are subjected to M-384 (Igen Inc., Gaithersburg, MD) analysis. Under these conditions, less than 10% of substrate is processed by BACE 1. The enzyme used in these studies is soluble
(transmembrane domain and cytoplasmic extension excluded) human protein produced in a baculovirus expression system. To measure the inhibitory potency for compounds, 12 concentrations of inhibitors are prepared starting from 100 μM with three fold series dilution. Solutions of the inhibitor in DMSO are included in the reaction mixture (final DMSO concentration is 10 %). All experiments are conducted at rt using the standard reaction conditions described above. To determine the IC50 of the compound, a four parameter equation is used for curve fitting. The errors in reproducing the dissociation constants are typically less than two-fold.
HPLC assay: A homogeneous end point HPLC assay is used with the substrate (coumarin-CO- REVNFEVEFR), which is cleaved by BACE 1 to release the N-terminal fragment attached with coumarin. The Km of the substrate is greater than 100 μM and can not be determined due to the limit of solubility of the substrate. A typical reaction contains approximately 2 nM enzyme, 1.0 μM of the substrate, and buffer (50 mM NaOAc, pH 4.5 or 6.5, 0.1 mg/ml BSA, 0.2% CHAPS, 15 mM EDTA and 1 mM deferoxamine) in a total reaction volume of 100 μl. The reaction is proceeded for 30 min and the reaction is stopped by the addition of 25 μL of 1 M Tris-HCl, pH 8.0. The resulting reaction mixture is loaded on the HPLC and the product is separated from substrate with 5 min linear gradient. Under these conditions, less than 10% of substrate is processed by BACE 1. The enzyme used in these studies is soluble (transmembrane domain and cytoplasmic extension excluded) human protein produced in a baculovirus expression system. To measure the inhibitory potency for compounds, 12 concentrations of inhibitors are prepared, and the concentration rage is dependent on the potency predicted by ECL. Solutions of inhibitor in DMSO are included in the reaction mixture (final DMSO concentration is 10 %). All experiments are conducted at rt using the standard reaction conditions described above. To determine the IC50 of the compound, four parameters equation is employed for curve fitting. The errors in reproducing the dissociation constants are typically less than two-fold.
In particular, the compounds of the following examples had activity in inhibiting the beta- secretase enzyme in the aforementioned assays, generally with an IC50 from about 1 nM to 500 μM, preferably 1 nM to 100 μM. Such a result is indicative of the intrinsic activity of the compounds in use as inhibitors of beta-secretase enzyme activity.
Several methods for preparing the compounds of this invention are illustrated in the schemes and examples herein. Starting materials are made according to procedures known in the art or as illustrated herein. The following examples are provided so that the invention might be more fully understood. These examples are illustrative only and should not be construed as limiting the invention in any way.
The following abbreviations are used throughout the text:
Me: methyl
Et: ethyl t-Bu: tert-buty\ Ar: aryl
Ph: phenyl
Bn: benzyl
Ac: acetyl
THF: tetrahydrofuran DMSO: dimethylsulfoxide
EDTA: ethylene diamine tetraacetic acid
Boc: tert-butyloxy carbonyl
CHAPS: 3-[(3-cholamidopropyl)dimethylammonio]-2-hydroxy-l-propanesulfonate
DCM: dichloromethane DCE: dichloroethane
BSA: bovine serum albumin
TFA: trifluoracetic acid
DMF: N,N-dimethylformamide
TMSCN: trimethylsilylnirrile PS-DIEA: N5N (diisopropyl) aminomethylpolystyrene
DEA: diethylamine
DMA: N5N dimethylacetamide
LDA: lithium diisopropylamide
DEAD: diethylazole dicarboxylate rt: room temperature
HPLC: high performance liquid chromatography A representative procedure for the Ugi four-component coupling, as depicted in Scheme 3 below, can be used in the synthesis of various compounds of the invention, including Examples (3-1) - (3-46) below. Examples (3-1) - (3-46) are depicted below in enamine form, but may also exist in tautomeric imine form, as described above.
Scheme 3
BnNC HoNPh
Figure imgf000031_0001
Figure imgf000031_0002
3-1 A
EXAMPLE 3-1 8-benzyl-4-(benzylamino)-l-phenyl-l,3,8-rriazaspiro[4.5]dec-3-en-2-one (3-1)
Figure imgf000031_0003
In a 10 mL flask N-benzyl piperidinone (833 mg, 4.41 mmol) and benzyl isocyanide (500 mg, 4.2 mmol) were dissolved in MeOH (2.2mL). A solution of KOCΝ (313 mg, 4.41 mmol) in H2O (0.9mL) was added in one portion with stirring. Aniline hydrochloride was added in portions over 5 min. After stirring for Ih the crude product precipitated from solution. The resulting solid was isolated via vacuum filtration, rinsed with H2O followed by Et2O, and dried in vacuo to give 150 mg of a white solid. A portion of this solid was further purified by RP-HPLC. Product containing fractions were poured onto a biphasic mixture of aq. NaHCO3 and EtOAc. The layers were separated and the organic layer washed with brine. Upon drying the organic layer over Na2SO4 and solvent removal under reduced pressure, the target compound, 8-benzyl-4-(benzylamino)-l-phenyl-l,3,8-triazaspiro[4.5]dec-3-en-2-one, was obtained as a white solid: 1H NMR (400 MHz, CDCl3) δ 9.05 (br s, IH), 7.4-7.2 (m, 8H), 6.88 (d, J = 6.9 Hz, 2H), 4.66 (d, J = 5.2 Hz, 2H), 3.37 (s, 2H), 2.75 (overlapping t's, J = 6.8 Hz, 2H), 2.30 (overlapping t's, J = 7.2 Hz, 2), 2.03 (m, 4H); LC-MS (M+H) = 425.03; HPLC = 98.6% (215nm); 100% (254 nM). The following examples were prepared in a similar manner, substituting the appropriately substituted isocyanide and/or the amine, to give the products in Table 1. For example 3-45, potassium thiocyanate was substituted for potassium cyanate. Examples (3-37)- (3-40) were prepare using 4-Boc amino analine followed by deprotection and acylation with an appropriate acylating reagent.
TABLE 1 - Compounds (or salts thereof) Synthesized According to Scheme 3
Figure imgf000032_0001
Figure imgf000033_0001
Figure imgf000034_0001
EX Structure Chemical Name Mass spec
8-benzyl-4-(cyclohexylamino)-l-(4- 451.1
3-16 chlorophenyl)- 1,3,8- triazaspiro [4.5 ]dec-3 -en-2-one
8-benzyl-4-(cyclohexylamino)- 1 -(4- 447.2
3-17 methoxyphenyl)-l ,3,8- triazaspiro[4.5]dec-3-en-2-one
8-benzyl-4-(cyclohexylamino)- 1 -(4- 465.1
3-18 methoxy-3 -fluorophenyl)- 1 ,3,8- triazaspiro[4.5 ] dec-3 -en-2-one
8-benzyl-4-(cyclohexylamino)- 1 - 485.1
3-19 (3,4-difluorophenyl)-l ,3,8- triazaspiro[4.5]dec-3-en-2-one
Figure imgf000035_0001
EX Structure Chemical Name Mass spec
8-benzyl-4-(cyclohexylamino)-l-(3- 485.2
3-20 trifluoromethylphenyl)-l ,3,8- triazaspiro[4.5]dec-3-en-2-one
8-benzyl-4-(cyclohexylamino)- 1 -(2- 431.2
3-23 methylphenyl)-l ,3,8- triazaspiro[4.5]dec-3-en-2-one
8-benzyl-4-(cyclohexylamino)- 1 -(3- 447.3
3-24 methoxyphenyl)-l ,3,8- triazaspiro[4.5]dec-3-en-2-one
8-benzyl-4-(cyclohexylamino)- 1 - 453.2
3-25 (3,4-dichlorophenyl)-l ,3,8- triazaspiro[4.5]dec-3-en-2-one
Figure imgf000036_0001
EX Structure Chemical Name Mass spec
8-benzyl-4-(cyclohexylamino)-l-(4- 485.2
3-26 trifluoromethylphenyl)-l ,3,8- triazaspiro[4.5]dec-3-en-2-one
8-benzyl-4-(cyclohexylamino)-l-(3- 451.2
3-27 chlorophenyl)-l ,3,8- triazaspiro[4.5]dec-3-en-2-one
8-benzyl-4-(cyclohexylamino)- 1 -(2- 451.2
3-28 chlorophenyl)- 1 ,3,8- triazaspiro [4.5] dec-3 -en-2-one
8-benzyl-4-(cyclohexylamino)- 1 - 485.1
3-29 (2,4-dichlorophenyl)-l ,3,8- triazaspiro[4.5 ] dec-3 -en-2-one
Figure imgf000037_0001
EX Structure Chemical Name Mass spec
8-benzyl-4-(cyclohexylamino)-l-(3- 442.3
3-30 cyanophenyl)-l,3,8- triazaspiro [4.5 ] dec-3 -en-2-one
8-benzyl-4-(cyclohexylamino)- 1 -(2- 515.2
3-31 trifluoromethyl-4-methoxyphenyl)- l,3,8-triazaspiro[4.5]dec-3-en-2-one
8-benzyl-4-(cyclohexylamino)-l1(2- 461.2
3-32 methyl-4-methoxyphenyl)-l,3,8- triazaspiro [4.5] dec-3 -en-2-one
8-benzyl-4-(cyclohexylamino)- 1 - 461.2
3-33 (l,3-benzodioxo-5-yl)-l,3,8- triazaspiro[4.5]dec-3-en-2-one
Figure imgf000038_0001
Figure imgf000039_0001
Figure imgf000040_0001
Figure imgf000041_0001
Scheme 4A, which depicts a method for preparing compounds of the invention wherein X=CH, can be used in the synthesis of various compounds of the invention, including Example 4A-6 below (Example 4A-6 is depicted in enamine form, but may also exist in tautomeric form). Scheme 4A
Figure imgf000042_0001
EXAMPLE 4A-6 -benzyl-l-(3-fluorophenyl)-4-[(4-fluorophenyl)amino]-l,8-diazaspiro[4.5]dec-3-en-2-one
Figure imgf000042_0002
Step 1: l-benzyl-4-[(3-fluorophenyl)amino]piperidine-4-carbonitrile (4A-1)
To a 0 0C solution of 15g (79mmol) N-benzyl piperidone in 80 mL acetic acid was added 7.6 mL (79 mmol) 3-fluoro aniline followed by dropwise addition of 10.5 mL (79 mmol) trimethylsilylnitrile (TMSCN). The reaction mixture was allowed to warm to rt and stirred for 1 hr, then poured onto a mixture of 12Og ice and 12Og concentrated NH4OH. The resulting mixture was extracted 2 x 300 mL CH2Cl2 and the combined extracts washed with brine, dried over MgSO4, filtered, and concentrated. The residue was suspended in 100 mL diisopropylether and stirred 30 min and filtered to give l-benzyl-4-[(3- fluorophenyl)amino]piperidine-4-carbonitrile. 1H NMR (CDCl3, 400MHz) δ 1.26-135 (m, 5H); 7.19 (app q, J= 8.06 Hz, IH); 6.55-6.66 (m, 3H); 3.78 (s, IH); 3.56 (s, 2H); 2.80 (br m, 2H); 2.48 (ddd, /=12.5, 12.5, 2.2 Hz, 2H); 2.35 (ddd, 7=13.4, 2.56, 2.56 Hz, 2H); 1.92 (ddd, J=13.2, 13.2, 3.1 Hz, 2H) High resolution mass spec (FT/ICR) calc M+H=310.1714 found 310.1749. Step 2: ethyl l-benzyl-4-[(3-fluorophenyl)amino]piperidine-4-carboxylate (4A-2) A solution of 5g (16 mmol) l-benzyl-4-[(3-fluorophenyl)amino]piperidine-4-carbonitrile in 20 mL concentrated H2SO4 was stirred vigorously for 18 hr, then cooled in an ice bath. The mixture was neutralized by slow addition of concentrated NaOH and ice chips, and the resulting heterogeneous mixture extracted with 500 mL CH2Cl2. The organic extract was dried over MgSO4, filtered, and concentrated to give 4.6g 1 -benzyl -4-[(3-fluorophenyl)amino]piperidine-4-carbonitrile as a tan solid, of which 3.5g (10.7 mmol) was dissolved in 25 mL ethylene glycol. To this was added 2.4g solid KOH and the mixture was heated to 190 0C for 4 hr then cooled to 0 0C. Water (100 mL) was added followed by acetic acid until the pH was neutral. The precipitate that formed was filtered, and a second crop was obtained and each crop was dissolved in 75 mL EtOH and 1.5 mL concentrated H2SO4 was added and the mixture was heated to reflux for 2 days, cooled and concentrated. Purification by automated flash chromatography (4Og silica gel cartridge 0-5% MeOH/ CH2C12/(10%NH4OH) over 15 min) afforded ethyl l-benzyl-4-[(3-fluorophenyl)amino]piperidine-4-carboxylate as a thick oil. 1H NMR (CDCl3, 400MHz) δ 7.31 (m, 4H); 7.25 (m, IH); 7.05 (app q, J= 8.24 Hz, IH); 6.41 (app dt, J= 8.42 and 2.38 Hz, IH); 6.33 (dd, J=8.24 and 2.20 Hz, IH); 6.27 (app dt, J=I 1.5 and 2.20 Hz, IH); 4.16 (q, J=7.14 Hz, 2H); 3.96 (s, IH); 3.51 (s, 2H); 2.63 (br m, 2H); 2.38 (ddd, /=12.3, 12.3, 2.01 Hz, 2H); 2.24 (ddd, J=13.7, 3.67, 3.67 Hz, 2H); 2.00 (br d, J=I 1.3 Hz, 2H); 1.16 (t, J=7.14, 3H). Electrospray mass spectrum M+H=357.1.
Step 3: ethyl 4-[acetyl(3-fluorophenyl)amino]-l-benzylpiperidrne-4-carboxylate (4A-3) A solution of 0.2g (0.56 mmol) ethyl l-benzyl-4-[(3-fluorophenyl)amino]piperidine-4-carboxylate in 2.6 mL (28 mmol) acetic anhydride (neat) was heated to 120 0C for 20 hr, then poured into 50 mL of a 1: 1 mixture of water and concentrated NH4OH, extracted with 100 mL EtOAc, washed with water then brine, dried over MgSO4, filtered, and concentrated. Purification by automated flash chromatography (4Og silica gel cartridge 0-5% MeOH/ CH2Cl2) over 15 min) afforded ethyl 4-[acetyl(3- fluorophenyl)amino]-l-benzylpiperidine-4-carboxylate. 1H NMR (CDCl3, 400MHz) δ 7.39 (m, IH); 7.20-7.31 (m, 4H); 7.06-7.15 (m, 4H); 4.25 (q, J=7.14 Hz, 2H); 3.46 (s, 2H); 2.59 (br m, 2H); 2.30-2.48 (m, 3H); 2.22 (m, 2H); 1.72 (s, 3H) 1.63 (m, 2H); 1.31 (t, J=7.15, 3H). Electrospray mass spectrum M+H=399.2
Step 4: 8-benzyl-l-(3-fluorophenyl)-l,8-diazaspiro[4.5]decane-2,4-dione (4A-4) To a 0 0C solution of 0.86g (2.2 mmol) ethyl 4-[acetyl(3-fluorophenyl)amino]-l-benzylpiperidine-4- carboxylate in 1 mL THF was added 3.2 mL (6.5mmol, 2M solution in heptane, THF, ethylbenzene) lithium diisopropylamide solution and the reaction mixture was allowed to slowly warm to rt and stirred for an additional 14 hr. To this mixture was added 50 mL water and 50 mL EtOAc and the pH was adjusted to pH=6 with IN HCl (approx 1 ImL). The aqueous layer was extracted 3xl00mL EtOAc and the combined extracts washed with 10OmL brine, dried over MgSO4, filtered, and concentrated to give 8- benzyl-l-(3-fluorophenyl)-l,8-diazaspiro[4.5]decane-2,4-dione as a solid. 1H NMR (CDCl3, 400MHz) δ 7.44 (ddd, J=8.06, 8.06 and 6.23 Hz, IH); 7.14-7.30 (m, 6H); 6.95 (br d, J=7.88Hz, IH); 6.89 (ddd, J= 9.16, 2.02, and 2.02 Hz, 1H);3.52 (s, 2H); 3.26 (s, 2H);2.73 (m, 2H); 2.65 (m, 2H); 1.85 (br m, 4H). Electrospray mass spectrum M+H=353.1
Step 6 to give 8-benzyl-l-(3-fluorophenyl)-4-[(4-fluorophenyl)amino]-l,8-diazaspiro[4.5]dec-3-en-2-one.
(4A-6)
To a solution of 55 mg (0.156 mmol) 8-benzyl-l-(3-fluorophenyl)-l,8-diazaspiro[4.5]decane-2,4-dione in 2 mL dry toluene was added 36 mg (0.187 mmol) />-toluenesulfonic acid monohydrate and 0.030 mL
(0.312 mmol) 4-fluoroaniline. The reaction mixture was refluxed for 24 hrs. The solvent was then removed by concentration in vacuum. The residue was purified by preparative HPLC (5 -> 95%
CH3CN/H2O over 30min, 0.05% added TFA, C18 PRO YMC 20x150 mm) to afford 8-benzyl-l-(3- fluorophenyl)-4-[(4-fluorophenyl)amino]-l,8-diazaspiro[4.5]dec-3-en-2-one as a white solid. 1H NMR (CD3OD, 400MHz): δ 7.50-7.20 (m, 7H), 7.20-6.98 (m 6H), 5.24 (s, IH), 3.60
(s, 2H), 2.99-2.80 (m, 2H), 2.36-2.43 (m, 2H), 2.24-1.98 (m, 2H), 2.10 (m, IH), 1.00 (m, 2H). High resolution mass spec (FT/ICR): calc M+H=446.2039 found 446.2035.
Scheme 4B depicts an alternative procedure for the preparation of compounds of the invention wherein X=CR4 or X'=CR4R4 , including Example 4B-7 below (Example 4B-7 is depicted in enamine form, but may also exist in tautomeric form). Strecker adduct 4A-1 is first acylated to give 4B-2 and then cyclized to 4B-3 using a base such as NaOMe. Structures of type 4B-3 and derivatives thereof are also of use for the intended invention described herein. Decarboxylation of structures of type 4B-3 using a strong acid, such as aqueous 6N HCl, gives initially structures of type 4B-4a, which are also claimed for use in the invention. Upon prolonged heating in acid intermediate 4B-4b (same as 4A-4 in scheme 4A) is generated. 4B-4b may then be treated with a suitable amine to give final compounds of type 4B-5 (4A-4). Additionally, for cases wherein X=CR4 and R4 = fluorine, penultimate compounds from either route 4A or 4B, for example 4B-5 can be treated with a fluorinating agent to give compounds of type 4B- 6.
Figure imgf000045_0001
4B-6 4B-5 (4A-4) C 4B-4a Y = NH 4B-4b Y = O
EXAMPLE 4B-7 8-Benzyl-4-[(2-ethylphenyl)amino]-l-(3-fluorophenyl)-l,8-diazaspiro[4.5]dec-3-en-2-one.
Figure imgf000045_0002
Step 1. Acylation to give Intermediate of type 4B-2. To a rt solution of 9.0 g (29.1 mmol) ethyl 3-[(l- benzyl-4-cyanopiperidin-4-yl)(3-fluorophenyl)amino]-3-oxopropanoate (intermediate 4A-1 as describe above) in 150 niL CH2Cl2 was added 4.9 mL (37.8 mmol) ethyl malonyl chloride and 5.1 mL (43.6 mmol) 2,6-lutidine. After 3 h, the reaction was diluted with 150 mL CH2Cl2 and washed with water and brine. The organic portion was dried over Na2SO4, filtered, and concentrated in vacuo to afford ethyl 3- [(l-benzyl-4-cyanopiperidin-4-yl)(3-fluorophenyl)amino]-3-oxopropanoate. LC/MS [M+H] = 424.0.
Step 2. Intermediate of type 4B-3: 8-benzyl-l-(3-fluorophenyl)-l,8-diazaspiro[4.5]decane-2,4-dione To a rt solution of 14.9 g (35.2 mmol) ethyl 3-[(l-benzyl-4-cyanopiperidin-4-yl)(3-fluorophenyl)amino]- 3-oxopropanoate in 20 mL methanol was added 7.6 mL (42.2 mmol) 30% w/v sodium methoxide in methanol. After 1 h, the reaction was concentrated to yield a mixture of ethyl 4-amino-8-benzyl-l-(3- fluorophenyl)-2-oxo-l,8-diazaspiro[4.5]dec-3-ene-3-carboxylate and methyl 4-amino-8-benzyl-l-(3- fluorophenyl)-2 -oxo-1, 8-diazaspiro[4.5]dec-3-ene-3-carboxylate, which was suspended in 200 mL 6N HCl and heated to 8O0C. After 18h the reaction was cooled to O0C, adjusted to pH=10 with concentrated NaOH, and extracted 9x200 mL EtOAc. The combined extracts were washed with brine, dried over Na2SO4, filtered, and concentrated to give a red foam. Crystallization from CH2Cl2 afforded ketoamide intermediate 8-benzyl-l-(3-fluorophenyl)-l,8-diazaspiro[4.5]decane-2,4-dione. LC/MS [M+H] = 353.1.
Step C. Condensation with amine to give structures of type 4B-4. 8-benzyl-4-[(2-ethylphenyl)amino]-l- (3 -fluorophenyl)- 1 ,8-diazaspiro[4.5]dec-3-en-2-one (4B-7)
To a solution of 100 mg (0.28 mmol) 8-benzyl-l-(3-fluorophenyl)-l,8-diazaspiro[4.5]decane-2,4-dione in 0.71 mL dry toluene was added 70 mg (0.37 mmol) />-toluenesulfonic acid monohydrate and 61 μL (0.50 mmol) 2-ethylaniline. The reaction was heated to reflux for 18 h and then diluted with EtOAc, washed with IN NaOH, dried over Na2SO4, filtered, and concentrated in vacuo. The crude material was purified on silica gel with 20-60% EtOAc/hexanes to afford title example 8-benzyl-4-[(2-ethylphenyl)amino]-l- (3-fluorophenyl)-l,8-diazaspiro[4.5]dec-3-en-2-one as a tan foam. 1H NMR (CD3OD, 400 MHz) δ 7.43 (q, J=7.38 Hz, IH), 7.32 (m, IH), 7.24 (m, 6H), 7.16 (m, 3H), 7.08 (m, 2H), 4.55 (s, IH), 3.41 (s, 2H), 2.80 (m, 2H), 2.64 (q, J=7.51 Hz, 2H), 2.38 (m, 2H), 2.19 (m, 2H), 2.10 (dt, J=I 1.5 and 3.85 Hz, 2H), 1.18 (t, /=7.51 Hz, 3H); LC/MS [M+H] = 456.1.
The compounds (or salts thereof) of the following type in Table 1 a can be prepared in a manner similar to one of the above mentioned methods described in Schemes 4A and 4B. Table Ia.
Figure imgf000047_0001
Figure imgf000048_0001
Figure imgf000049_0001
Figure imgf000050_0001
EXAMPLE 4B-24 -benzyl-4-(cyclohexylamine)-3-fluoro-l-(3-fluorophenyl)-l,8-diazaspiro[4.5]dec-3-en-2-one (4B-24)
Figure imgf000051_0001
To a solution of vinylgous amide 8-benzyl-4-(cyclohexylamine)-l-(3-fluorophenyl)-l,8- diazaspiro[4.5]dec-3-en-2-one (11 mg 0.025 mmol) in anhydrous DMA was added Selectfluor (9 mg, 0.025 mmol). The solution stirred overnight at rt. Purification by preparative HPLC (5 -> 95% CH3CN/H2O over 30min, 0.05% added TFA, Cl 8 PRO YMC 20x150 mm) yielded the product as a solid. 1H NMR (CD3OD, 400MHz) δ 7.51-7.11 (m, 9H), 4.17 (s, 2H), 3.51-3.41 (m, 3H), 2.54 (m, 3H), 2.34- 2.30 (m, 2H), 1.80 (m, 2H), 1.60 (m, 2H), 1.40 (m, 3H), 1.37-1.12 (m, 5H). HRMS (FT/ICR): calc M+H=452.2508, found 452.2513.
EXAMPLE 4B-25 Ethyl 4-amino-8-benzyl-l-(5-bromo-2-fluorophenyl)-2 -oxo-1, 8-diazaspiro[4.5]dec-3-ene-3-carboxylate
Figure imgf000051_0002
To a solution of l-benzyl-4-[(2-bromo-5-fluorophenyl)amino]piperidine-4-carbonitrile (100 mg, 0.258 mmol, prepared from Strecker reaction using 2-bromo-4-fluoroaniline) in 2 mL dichloromethane was added ethyl malonyl chloride (43 μL, 0.335 mmol). The solution stirred for 1 hr at rt. The solvent was removed in vacuo and the residue purified by preparative HPLC (5 -> 95% CH3CN/H2O over 30min, 0.05% added TFA, C18 PRO YMC 20x150 mm) to afford the product as a white solid. 1H NMR (CD3OD, 400MHz): δ 7.60-7.05 (m, 8M), 4.29-4.15 (m, 4H), 3.53-3.50 (m, 2H), 2.69-2.53 (m, 4H), 1.30 (m, 3H). LC/MS [M+l]=502.0 EXAMPLE 4B-26
4-amino-8-benzyl-l-[4-fluoro-4'-(methylsulfonyl)biphenyl-2-yl]-l,8-diazaspiro[4.5]dec-3-en-2- one
Figure imgf000052_0001
Decarboxylation of 4B-25 and isolation using conditions similar to example 4B- 1 followed by Suzuki coupling using [4(methylsulfonyl)phenyl]boronic acid as described for example 15-2 and purification using RP-HPLC provided title compound as a white solid. LC/MS [M+H] = 506.3.
Scheme 5 depicts a method for synthesizing compounds with alternative R.3 groups, such as Example (5-3) below (Example (5-3) is depicted in enamine form, but may also exist in tautomeric imine form).
Scheme 5
Figure imgf000053_0001
EXAMPLE 5-3 -(3-Bromobenzyl)-4-(cyclohexylamino)-l-(3-fluorophenyl)-l,3,8-triazaspiro[4.5]dec-3-en-2-one
Figure imgf000053_0002
Stepl : tert-Butyl 4-(cyclohexylamino)-l-(3-fluorophenyl)-2-oxo-l,3,8-triazaspiro[4.5]dec-3-ene-8- carboxylate (5-1)
To a 10 mL MeOH suspension of 4.05g (20.3 mmol) N-boc piperidinone and 2.1 Ig (19.3 mmol) cyclohexyl isocyanide was added a solution of 2.06g (25.4 mmol) potassium isocyanate in 2.8 mL H2O in one portion with stirring followed by 3.Og (20.3mmol) 3-fluoroaniline hydrochloride in portions over 5m. After stirring for 2h the reaction was treated with 250 ml CH2Cl2. The organic layer was washed with water (2x50 ml), brine (1x50 ml), dried over Na2SO4, filtered and concentrated to dryness in vacuo to give a crude oil (9.68 g). Purification by automated flash chromatography (0-5.5% MeOH in CH2Cl2 over 28m) afforded tert-butyl 4-(cyclohexylamino)-l-(3-fluorophenyl)-2-oxo-l,3,8-triazaspiro[4.5]dec-3- ene-8-carboxylate as a white solid. 1H NMR (CDCl3, 400MHz): δ 7.41 (m, IH), 7.11 (m, IH), 7.05 (d, J = 7.88 Hz, IH), 6.99 (m, IH), 5.40 (br s, IH), 4.02 (m, IH), 3.58 (m, 2H), 3.27 (m, 2H), 2.05 (m, 4H), 1.92 (m, 2H), 1.71 (m, 4H), 1.44 (m, 12H), 1.24 (m, 2H). Electrospray mass spectrum: M+H = 445.2
Step 2: 2: 4-(Cyclohexylamino)-l-(3-fluorophenyl)-2-oxo-l,3,8-triazaspiro[4.5]dec-3-ene dihydrochloride 5-2
To a suspension of 2.74g (6.16 mmol) tert-butyl 4-(cyclohexylamino)-l-(3-fluorophenyl)-2-oxo-l,3,8- triazaspiro[4.5]dec-3-ene-8-carboxylate in 50 mL EtOAc at 0 0C was bubbled in HCl gas until the solvent was saturated. The reaction was stirred in the cold for 30m and concentrated in vacuo. The solid residue was reconcentrated to dryness (2x ethyl ether) and dried under high vacuum to give 4-(cyclohexylamino)- l-(3-fluorophenyl)-2-oxo-l,3-triazaspiro[4.5]dec-3-ene as its dihydrochloride salt as a fine white solid. 1H NMR (DMSO, 400MHz): δ 10.73 (br s, IH), 9.58 (br s,lH), 9.21 (s, IH), 8.36 (br s, IH), 7.46 (m, 4H), 3.82 (br m, IH), 3.36 (br s, 2H), 2.92 (br s, 2H), 2.55 (m, 2H), 2.33 (br m, 2H), 1.87 (br s, 2H), 1.75 (br s, 2H), 1.52 (br m, 3H), 1.29 (br m, 2H), 1.16 (m, IH). Electrospray mass spectrum: M+H = 345.2
Step 3: 8-(3-Bromobenzyl)-4-(cyclohexylamino)-l-(3-fluorophenyl)-l,3,8-triazaspiro[4.5]dec-3-en-2-one (5-3)
To a suspension of 600 mg (1.44 mmol) 4-(cyclohexylammonio)-l-(3-fluorophenyl)-2-oxo-l,3-diaza-8- azoniaspiro[4.5]dec-3-ene dihydrochloride, 376μL (2.16 mmol) diisopropylethylamine, and 427 mg (2.01 mmol) triacetoxy sodium borohydride in 20 mL DCE was added dropwise a 4mL DCE solution of 251/xL (2.16 mmol) 3-bromobenzaldehyde and the resulting heterogeneous mixture was stirred at rt overnight under a nitrogen atmosphere. The reaction mixture was treated with 5OmL CH2Cl2 and washed with 2OmL saturated NaHCO3 (aq), 2OmL brine, dried over Na2SO4, filtered, and concentrated in vacuo. Purification by automated flash chromatography (0-5% MeOH in CH2Cl2 over 25m) afforded the product as a white solid. 1H NMR (CDCl3, 400 MHz): δ 7.75 (d, J = 8.15 Hz, IH), 7.45 (m, 2H), 7.36 (m, IH), 7.22 (m, IH), 7.15 (d, J = 7.69 Hz, IH), 7.02 (m, 3H), 3.97 (m, IH), 3.50 (s, 2H), 2.76 (m, 2H), 2.43 (m, 2H), 2.09 (m, 4H), 1.95 (m, 2H), 1.75 (m, 2H), 1.68 (m, IH), 1.41 (m, 2H), 1.23 (m, 3H). High resolution mass spec (FT/ICR): calc M+H = 513.1660, found 513.1697
EXAMPLE (5-4)
4-(cyclohexylamino)- 1 -(3-fluorophenyl)-8- {3-[( 1 -methylprop-2-enyl)oxy]benzyl } - 1 ,3 ,Σ triazaspiro[4.5]dec-3-en-2-one
Figure imgf000055_0001
Step 1
Step 1 : 3-[(l-methylprop-2-enyl)oxy]benzaldehyde
Added DEAD (0.964 rtiL, 6.142 mmole) dropwise to a solution of triphenylphosphine (0.1.611 g, 6.142 mmole), 3-buten-2-ol (Fluka, 0.423 mL, 4.91 mmole), and 3-hydroxy benzaldehyde (0.5g, 4.09 mmole) in 10 mL dry THF, at rt, under Argon. After 10 min, the reaction was concentrated in vacuo and was purified on a 35g Redisep column eluting with a gradient of 5%-30% EtOAc in hexanes.
Step 2: 4-(cyclohexylamino)-l-(3-fluorophenyl)-8-{3-[(l-methylprop-2-enyl)oxy]benzyl}-l,3,8- triazaspiro [4.5] dec-3 -en-2-one
The compound was prepared as described for Example (5-3) using the above aldehyde. 1H NMR (CDCl3, 400 Mh), δ 8.07 (d, J=7.9 Hz, IH); 7.34 (m, IH); 7.23 (t, J=8.24, 8.06 Hz, IH); 7.00 (m, 3H); 6.84 (m, 3H); 5.89 (ddd, J=6.4, 5.9, 11.0, 21.9 Hz, IH); 5.25 (dd, J=Ll, 17.4 Hz, IH); 5.17 (d, J=10.6 Hz, IH); 4.80 (m, IH); 3.95 (m, IH); 3.49 (s, 2H); 2.78 (m, 2H); 2.44 (m, 2H); 2.12 (m, 2H); 2.07 (m, 2H); 1.94 (m, 2H); 1.74 (m, 2H); 1.67 (m, 2H); 1.43 (d, J=6.5 Hz, 3H); 1.39 (m, IH); 1.22 (m, 3H). Mass spec (m+1) = 505.
EXAMPLE (5-5) 4-(cyclohexylamino)-l-(3-fluorophenyl)-8-(3-isopropoxybenzyl)-l,3,8-triazaspiro[4.5]dec-3-en-2-one
Figure imgf000056_0001
Step 1: 3- isopropoxybenzyaldehyde
Figure imgf000056_0002
This method of alkylation is similar to that described in J Med Chem (2002), 45(18), 3891-3904. Dissolved 3-Hydroxy benzaldehyde (0.500g, 4.094 mmole) in 10 mL EtOH at rt, under Argon, and magnetically stirred. Added K2CO3. (1.132g, 8.189mmole), then 2-iodopropane (0.819 mL, 8.819 mmole). Warmed to 6O0C. After 18 hr, added a second equivalent of alkyl iodide of (0.819 mL, 8.189 mmole) and continued heating at 6O0C. After 4 hr, cooled to rt and concentrated in vacuo. Partitioned residue between EtOAc, and H2O. Washed organic layer with 1 M NaOH, 2x 2OmL , dried organic layer over MgSO4, filtered and concentrated in vacuo to give the aldehyde.
Step 2: 4-(cyclohexylamino)-l-(3-fluorophenyl)-8-(3-isopropoxybenzyl)-l,3,8-triazaspiro[4.5]dec-3-en- 2-one (5-6)
Suspended 4-(cyclohexylamino)-l-(3-fluorophenyl)-2-oxo-l,3-triazaspiro[4.5]dec-3-ene dihydrochloride salt (5-2, 0.50Og, 1.198 mMole) and 3-isopropoxyaldehyde (0.197g, 1.198 mmole)in 5 mL of CHC13. Added Hunigs Base (0.313 mL, 1.795 mmole). Let stir for 0.5 hr, then added cyanoborohydride silica bound (1 mmole/g, 1.318g, 1.318mmole) (Aldrich), then 0.034mL HOAc. Let sit for 1 hr, then heated in microwave for 20 min at 1500C. Filtered off silica gel and concentrated in vacuo. Purified using a Redi- sep 4Og silica gel column eluting with 0-5% methanol / CH2C12 saturated with NH3 and collected impure product as a solid. Rinsed solid with EtOAc, and collected purified solids to give product. 1H NMR (CDCl3, 400 Mh), δ 8.11 (d, J=7.4 Hz, IH); 7.40 (m, IH); 7.24 (m, IH); 7.02 (m, 3H); 6.80 (m, 3H); 4.55 (quintet, J=6.04Hz, IH); 3.98 (m, IH); 3.50 (s, 2H); 2.79 (m, 2H); 2.43 (m, 2H); 2.10 (m, 2H); 2.02 (m, 2H); 1.97 (m, 2H); 1.74 (m, 2H); 1.64 (m, 2H); 1.38 (m, IH); 1.33(d, J=6.0 Hz, 6H); 1.23 (m,
3H).
Mass Spec (m+l) = 493.
Scheme 6 depicts a method for preparing compounds wherein Rl is methyl, such as Examples (6-3) - (6-6) below. Examples (6-3)-(6-6) are depicted in enamine form, but may also exist in tautomeric imine form as described above.
Scheme 6
Figure imgf000057_0001
EXAMPLE 6-3 4-methyl-l-(3-fluorophenyl)-2-oxo-l,3,8-triazaspiro[4.5]dec-3-ene (6-3)
Figure imgf000057_0002
Intermediate 6-1 : tert-Butyl l-(3-fluorophenyl)-2-oxo-4-[(trimethylsilyl)methyl] amino-l,3,£ triazaspiro [4.5 ]dec-3 -ene-8-carboxylate
Intermediate 6-1 was prepared in the same manner as Intermediate 5-1 above. Intermediate 6-2: tert-Butyl l-(3-fluorophenyl)-4-(methylamino)-2-oxo-l,3,8-triazaspiro[4.5]dec-3-ene-8- carboxylate
To a 50 ml THF solution of 1.04g (2.41 mmol) tert-butyl l-(3-fluorophenyl)-2-oxo-4- {[(trimethylsilyl)methyl]amino}-l,3,8-triazaspiro[4.5]dec-3-ene-8-carboxylate (prepared in the same manner as Intermediate 5-1 above) was added 3.6ImL (3.61 mmol) of a 1.0M tetrabutylammonium fluoride in THF solution over 5m and the reaction warmed to 60 0C overnight. The reaction was concentrated to dryness in vacuo and the residue treated with 10OmL CH2Cl2. The organic layer was washed with water (lx25mL), brine (lx25mL), dried over Na2SO4, filtered and concentrated to dryness in vacuo to give a crude oil (1.6 g). Purification by flash chromatography (0-7.5% MeOH in CH2Cl2 over 25 m) afforded tert-butyl l-(3-fluorophenyl)-4-(methylamino)-2-oxo-l,3,8-triazaspiro[4.5]dec-3-ene-8- carboxylate 6-2 as a white solid. 1H NMR (CDCl3, 400MHz) δ 7.39 (m, IH), 7.12 (m, IH), 7.03 (d, J = 7.95 Hz, IH), 6.97 (m, IH), 5.70 (br s, IH), 3.54 (m, 2H), 3.11 (d, /= 4.76 Hz, 3H), 2.02 (m, 2H), 1.92 (m, 2H), 1.42 (s, 9H). High resolution mass spec (FT/ICR): calc M+H = 377.1984, found 377.2010
4-methyl-l-(3-fluorophenyl)-2-oxo-l,3,8-triazaspiro[4.5]dec-3-ene (6-3) was prepared in analogy to
Intermediate 5-2 and the following examples in Table 2 and their pharmaceutically acceptable salts were prepared according to Scheme 6 and in analogy to Intermediate 5-3.
Table 2 - Compounds (or salts thereof) Synthesized According to a manner similar to that described in Scheme 6
Figure imgf000058_0001
Figure imgf000059_0001
Scheme 7 demonstrates another method for preparing compounds with alternate R.3 groups (such as Example (7-2) and (7-3). Example (7-2) and (7-3) are depicted in enamine form but may also exist in tautomeric imine form.
Scheme 7
Figure imgf000060_0002
Figure imgf000060_0001
Figure imgf000060_0003
EXAMPLE (7-2)
4-(cyclohexylamino)-l-(3-fluorophenyl)-8-[(2'-vinyl-l,r-biphenyl-3-yl)methyl]-l,3,8-triazaspiro[4.5]dec- 3-en-2-one (7-2)
Figure imgf000061_0001
To a solution of 0.02Og (0.039mmol) 8-(3-bromobenzyl)-4-(cyclohexylamino)-l-(3-fluorophenyl)-l,3,8- triazaspiro[4.5]dec-3-en-2-one (5-3) in 0.5 mL degassed DMFiH2O (4:1) was added 0.006 g (0.039mmol) (2-vinylphenyl) boronic acid and 0.003g (O.OOόmmol) 3,3',3"-Phosphinidynetris(benzene sulfonic acid) and 0.00 Ig (0.002mmol) palladium II acetate and 16μL (.117mmol) diisopropylamine. The reaction was heated in the microwave at 100 0C for 10 mins. Purification by preparative HPLC (5-95% CH3CN/H2O over 30min, 0.05% added TFA, C18 PRO YMC 20x150 mm) afforded 4-(cyclohexylamino)-l-(3- fluorophenyl)-8-[(2'-vinyl-l,l'-biphenyl-3-yl)methyl]-l,3,8-triazaspiro[4.5]dec-3-en-2-one as a white solid. NMR 1H NMR (CD3OD) δ 7.65 (dd, J= 6.8 Hz, 2.2 Hz, IH), 7.43 (dt, J= 7.96 Hz, 6.32 Hz, IH), 7.34(m, 3H) 7.17 (m, 7H), 6.61 (dd, J= 17.49 Hz, 10.99 Hz, IH), 5.70 (d, J= 17.58, IH), 5.15 (d, J = 10.99 Hz, IH), 3.75 (m, IH), 3.46 (s, IH), 2.78 (m, 2H), 2.14 (m, 6H), 1.93 (m, 2H), 1.74 (m, 2H), 1.63 (m, IH), 1.34 (m, 4H), 1.17 (m, IH). High resolution mass spec (FT/ICR) calc M+H=537.3024 found 537.3038.
EXAMPLE (7-3)
4-(cyclohexylamino)-l-(3-fluorophenyl)-8-[3-(4-methylpyridin-3-yl)benzyl]-l,3,8-triazaspiro[4.5]dec-3- en-2-one (7-3)
Figure imgf000061_0002
Step 1: 3-{[4-(cyclohexylamino)-l-(3-fluorophenyl)-2 -oxo-1, 3,8-triazaspiro[4.5]dec-3-en-8- yl]methyl}phenylboronic acid (7-1)
Figure imgf000062_0001
To a solution of 3.Og (7.188mmol) 4-(cyclohexylamino)-l-(3-fluorophenyl)-2-oxo-l,3-diaza-8- azoniaspiro[4.5]dec-3-ene dihydrochloride in 30 mL THFrAcOH (9:1) was added 1.8 g (12.005mmol) 3- formylphenylboronic acid and 5.53g (21.567mmol) PS-DIEA resin and 5.97g (14.388mmol) MP- cyanoborohydride resin. The heterogeneous reaction mixture was stirred at rt for 24 hrs, then filtered, washed with 10OmL methanol, and concentrated. Purification by automated flash chromatography (8- 30% CH3CN/H2O over 41 min, 0.05% added TFA reverse phase YMC ODSA 12θA, 15-30μM particle size,) afforded 3 - { [4-(cyclohexylamino)- 1 -(3 -fluorophenyl)-2-oxo- 1,3, 8-triazaspiro [4.5 ]dec-3 -en-8- yl]methyl}phenylboronic acid as a solid. 1H NMR (CD3OD, 400MHz) δ 7.44 (m, IH), 7.38 (d, J =7.32 Hz, IH), 7.29 (s, IH), 7.18 (m, IH), 7.09 (m, 3H) 6.93 (m, IH), 3.75 (m, IH), 3.31 (s, 2H), 2.78 (m, 2H), 2.12 (m, 4H), 1.97 (m, 4H), 1.78 (m, 2H), 1.65 (m, IH), 1.35 (m, 5H). High resolution mass spec (FT/ICR) calc M+H=478.2661 found 478.2709.
Step 2 : 4-(cyclohexylamino)- 1 -(3 -fluorophenyl)-8-[3-(4-methylpyridin-3-yl)benzyl] -1,3,8- triazaspiro[4.5]dec-3-en-2-one (7-3)
To a solution of 0.100g (0.209mmol) 3-{[4-(cyclohexylamino)-l-(3-fluorophenyl)-2-oxo-l,3,8- rriazaspiro[4.5]dec-3-en-8-yl]methyl}phenylboronic acid (7-1) in 1 mL CH3CNiH2O was added 0.030 g (0.174mmol) 3-bromo-4-methylpyridine and 0.007g (0.01 lmmol) Tris(4,6-dimethyl- 3sulfanatophenyl)phosphine and O.OOlg (0.004mmol) palladium II acetate and 0.037g (0.349mmol) sodium carbonate. The reaction was heated in the microwave at 120 0C for 20 mins. Purification by preparative HPLC (5-95% CH3CN/H2O over 30min, 0.05% added TFA, C18 PRO YMC 20x150 mm) afforded 4-(cyclohexylamino)-l-(3-fluorophenyl)-8-[3-(4-methylpyridin-3-yl)benzyl]-l,3,8- triazaspiro[4.5]dec-3-en-2-one as a white solid. NMR 1H NMR (CD3OD) δ 8.37 (d, J= 5.04 Hz, IH), 8.29 (s, IH), 7.42 (m, 3H) 7.19 (m, 6H), 3.76 (m, IH), 3.47 (s, 2H), 2.77 (m, 2H), 2.29 (s, 3H), 2.14 (m, 6H), 1.95 (m, 2H), 1.77 (m, 2H), 1.66 (m, IH), 1.36 (m, 4H), 1.18 (m, IH). High resolution mass spec (FT/ICR) calc M+H=526.2977 found 526.3012.
Examples (7-4)- (7-109) listed below in Table 3 were prepared in a manner similar to that described in Schemes 3, 5 and 7. Examples (7-4) - (7-109) and their pharmaceutically acceptable salts are depicted in enamine form, but may also exist in tautomeric imine form. Table 3- Compounds (or salts thereof) Synthesized According to Schemes 5 and 7, using methods similar to that described for Examples (5-3) - (5-5) and (7-2) - (7-3).
EX Structure Chemical Name Mass spec
8-benzyl-4-(cyclohexylamino)-l-(3- 435.2
7-4 fluorophenyl)-l ,3,8- triazaspiro [4.5 ] dec-3 -en-2-one
8-(2-trifluoromethoxybenzyl)-4- 519.2
7-5 (cyclohexylamino)-l-(3- fluorophenyl)-l ,3,8- triazaspiro[4.5]dec-3-en-2-one
4-(cyclohexylamino)-8-[2- 501.2
7-6 (difluoromethoxy)benzyl]-l -(3- fluorophenyl)-l ,3,8- triazaspiro[4.5]dec-3-en-2-one
Figure imgf000063_0001
EX Structure Chemical Name Mass spec
8-[2-(tert-butylthio)benzyl]-4- 523.2
7-7 (cyclohexylamino)- 1 -(3 - fluorophenyl)- 1 ,3,8- triazaspiro [4.5] dec-3 -en-2-one
8-[2-methylbenzyl]-4- 449.2
7-8 (cyclohexylamino)- 1 -(3 - fluorophenyl)-l,3,8- triazaspiro[4.5]dec-3-en-2-one
8-[2-nitrobenzyl] -4- 480.2
7-9 (cyclohexylamino)- 1 -(3 - fluorophenyl)-l,3,8- triazaspiro[4.5]dec-3-en-2-one
N-(4-{[4-(cyclohexylamino)-l-(3- 492.3
7-10 fluorophenyl)-2-oxo-l ,3,8- triazaspiro[4.5]dec-3-en-8- yl]methyl } phenyl)acetamide
Figure imgf000064_0001
Figure imgf000065_0001
EX Structure Chemical Name Mass spec
8-[3-fluorobenzyl]-4- 453.3
7-15 (cyclohexylamino)- 1 -(3- fluorophenyl)- 1 ,3,8- triazaspiro [4.5 ] dec-3 -en-2-one
8-[2-cyanobenzyl]-4- 460.2
7-16 (cyclohexylamino)- 1 -(3 - fluorophenyl)- 1 ,3,8- triazaspiro[4.5]dec-3-en-2-one
4-(cyclohexylamino)- 1 -(3 - 441.2
7-17 fluorophenyl)-8-(2-thienylmethyl)- l,3,8-triazaspiro[4.5]dec-3-en-2-one
4-(cyclohexylamino)-l-(3- 449.2
7-18 fluorophenyl)-8-( 1 -phenylethyl)- l,3,8-triazaspiro[4.5]dec-3-en-2-one
Figure imgf000066_0001
Figure imgf000067_0001
Figure imgf000068_0001
Figure imgf000069_0001
EX Structure Chemical Name Mass spec
4-(cyclohexylamino)-8-(2,3-dihydro- 476.2
7-32 lH-indol-7-ylmethyl)-l -(3- fluorophenyl)-l,3,8- triazaspiro[4.5]dec-3-en-2-one
4-(cyclohexylamino)-8-(2,3-dihydro- 461.2
7-33 lH-inden-2-yl)-l-(3-fluorophenyl)- l,3,8-triazaspiro[4.5]dec-3-en-2-one
4-(cyclohexylamino)-l-(3- 503.4
7-34 fluorophenyl)-8-(3- phenylcyclohexyl)-l ,3,8- triazaspiro[4.5]dec-3-en-2-one
4-(cyclohexylamino)- 1 -(3 - 537.3
7-35 fluorophenyl)-8-( 1 -phenyl-2,3- dihydro-lH-inden-2-yl)-l ,3,8- triazaspiro[4.5]dec-3-en-2-one
Figure imgf000070_0001
Figure imgf000071_0001
EX Structure Chemical Name Mass spec
8-(biphenyl-3-ylmethyl)-4- 511.2866
7-39 (cyclohexylamino)- 1 -(3 - fluorophenyl)-l,3,8- triazaspiro[4.5 ] dec-3 -en-2-one
4-(cyclohexylamino)- 1 -(3 - 525.3
7-40 fluorophenyl)-8-[(2'-methylbiphenyl- 3-yl)methyl]-l,3,8- triazaspiro[4.5]dec-3-en-2-one
8-(3-chlorobenzyl)-4- 469.2
7-41 (cyclohexylamino)- 1 -(3 - fluorophenyl)-l,3,8- triazaspiro[4.5]dec-3-en-2-one
4-(cyclohexylamino)-l-(3- 449.2
7-42 fluorophenyl)-8-(3-methylbenzyl)- l,3,8-triazaspiro[4.5]dec-3-en-2-one
Figure imgf000072_0001
EX Structure Chemical Name Mass spec
4-(cyclohexylammo)- 1 -(3 - 503.3
7-43 fluorophenyl)-8-[3- (trifluoromethyl)benzyl]-l ,3,8- tπazaspiro [4.5 ]dec-3 -en-2-one
4-(cyclohexylamino)-l-(3- 461.2
7-44 fluorophenyl)-8-(3 -vmylbenzyl)- l,3,8-triazaspiro[4.5]dec-3-en-2-one
methyl 3 - { [4-(cyclohexylammo)- 1 - 493.2
7-45 (3-fluorophenyl)-2 -oxo-1 ,3,8- tnazaspiro[4.5]dec-3-en-8- yl] methyl } benzoate
4-(cyclohexylammo)- 1 -(3 - 451.2
7-46 fluorophenyl)-8-(3-hydroxybenzyl)- l,3,8-triazaspiro[4.5]dec-3-en-2-one
Figure imgf000073_0001
EX Structure Chemical Name Mass spec
4-(cyclohexylamino)- 1 -(3 - 465.2
7-47 fluorophenyl)-8-(3-methoxybenzyl)- l,3,8-triazaspiro[4.5]dec-3-en-2-one
4-(cyclohexylamino)-8-(3- 479.2
7-48 ethoxybenzyl)- 1 -(3-fluorophenyl)- l,3,8-triazaspiro[4.5]dec-3-en-2-one
4-(cyclohexylamino)-8-[3- 519.3
7-49 (cyclopentyloxy)benzyl] - 1 -(3 - fluorophenyl)- 1 ,3,8- triazaspiro[4.5]dec-3-en-2-one
4-(cyclohexylamino)- 1 -(3 - 551.2
7-50 fluorophenyl)-8-[3-(l , 1 ,2,2- tetrafluoroethoxy)benzyl]-l ,3,8 triazaspiro[4.5]dec-3-en-2-one
Figure imgf000074_0001
EX Structure Chemical Name Mass spec
4-(cyclohexylamino)- 1 -(3 - 527.2
7-51 fluorophenyl)-8-(3-phenoxybenzyl)- l,3,8-triazaspiro[4.5]dec-3-en-2-one
Figure imgf000075_0001
8-[3-(4-tørt-butylphenoxy)benzyl]-4- 583.3
7-52 (cyclohexylamino)- 1 -(3 - fluorophenyl)- 1 ,3,8- triazaspiro[4.5]dec-3-en-2-one
Figure imgf000075_0002
4-(cyclohexylamino)-8-[3-(3,5- 595.2
7-53 dichlorophenoxy)benzyl] - 1 -(3 - fluorophenyl)- 1,3,8- triazaspiro[4.5 ] dec-3 -en-2-one
Figure imgf000075_0003
8-[3 -(benzyloxy)benzyl]-4- 541.3
7-54 (cyclohexylamino)- 1 -(3 - fluorophenyl)- 1,3,8- triazaspiro[4.5]dec-3-en-2-one
Figure imgf000075_0004
EX Structure Chemical Name Mass spec
4-(cyclohexylamino)- 1 -(3- 480.2
7-55 fluorophenyl)-8-(3-nitrobenzyl)- l,3,8-triazaspiro[4.5]dec-3-en-2-one
3 - { [4-(cyclohexylamino)- 1 -(3 - 493.2
7-56 fluorophenyl)-2-oxo-l ,3,8- triazaspiro[4.5]dec-3-en-8- yl]methyl} phenyl acetate
4-(cyclohexylamino)- 1 -(3 - 515.2
7-57 fluorophenyl)-8-[3-(2-methyl-lH- imidazol- 1 -yl)benzyl] -1,3,8- triazaspiro[4.5]dec-3-en-2-one
4-(cyclohexylamino)-8-[3-(2-ethyl- 529.3
7-58 lH-imidazol-1 -yl)benzyl]-l -(3- fluorophenyl)-l ,3,8- triazaspiro[4.5]dec-3-en-2-one
Figure imgf000076_0001
Figure imgf000077_0001
Figure imgf000078_0001
EX Structure Chemical Name Mass spec
4-(cyclohexylamino)-l-(3- 526.2
7-67 fluorophenyl)-8-[3-(3-methylpyridin- 4-yl)benzyl]-l,3,8- triazaspiro [4.5 ] dec-3 -en-2-one
4-(cyclohexylamino)- 1 -(3 - 525.3
7-68 fluorophenyl)-8-[(4'-methylbiphenyl- 3-yl)methyl]-l,3,8- triazaspiro[4.5]dec-3-en-2-one
4-(cyclohexylamino)-l-(3- 525.3
7-69 fluorophenyl)-8-[(3'-methylbiphenyl- 3-yl)methyl]-l,3,8- triazaspiro [4.5] dec-3 -en-2-one
4-(cyclohexylamino)-8-{[6-(2- 540.3
7-70 ethylphenyl)pyridin-2-yl]methyl}-l- (3-fluorophenyl)-l ,3,8- triazaspiro[4.5]dec-3-en-2-one
Figure imgf000079_0001
Figure imgf000080_0001
EX Structure Chemical Name Mass spec
4-(cyclohexylamino)- 1 -(3 - 526.3
7-75 fluorophenyl)-8-[3-(2-methylpyridin- 3-yl)benzyl]-l,3,8- triazaspiro[4.5]dec-3-en-2-one
4-(cyclohexylamino)-8-[3-(3,5- 530.3
7-76 dimethylisoxazol-4-yl)benzyl] - 1 -(3 - fluorophenyl)- 1 ,3,8- triazaspiro[4.5]dec-3-en-2-one
4-(cyclohexylamino)-8-[(2'- 535.2
7-77 ethynylbiphenyl-3 -yl)methyl] - 1 -(3 - fluorophenyl)- 1 ,3,8- triazaspiro[4.5]dec-3-en-2-one
8-[(2'-but-3-en-l-ylbiphenyl-3- 565.3
7-78 yl)methyl] -4-(cyclohexylamino)- 1 - (3-fluorophenyl)-l,3,8- triazaspiro[4.5]dec-3-en-2-one
Figure imgf000081_0001
EX Structure Chemical Name Mass spec
4-(cyclohexylamino)- 1 -(3 - 553.3
7-79 fluorophenyl)-8-[(2'- isopropylbiphenyl-3-yl)methyl]- l,3,8-triazaspiro[4.5]dec-3-en-2-one
4-(cyclohexylamino)-l-(3- 526.3
7-80 fluorophenyl)-8-[3-(3-methylpyridin- 2-yl)benzyl]-l,3,8- triazaspiro[4.5]dec-3-en-2-one
4-(cyclohexylamino)-l -(3- 515.3
7-81 fluorophenyl)-8-[3-( 1 -methyl- IH- imidazol-2-yl)benzyl]-l ,3,8- triazaspiro [4.5 ] dec-3 -en-2-one
4-(cyclohexylamino)-l -(3- 526.3
7-82 fluorophenyl)-8-[3-(4-methylpyridin- 3-yl)benzyl]-l,3,8- triazaspiro[4.5]dec-3-en-2-one
Figure imgf000082_0001
EX Structure Chemical Name Mass spec
4-(cyclohexylamino)- 1 -(3 - 515.2
7-83 fluorophenyl)-8-[3 -( 1 -methyl- 1 H- imidazol-5-yl)benzyl]-l,3,8- triazaspiro [4.5] dec-3-en-2-one
4-(cyclohexylamino)- 1 -(3 - 515.3
7-84 fluorophenyl)-8-[3-( 1 -methyl-lH- imidazol-4-yl)benzyl]-l ,3,8- triazaspiro[4.5]dec-3-en-2-one
4-(cyclohexylamino)- 1 -(3 - 542.3
7-85 fluorophenyl)-8-[3-(4-methyl-l - oxidopyridin-3-yl)benzyl]-l ,3,8- triazaspiro[4.5]dec-3-en-2-one
4-(cyclohexylamino)-8-[(2',4'- 585.3
7-86 dimethoxy-6'-methylbiphenyl-3 - yl)methyl]-l-(3-fluorophenyl)-l,3,8- triazaspiro[4.5]dec-3-en-2-one
Figure imgf000083_0001
EX Structure Chemical Name Mass spec
4-(cyclohexylamino)- 1 -(3 - 565.3
7-87 fluorophenyl)-8- { [2'-(2-methylprop- 2-en- 1 -yl)biphenyl-3-yl]methyl } - l,3,8-triazaspiro[4.5]dec-3-en-2-one
4-(cyclohexylamino)- 1 -(3 - 570.3
7-88 fluorophenyl)-8-[(2'-methyl-5'- nitrobiphenyl-3 -yl)methyl] - 1 ,3 , 8- triazaspiro[4.5]dec-3-en-2-one
4-(cyclohexylamino)-8-[(5'-fluoro-2'- 543.2
7-89 methylbiphenyl-3 -yl)methyl] - 1 -(3 - fluorophenyl)-l,3,8- triazaspiro[4.5]dec-3-en-2-one
Figure imgf000084_0001
EX Structure Chemical Name Mass spec
8-[(5'-chloro-2'-methylbiphenyl-3- 559.2
7-90 yl)methyl]-4-(cyclohexylarnino)-l- (3-fluorophenyl)-l,3,8- triazaspiro[4.5]dec-3-en-2-one
8-[(5 '-amino-2'-methylbiphenyl-3 - 540.3
7-91 yl)methyl] -4-(cyclohexylamino)- 1 - (3-fluorophenyl)-l,3,8- triazaspiro[4.5]dec-3-en-2-one
7-92 4-(cyclohexylamino)- 1 -(3 - 451 fluorophenyl)-8-(3-hydroxybenzyl)- l,3,8-triazaspiro[4.5]dec-3-en-2-one
7-93 8-(3-tert-butoxybenzyl)-4- 507 (cyclohexylamino)-l-(3- fluorophenyl)-l ,3,8- triazaspiro[4.5]dec-3-en-2-one
7-94 8-[3-(allyloxy)benzyl]-4- 491 (cyclohexylamino)-l -(3- fluorophenyl)-l,3,8- triazaspiro[4.5]dec-3-en-2-one
Figure imgf000085_0001
EX Structure Chemical Name Mass spec
7-95 8-[3-(but-3-enyloxy)benzyl]-4- 505 (cyclohexylamino)- 1 -(3- fluorophenyl)-l ,3,8- triazaspiro [4.5] dec-3 -en-2-one
7-96 4-(cyclohexylamino)-8-(2,3-dihydro- 477 1 -benzofuran-7-ylmethyl)- 1 -(3 - fluorophenyl)-l,3,8- triazaspiro[4.5]dec-3-en-2-one
7-97 8-[3-(allyloxy)benzyl]-4- 473
(cyclohexylamino)-l-phenyl-l,3,8- triazaspiro[4.5]dec-3-en-2-one
7-98 4-(cyclohexylamino)-l -(3- 489 fluorophenyl)-8-[3-(prop-2- ynyloxy)benzyl]-l ,3,8- triazaspiro[4.5]dec-3-en-2-one
7-99 4-(cyclohexylamino)-8-[3- 505 (cyclopropylmethoxy)benzyl] - 1 -(3 - fluorophenyl)- 1 ,3,8- triazaspiro[4.5]dec-3-en-2-one
Figure imgf000086_0001
Figure imgf000087_0001
Figure imgf000088_0001
Scheme 8 describes a method for preparation of compounds containing an aminopyridine R.3 substituent, such as Examples (8-1) - (8-4). Examples (8-1) - (8-4) are depicted in enamine form, but may also exist in tautomeric imine form.
Scheme 8
Figure imgf000089_0002
Figure imgf000089_0001
Figure imgf000089_0003
EXAMPLE (8-1)
8-[(6-bromopyridin-3-yl)methyl]-4-(cyclohexylamino)-l-(3-fluoφhenyl)-l,3,8-triazaspiro[4.5]dec-3-en- 2-one (8-1)
Figure imgf000090_0001
Example (8-1) was prepared in the same manner as Intermediate 5-3, electrospray mass spectrum M+H=418.2.
EXAMPLE (8-2)
8- { [6-(Benzylamino)pyridin-3 -yl]methyl } -4-(cyclohexylamino)- 1 -(3 -fluorophenyl)- 1 ,3 , 8- triazaspiro[4.5]dec-3-en-2-one (8-2)
Figure imgf000090_0002
To a 600μL dried degassed toluene suspension of 27 mg (0.052 mmol) 8-[(6-bromopyridin-3-yl)methyl]- 4-(cyclohexylamino)-l-(3-fluorophenyl)-l,3,8-triazaspiro[4.5]dec-3-en-2-one (8-1, prepared in the same manner as Intermediate 5-3), 9 mg (0.094 mmol) sodium t-butoxide, 2 mg (0.003 mmol) racemic-2,2'- bis(diphenylphosphino)-l,l '-binaphthyl (BlNAP), and 2 mg (0.003 mmol) tris(dibenzylideneacetone)dipalladium (0) was added 29μL (0.262 mmol) benzylamine. The reaction vessel was capped and warmed to 110 0C overnight. The clear toluene layer was decanted and the residue extracted (2x hot toluene). The combined organic extracts were concentrated to dryness in vacuo, the residue dissolved in 900μL DMF and purified by preparative HPLC (5->95% CH3CN/H2O over 30m, 0.05% added TFA, C18 PRO YMC 20x150 mm)to afford, after lyophilization, 8-{[6- (benzylamino)pyridinium-3-yl]methyl}-4-(cyclohexylamino)-l-(3-fluorophenyl)-2 -oxo-1, 3-diaza-8- azoniaspiro[4.5]dec-3-ene bis(trifluoroacetate) as a white fluffy solid. 1H NMR (CD3OD with K2CO3, 400MHz): δ 7.70 (s, IH), 7.34 (m, 5H), 7.23 (m, 2H), 7.08 (m, 3H), 6.47 (d, J= 8.60 Hz, IH), 4.49 (s, 2H), 3.77 (m, IH), 3.28 (s, 2H), 2.68 (m, 2H), 2.12 (m, 4H), 2.00 (m, 4H), 1.80 (m, 2H), 1.68 (m, IH), 1.33 (m, 5H). High resolution mass spec (FT/ICR): calc M+H = 541.3086, found 541.3103
EXAMPLE (8-3) tert-Butyl 5-{[4-(cyclohexylamino)-l-(3-fluorophenyl)-2-oxo-l,3,8-triazaspiro[4.5]dec-3-en-8- yl]methyl } pyridin-2-ylcarbamate(8-3)
Figure imgf000091_0001
To a solution of 188 mg (0.45 mmol) 4-(cyclohexylarnmonio)-l-(3-fluorophenyl)-2-oxo-l,3-diaza-8- azoniaspiro[4.5]dec-3-ene dihydrochloride (5-2) and 136 mg (0.473 mmol) tert-butyl 5-
(bromomethyl)pyridin-2-ylcarbamate ( prepared in a manner similar to that described in PCT application WO 00/0665570, substituting Methanesulfonicanhydredl/lutidine/LiBr/THF 0-55° C in the bromination step) in 2.5mL DMF was added 399 mg (2.89 mmol) granular potassium carbonate and the mixture stirred vigorously at 55 0C overnight. The reaction mixture was treated with 3OmL H2O and extracted with EtOAc (3x25mL). The combined extracts were washed with H2O (lx20mL), brine (lx20mL), dried over Na2SO4, filtered, and concentrated to dryness in vacuo to give a crude oily solid (390 mg). Purification by automated flash chromatography (0-6% MeOH in CH2Cl2 over 20m) afforded tert-butyl 5-{[4-(cyclohexylamino)-l-(3-fluorophenyl)-2-oxo-l,3,8-triazaspiro[4.5]dec-3-en-8-yl]methyl}pyridin-2- ylcarbamate as a white solid. 1H NMR (DMSO, 400 MHz): δ 9.67 (s, IH), 8.09 (d, J= 7.78 Hz, IH), 7.97 (s, IH), 7.69 (d, J= 8.42 Hz IH), 7.46 (dd, J = 8.52, 2.10 Hz IH), 7.36 (m, IH), 7.14 (m, 2H), 7.07 (d, J= 8.15 Hz IH), 3.68 (m, IH), 3.22 (s, 2H), 2.53 (m, 2H), 2.09 (m, 2H), 1.82 (m, 4H), 1.73 (m, IH), 1.61 (m, IH), 1.47 (s, 9H), 1.29 (m, 5H), 1.12 (m, IH). High resolution mass spec (FT/ICR): calc M+H = 551.3141, found 551.3157
EXAMPLE (8-4)
8-[(6-aminopyridin-3-yl)methyl]-4-(cyclohexylamino)-l-(3-fluorophenyl)-2 -oxo-1, 3,8- triazaspiro[4.5]dec-3-ene (8-4)
Figure imgf000092_0001
To a suspension of 64 mg (0.116 mmol) tert-butyl 5-{[4-(cyclohexylamino)-l-(3-fluorophenyl)-2-oxo- l,3,8-triazaspiro[4.5]dec-3-en-8-yl]methyl}pyridin-2-ylcarbamate in 1.5mL EtOAc at 0 0C was bubbled in HCl gas until the solvent was saturated. The reaction was stirred in the cold for 30 min and concentrated in vacuo. The solid residue was reconcentrated to dryness (2x ethyl ether) and dried under high vacuum to give 8-[(6-ammopyridinium-3-yl)methyl]-4-(cyclohexylamino)-l-(3-fluorophenyl)-2- oxo-1, 3-diaza-8-azoniaspiro[4.5]dec-3-ene dichloride dichloride as a fine white solid. 1H NMR (CD3OD with K2CO3, 400MHz): δ 7.65 (s, IH), 7.41 (m, IH), 7.27 (dd, J = 8.48, 2.34 Hz IH), 7.16 (m IH), 7.07 (m, 2H), 6.51 (d, J= 8.52 Hz, IH), 3.77 (m, IH), 3.28 (s, 2H), 2.68 (m, 2H), 2.13 (m, 4H), 1.99 (m, 4H), 1.80 (m, 2H), 1.68 (m, IH), 1.34 (m, 5H). High resolution mass spec (FT/ICR) calc M+H = 451.2616, found 451.2617.
The aminopyridine Examples (8-5) - (8-25) listed below in Table 4 were prepared in a manner similar to that described in Scheme 8. Examples (8-5) - (8-25) and their pharmaceutically acceptable salts are depicted in enamine form, but may also exist in tautomeric imine form. Example (8-26) was prepared in the same manner as (8-5)-(8-25) starting with 8-[(6-bromophenyl)methyl]-4- (cyclohexylamino)-l-(3-fluorophenyl)-l,3,8-triazaspiro[4.5]dec-3-en-2-one.
Table 4- Compounds (or salts thereof) Synthesized According to Scheme 8
Figure imgf000092_0002
Figure imgf000093_0001
Figure imgf000094_0001
EX Structure Chemical Name Mass spec
4-(cyclohexylamino)-l -(3- 507.3
8-16 fluorophenyl)-8-{[2-
(isobutylamino)pyridin-3-yl]methyl}- l,3,8-triazaspiro[4.5]dec-3-en-2-one
Figure imgf000095_0001
4-(cyclohexylamino)-8-( {2- 505.3
8-17 [(cyclopropylmethyl) amino]pyridin-3 - yl}methyl)-l-(3-fluorophenyl)-l,3,8- triazaspiro[4.5]dec-3-en-2-one
Figure imgf000095_0002
4-(cyclohexylamino)- 1 -(3 - 569.3
8-18 fluorophenyl)-8-({2-[(3-phenylpropyl) amino]pyridin-3-yl } methyl)- 1,3,8- triazaspiro[4.5]dec-3-en-2-one
Figure imgf000095_0003
8-19 8- { [2-(sec-butylamino)pyridin-3- 507.3 yl]methyl}-4-(cyclohexylamino)-l-(3- fluorophenyl)-l ,3,8- triazaspiro[4.5]dec-3-en-2-one
Figure imgf000095_0004
Figure imgf000096_0001
Figure imgf000097_0001
A representative procedure for elaboration of the R.3 substituent, as depicted in Scheme 3 below, can be used in the synthesis of various compounds of the invention, including Examples (9-4) - (9-11) below. Examples (9-4) - (9-11) are depicted below in enamine form, but may also exist in tautomeric imine form, as described above
Figure imgf000098_0001
EXAMPLE 9-4 tert-Butyl 2-(3-{[4-(cyclohexylamino)-l-(3-fluorophenyl)-2-oxo-l,3,8-triazaspiro[4.5]dec-3-en-8- yl]methyl}phenoxy)propylcarbamate
Figure imgf000099_0001
Step 1: tert-Butyl 2-hydroxypropylcarbamate (9-2): tert-Butyl 2-hydroxypropylcarbamate (2): Biorg. Med Chem., 6, 1998 2405-2419 Added Boc anyhdride (8.19g, 37.4 mmole) in CH2Cl2 (30mL)to a solution of l-amino-2-propanol in 77 mL of 10% Et3N in MeOH. Let stir at rt under Argon. After 6 hr, concentrated in vacuo. Purified on a 12Og redisep coumn eluting with 1-1 EtOAc Hex. Concentrated clean fractions in vacuo.
Step 2: t-Butyl 2,3-(formylphenoxy)propylcarbamate (9-3) t-Butyl 2,3-(formylphenoxy)propylcarbamate Dissolved triphenylphosphine (0.805g, 3.07 mmole), 3-hydroxybenzaldehyde (0.25g, 2.047 mmole) and t-butyl 2-hydroxypropylcarbamate(0.395g, 2.25 mmole, ) in dry toluene (5 mL) at rt. Added ADDP
(azodicarbonyldipiperdine) (0.755g, 3.07 mmole) at once. Warmed quickly to 800C. After 5 hr, cooled to rt. Diluted with CH2Cl2 and filtered off solids, washing with CH2CI2 - Concentrated filtrate in vacuo.
Dissolved in 50 mL CH2CI2. Washed with 1 N NaOH (2x20 mL), and then with brine. Dried over Na2SO4, filtered and cone in vacuo. Purified using a 12Og isco redisep column eluting with 5% EtOAc to 25 % EtOAc in hexanes to give the aldehyde.
tert-Butyl 2-(3-{[4-(cyclohexylamino)-l-(3-fluorophenyl)-2-oxo-l,3,8-triazaspiro[4.5]dec-3-en-8- yljmethyl } phenoxy)propylcarbamate (9-4) : t-Butyl 2,3-(formylphenoxy)propylcarbamate and 4-(cyclohexylamino)-l -(3-fluorophenyl)-2-oxo-l ,3- triazaspiro[4.5]dec-3-ene dihydrochloride salt (5-2) were coupled using a procedure similar to that described for Example (5-6).
1H NMR (CDCl3, 400 Mh), δ 7.98 (bd, J=8.05 Hz, IH); 7.35 (m, IH); 7.24 (m, IH); 7.03 (m, 2H); 6.97 (m, IH); 6.82 (m, 3H); 4.88 (bs, IH); 4.50 (bs, IH); 3.97 (m, IH); 3.49 (s, 2H); 3.44 (m, 2H); 3.25 (m, IH); 2.78 (m, 2H); 2.44 (m, 2H); 2.07 (m, 4H); 1.95 (m, 2H); 1.72 (m, 3H); 1.44 (s, 9H); 1.39 (m, 2H); 1.27 (d, J=6.0 Hz, 3H); 1.19 (m, 3H). Mass Spec (m+1) = 608.
EXAMPLE 9-5
8-[3-(2-amino-l -methylethoxy)benzyl]-4-(cyclohexylamino)-l -(3 -fluorophenyl)- 1 ,3,8- triazaspiro[4.5]dec-3-en-2-one(9-5)
Figure imgf000100_0001
Added 2 mL of TFA to an ice cold solution of (4) (0.103g, 0.169 mmole) in 5 mL CH2CI2 at rt while magnetically stirring. After 15 min the reaction was concentrated in vacuo. The residue was dissolved in CH3CN, then purified on the Gilson reverse phase 100x30 mm YMC J-sphere column, eluting with 10-60% CH3CN in H2O with 0.1% TFA. Concentrated appropriate fractions in vacuo on the Genie vac. The dry fractions were partitioned between NaHCO3(aq), and CH2CI2, separated, and the aqueous layer was washed with CH2CI2. The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated in vacuo to yield 0.123 mg. NMR in CDCI3 showed an impurity present. Repeated the above purification until there were no impurities present to yield the product. 1H NMR (CDCl3, 400 Mh), δ 8.01 (bd, J=8.5 Hz, IH); 7.35 (m, IH); 7.25 (m, IH); 7.01 (m, 3H); 6.86 (d, J=9.3 Hz, IH); 6.81 (m, 2H); 4.37 (q, J=5.8, 5.4, IH); 3.97 (m, IH); 3.51 (d, J=2.4 Hz, 2H); 2.9 (m, 2H); 2.79 (m, 4H); 2.41 (m, 2H); 2.13 (m, 2H); 2.03 (m, 4H); 1.72 (m, 2H); 1.65 (m, IH); 1.45 (m, 2H); 1.28 (d, J=6.0 Hz, 3H); 1.24 (m, 3H).
Mass spec (m+1) = 508 8-[3-(2-amino-l-(R)- methylethoxy)benzyl]-4-(cyclohexylamino)-l-(3-fluorophenyl)-l,3,8- triazaspiro[4.5]dec-3-en-2-one and 8-[3-(2-amino-l-(S)- methylethoxy)benzyl]-4-(cyclohexylamino)-l- (3-fluorophenyl)-l,3,8-triazaspiro[4.5]dec-3-en-2-one (9-5 and 9-5)
The racemic mixture of 8-[3-(2-amino-l-methylethoxy) benzyl]-4-(cyclohexylamino)-l-(3-fluorophenyl)- l,3,8-triazaspiro[4.5]dec-3-en-2-one (100 mg) was submitted for separation via chiral chromatography. The compound was eluted with 20% EtOH in Hexanes with 1 niL/L of DEA on a Chiral Pak AD column. Mass spec (m+1) = 508
. EXAMPLE 9-6 N-[4-(3-{[4-(cyclohexylamino)-l-(3-fluorophenyl)-2-oxo-l,3,8-triazaspiro[4.5]dec-3-en-8- yl]methyl}phenoxy)butyl]methanesulfonamide. (9-6).
Figure imgf000101_0001
Methanesulfonyl chloride(.019 mL, 0.245 mmole) was added dropwise to a solution of 8-{3-[(6- aminohexyl)oxy]benzyl}-4-(cyclohexylamino)-l-(3-fluorophenyl)-l,3,8-triazaspiro[4.5]dec-3-en-2-one (0.116 mg, 0.222 mmole)in 5 mL CH2CI2 at rt, and EtβN (0.034 mL, 0.245 mmole. After stirring for 0.5 hr at rt, the reaction was concentrated in vacuo. The residue was redissolved in CH2CI2, washed with H2O, and then brine. Dried over Na2SO4, filtered and cone in vacuo. The residue was purified on a 40 g silica gel column eluting with 100% CH2CI2 saturated with ammonia to 4% MeOH in CH2CI2 saturated with ammonia. The clean fractions were combined and concentrated in vacuo to yield the product. 1H NMR (CDCl3, 400 Mh), δ 7.73 (bd, J=8.0 Hz, IH); 7.35 (dd, J=8.1, 14.6 Hz, IH); 7.23 (m, IH); 7.01 (m, 3H); 6.83 (m, 3H); 4.70 (m, IH); 4.55 (m, IH); 3.97 (m, IH); 3.49 (d, J=3.8 Hz, 2H); 3.41 (m, IH); 3.27 (m, IH); 2.99 (s, 3H); 2.74 (m, 2H); 2.40 (m, 2H); 2.09 (m, 4H); 1.97 (m, 2H); 1.72 (m, 3H); 1.41 (m, 2H); 1.30 (d, J=6.1 Hz, 3H); 1.24 (m, 3H). Mass spec (m+1) = 600
Table 5: The following compounds (or salts thereof) of Table 5 were prepared by methods similar to that described for 9-4, 9-5, and 9-6, utilizing the appropriate reagents.
Figure imgf000102_0001
Figure imgf000103_0002
A representative procedure for elaboration of the R.3 substituent, as depicted in Scheme 10 below, can be used in the synthesis of various compounds of the invention, including Examples (10-1) ■ (10-3) below. Examples (10-1) - (10-3) are depicted below in enamine form, but may also exist in tautomeric imine form, as described above
Scheme 10
Figure imgf000103_0001
EXAMPLE 10-2
8-[3-(aminomethyl)benzyl]-4-(cyclohexylamino)-l-(3-fluorophenyl)-l,3,8-triazaspiro[4.5]dec-3-en-2- one.
Figure imgf000104_0001
A 5OmL EtOH suspension of 0.470g(1.02mmol) 8-[3-cyanobenzyl]-4-(cyclohexylamino)-l-(3- fluorophenyl)-l,3,8-triazaspiro[4.5]dec-3-en-2-one (Example (7-12)) and a small amount of Raney Nickel (in water) was first evacuated and flushed with N2 3 times then put under a H2 balloon and allowed to stir overnight. The catalyst was filtered and the filtrate concentrated in vacuo to pure product. 1H NMR (400MHz, CDCl3) δ 7.98-8.0 (m, IH), 7.28-7.52 (m, 4H), 7.20-7.24 (m, IH), 7.12-7.14 (m, IH), 6.97-7.04 (m, 2H), 4.70 (s, 2H), 3.95-4.05 (m, IH), 3.69-3.73 (m, IH), 2.74-2.81 (m, 2H), 2.4-2.46 (m, 2H), 2.05-2.14 (m, 4H), 1.92-2.03 (m, 2H), 1.35-1.75 (m, 9H). exact MS found 464.2806 theory 464.2820
EXAMPLE 10-3
N-(3-{[4-(cyclohexylamino)-l-(3-fluorophenyl)-2-oxo-l,3,8-triazaspiro[4.5]dec-3-en-8- yl]methyl}benzyl)methanesulfonamide.
Figure imgf000105_0001
A 2mL CH2Cl2 suspension of 0.05g(0.1 lmmol) 4-(cyclohexylamino)-8-[3-(aminomethyl)benzyl]-l-(3- fluorophenyl)-l,3,8-triazaspiro[4.5]dec-3-en-2-one (Example (7-12)), 0.02mL(0.22mmol) methanesulfonyl chloride and excess K2CO3 was allowed to stir at rt overnight. The reaction was filtered and concentrated. The remaining oil was dissolved in 0.5mL CH2Cl2 and purified on an Isco automated system affixed with a Biotage Flash 25(S) cartridge eluted at 20mL/min with 0-5% MeOH in CH2Cl2 over 15min and hold at 5% MeOH for 30 min. The product eluted second, pure by HPLC/MS and NMR. 1H NMR (400MHz, CDCl3) δ 7.79-7.83 (m, IH), 7.45-7.54 (m, 2H), 7.33-7. 4 (m, 2H), 7.12-7.14 (m, IH), 6.96-7.05 (m, 3H), 4.31-4.39 (m, IH), 3.92-4.05 (m, IH), 3.48-3.52 (m, IH), 2.65-2.80 (m, 2H), 2.4- 2.50 (m, 2H), 1.90-2.20 (m, 6H), 1.62-1.8 (m, 4H), 1.55 (s, 3H), 1.30-1.50 (m, 2H), 1.15-1.30(m, 4H). MS 542.4
A representative procedure for elaboration of the R3 substituent, as depicted in Scheme 11 below, can be used in the synthesis of various compounds of the invention, including Examples (11-2) - (11-8) below. Examples (11-2) - (11-8) are depicted below in enamine form, but may also exist in tautomeric imine form, as described above
Figure imgf000106_0001
EXAMPLE 11-2 -(3-aminobenzyl)-4-(cyclohexylamino)-l-(3-fluorophenyl)-l,3,8-triazaspiro[4.5]dec-3-en-2-one
Figure imgf000106_0002
A 10OmL EtOH solution of 1.Og (2.1mmol) 8-(3-nitorobenzyl)-4-(cyclohexylamino)-l-(3-fluorophenyl)- l,3,8-triazaspiro[4.5]dec-3-en-2-one (example 104) and 0.57g(2.5mmol) SnCl2 dihydrate was heated to reflux and allowed to stir overnight. HPLC/MS showed complete conversion so the reaction mixture was filtered through celite washed with EtOH then the filtrate was concentrated. The remaining oil was partitioned between 3N NaOH and EtOAc. A thick white precipitate formed in the aqueous layer. The organic layer was washed with brine, dried over Na2SO4, filtered and concentrated to pure product. 1H NMR (400MHz, CDCl3) δ 8.09-8.11 (m, IH), 7.32-7.36 (m, IH), 7.10-7.13 (m, IH), 6.96-7.03 (m, 3H), 6.60-6.63 (m, 2H), 6.53 (s, IH), 3.95-4.0 (m, IH), 3.43 (s, 2H), 2.75-2.80 (m, 2H), 2.37-2.42 (m, 2H), 1.93-2.12 (m, 5H), 1.64-1.75 (m, 3H), 1.35-1.41 (m, 2H), 1.16-1.27 (m, 4H). MS 450.4
EXAMPLE 11-3
N-(3-{[4-(cyclohexylamino)-l-(3-fluorophenyl)-2 -oxo-1, 3,8-triazaspiro[4.5]dec-3-en-8- yl]methyl}phenyl)acetamide
Figure imgf000107_0001
A 2mL CH2Cl2 suspension of 0.05g(0.1 lmmol) 4-(cyclohexylamino)-8-[3-aminobenzyl]-l-(3- fluorophenyl)-l,3,8-triazaspiro[4.5]dec-3-en-2-one, 0. ImL(0.1 lmmol) acetyl chloride and excess K2CO3 was allowed to stir at rt overnight. The reaction was filtered and concentrated then the remaining oil was dissolved in ImL CH2Cl2 and purified on an Isco automated system affixed with a Biotage Flash 25(S) cartridge eluted at 20mL/min with 0-5% MeOH in CH2Cl2 over 15min and hold at 5% MeOH for 30 min. The product eluted second, pure by HPLC/MS and NMR.
1H NMR (400MHz, CDCl3) δ 7.88-7.90 (m, IH), 7.63-7.70 (m, 2H), 7.30-7.35 (m, IH), 7.19-7.24 (m, IH), 6.92-7.04 (m, 4H), 3.90-3.94 (m, IH), 3.47 (s, 2H), 2.72-2.78 (m, 2H), 2.29-2.36 (m; 4H), 2.14 (s, 3H), 1.98-2.1 (m, 6H), 1.62-1.73 (m, 2H), 1.13-1.41 (m, 4H).MS 492.4 EXAMPLE 11-4
N-(3-{[4-(cyclohexylamino)-l-(3-fluorophenyl)-2-oxo-l,3,8-triazaspiro[4.5]dec-3-en- yl]methyl}phenyl)methanesulfonamide
Figure imgf000108_0001
Produced by the method for Example 11-3 above but substituting sulfonyl chloride for acetyl chloride. 1H NMR (400MHz, CDCl3) δ 7.60-7.62 (m, IH), 7.30-7.38 (m, 2H), 7.20 (s, IH), 7.12-7.14 (m, IH), 6.96-7.07 (m, 4H), 3.92-3.96 (m, IH), 3.51 (s, 2H), 3.00 (s, 3H), 2.69-2.75 (m, 2H), 2.36-2.43 (m, 2H), 1.97-2.14 (m, 6H), 1.68-1.74 (m, 2H), 1.16-1.42 (m, 6H). MS 528.1
EXAMPLE 11-5
4-(cyclohexylamino)- 1 -(3-fluorophenyl)-8- {3-[(2-methylpentyl)amino]benzyl} -1,3,8- triazaspiro[4.5]dec-3-en-2-one
Figure imgf000109_0001
Method Z: A 5ml dichloroethane suspension of 0.05g(0.1 lmmol) 4-(cyclohexylamino)-8-[3- aminobenzyl]-l-(3-fluorophenyl)-l,3,8-triazaspiro[4.5]dec-3-en-2-one (Example 11-2), 0.01mL(0.13mmol) 2-methylpentan-l-al, 0.05mL HOAc, and 0.05g (0.22mmol) sodium triacetoxyborohydride was allowed to stir at rt overnight. The reaction was quenched with saturated aqueous NaHCO3, diluted with CH2CI2 and allowed to stir vigorously for 15 min. The organic layer was washed with brine, dried over Na2SO4, filtered and concentrated. The remaining oil was purified on an Isco automated system affixed with a Biotage Flash 25(S) cartridge eluted with 5% MeOH in CH2Cl2 at 20mL/min for 30 min. The product eluted second.
1H NMR (400MHz, CDCl3) δ 8.22-8.24 (m, IH), 7.31-7.37 (m, IH), 7.11-7.15 (m, IH), 6.94-7.02 (m, 3H), 6.52-6.56 (m, 2H), 6.43 (s, IH), 3.94-3.97 (m, IH), 3.65-3.70 (m, IH), 3.45 (s, 2H), 3.00-3.06 (m, IH), 2.77-2.90 (m, 3H), 2.39-2.45 (m, 2H), 1.87-2.14 (m, 7H), 1.64-1.74 (m, 3H), 1.13-1.44 (m, 8H), 0.89-0.97 (m, 6H).MS 534.3
EXAMPLE 11-6
4-(cyclohexylamino)-l-(3-fluorophenyl)-8-[3-(isopropylamino)benzyl]-l,3,8-triazaspiro[4.5]dec- 3-en-2-one
Figure imgf000110_0001
This compound was produced using Method Z substituting acetone for the aldehyde. 1H NMR (400MHz, CDCl3) δ 8.18-8.2 (m, IH), 7.31-7.36 (m, IH), 7.11-7.14 (m, IH), 6.96-7.03 (m, 3H), 6.50-6.54 (m, 2H), 6.41 (s, IH), 3.94-3.97 (m, IH), 3.59-3.65 (m, IH), 3.45 (s, 2H), 2.77-2.83 (m, 2H), 2.38-2.44 (m, 2H), 1.91-2.13 (m, 3H), 1.63-1.75 (m, 3H), 1.34-1.43 (m, 2H), 1.14-1.25 (m, 6H). MS 492.4
EXAMPLE 11-7
4-(cyclohexylamino)-l-(3-fluorophenyl)-8-[2-(isopropylamino)benzyl]-l,3,8-triazaspiro[4.5]dec-3-en-2- one.
Figure imgf000110_0002
Produced using Method Z substituting acetone for the aldehyde and 8-(2-aminobenzyl)-4- (cyclohexylamino)-l-(3-fluorophenyl)-l,3,8-triazaspiro[4.5]dec-3-en-2-one (example 80) for the substrate. MS 492.4 EXAMPLE 11-8
4- [(2- { [4-(cyclohexylamino)- 1 -(3 -fluorophenyl)-2-oxo- 1 ,3 , 8-triazaspiro [4.5] dec-3 -en- yl]methyl}phenyl)amino]butanenitrile
Figure imgf000111_0001
A 2mL CH3CN suspension of 0.05g(0.1 lmmol) 8-(2-arninobenzyl)-4-(cyclohexylamino)-l-(3- fluorophenyl)-l,3,8-triazaspiro[4.5]dec-3-en-2-one(example 80), excess 4-bromobutyronitrile and Cs2CO3 was heated to 600C and allowed to stir for 2 days. HPLC/MS showed a small amount of product so the reaction was filtered and concentrated. The remaining oil was purified on an Isco automated system affixed with a Biotage Flash 25(M) cartridge eluted with 0-5% MeOH + 0.5M NH3 in CH2Cl2 over 30 min at 20mL/min. The product eluted last.
1H NMR (400MHz, CDCl3) δ 7.31-7.42 (m, IH), 6.83-7.18 (m, 5H), 6.57-6.70 (m, 2H), 4.6-4.8 (br m, IH), 3.57-3.97 (m, 6H), 3.28 (m, IH), 2.65-2.70 (m, IH), 2.39-2.58 (m, 4H), 2.21-2.25 (m, IH), 1.67- 2.08 (m, 9H), 1.26-1.43 (m, 4H). MS 517.1
A representative procedure for elaboration of the R.3 substituent, as depicted in Scheme 12 below, can be used in the synthesis of various compounds of the invention, including Example (12-4) below. Example (12-4) is depicted below in enamine form, but may also exist in tautomeric imine form, as described above Scheme 12
Figure imgf000112_0001
Figure imgf000112_0002
EXAMPLE 12-4
3-(3-{[4-(cyclohexylamino)-l-(3-fluorophenyl)-2-oxo-l,3,8-triazaspiro[4.5]dec-3-en- yl]methyl}phenyl)-2-methylpropanenitrile (12-4).
-Ill-
Figure imgf000113_0001
Step 1: 3-(3-bromophenyl)-2-methylpropanenitrile (12-2).
To a 1OmL THF solution of 2.5mL (5mmol) LDA (2M in THF) on a dry ice - acetone bath went 0.7mL (4.76mmol) 3-bromopropionitrile(9-l) dropwise. The solution was allowed to stir for 15min, then transferred by cannula to a 1OmL THF solution of 0.31mL(5mmol) MeI also cooled to -780C. The bath was removed and the reaction was allowed to warm to rt and stir for 30min. The reaction was quenched with saturated aqueous NH4Cl and the product was extracted into EtOAc. The organic layer was dried over Na2SO4, filtered and concentrated. The remaining oil was dissolved in ImL CH2Cl2 and purified on an Isco automated system affixed with a Biotage Flash 40(M) cartridge eluted with 50-100% EtOAc in hexane. The product eluted last. MS 224.0 NB#212867-102
Step 2: 3-(3-formylphenyl)-2-methylpropanenitrile (12-3).
A 3-neck flask equipped with a condenser and 2 septa was flushed with N2, then the flask was charged with 0.6g(2.7mmol) 3-(3-bromophenyl)-2-methylpropionitrile(9-2), 0.275g(4mmol) sodium formate, 0.155g(0.13mmol) tetrakis(triphenylphospine)Palladium and flushed with CO from a balloon for 5 min. The solids were suspended in 1OmL DMF and CO continued to bubble into the liquid. The flask was heated in an oil bath at 100' for 20min then 110' while stirring. The color changed from yellow to a deep orange color after 1.5 h, and HPLC/MS analysis showed no starting material and one major product. The reaction was cooled and quenched with brine. The product was extracted into EtOAc, dried over Na2SO4, filtered and concentrated. The product was dissolved in ImL CH2CI2 and purified on an Isco automated system affixed with a Biotage Flash 25(M) cartridge eluted with 0-50% EtOAc in hexane at 25mL/min over 15 min and hold for 30 min. The product eluted last. MS 174.1 NB#212867-104
Step 3: 3-(3-{[4-(cyclohexylamino)-l-(3-fluorophenyl)-2-oxo-l,3,8-triazaspiro[4.5]dec-3-en-8- yl]methyl}phenyl)-2-methylpropanenitrile (12-4). To a 2OmL dichloroethane solution of 0.35g(0.92mmol) 4-(cyclohexylamino)-l-(3-fluorophenyl)-l,3,8- triazaspiro[4.5]dec-3-en-2-one and 0.25mL(1.4mmol) DIEA went 0.16g(0.92mmol) 3-(3-formylphenyl)- 2-methylpropanenitrile(9-3). The suspension was allowed to stir for 10 min then 0.4g(1.9mmol) sodium triacetoxyborohydride was added and the reaction was allowed to stir at rt overnight. HPLC/MS showed no starting material so the reaction was quenched with 10OmL sat NaHCO3 and diluted with CH2Cl2.
The organic layer was washed with brine, dried over Na2SO4, filtered and concentrated. The remaining oil was purified on an Isco automated system affixed with a Biotage Flash 25(M) cartridge eluted with
5% MeOH + 0.5M NH3 in CH2Cl2 at 25mL/min over 30min. The product eluted second.
1H NMR (400MHz, CDCl3) δ 7.80-7.82 (d, IH J=SHz), 7.28-7.37 (m, 2H), 7.14-7.19 (m, 3H), 6.96-7.04
(m, 3H), 3.94-3.97 (m, IH), 3.51 (s, 2H), 2.84-2.87 (m, 3H), 2.71-2.78 (m, 2H), 2.34-2.41 (m, 2H), 1.97-
2.11 (m, 6H), 1.65-1.75 (m, 3H), 1.33-1.41 (m, 5H), 1.17-1.25 (m, 3H).
MS 502.0
Scheme 13
Figure imgf000114_0001
13-1 13-2 13-3
Figure imgf000114_0002
A representative procedure for elaboration of the R3 substituent, as depicted in Scheme 13 below, can be used in the synthesis of various compounds of the invention, including Examples (13-4) (13-5) below. Examples (13-4) - (13-5) are depicted below in enamine form, but may also exist in tautomeric imine form, as described above EXAMPLE 13-4
4-(cyclohexylamino)-l-(3-fluorophenyl)-8-[(6-isopropoxypyridin-2-yl)methyl]-l,3,8-triazaspiro[4.5]dec- 3-en-2-one
Figure imgf000115_0001
Step 1: 2-bromo-6-isopropoxypyridine
The compound was prepared in a manner similar to that described in WO 02/076983 (page 80). Dry isopropanol (25 mL, 42.2 mmole) was placed in an oven-dried 250 ml 3 necked flask under nitrogen, sodium spheres (0.5g, 21.1 mmol) were added and the reaction was heated to 80° C to dissolve the sodium. 2,6 dibromopyridine (1Og, 42.2 mmole) was added as a solid and the reaction was heated at 95 0C . After heating for -2.5 hr the reaction was cooled and partitioned between ether and water. The organic layer was evaporated to give a solid plus oil, the mixture was suspended in hexanes, cooled, and filtered to remove the solid. The filtrate was evaporated carefully and chromatographed on silica eluting with hexanes to give the product as a clear, colorless oil.
1H NMR (400MHz, CDCl3) δ 8.23 (d, J = 7.8 Hz, IH), 7.53 (t, J = 8.2 Hz, IH), 7.33 (dd, J= 8.0, 14.7 Hz, IH), 7.0 (m, 3H), 6.75 (d, 7=7.2 Hz, IH), 6.60 (d, J= 8.3 Hz, IH), 5.22 (m, IH), 3.93 (m, IH), 3.59 (s, 2H), 2.90 (m, 2H), 2.55 (m, 2H), 2.12 (m, 2H), 2.0 (m, 4H), 1.7-1.5 (m, 4H), 1.4-1.3 (m, 2H), 1.33 (d, J= 6.2 Hz, 6H), 1.15 (m, 3H). LCMS (m+l) = 215.1, 217.1
Step 2: 6-isopropoxypyridine-2-carbaldehyde
ό-isopropoxypyridine^-carbaldehyde was prepared in a manner similar to that described in D. L Comins, M.O. Killpack, J. Org. Chem. 1990 55 69-73 for the methoxy analog. 2-bromo-6-isopropoxypyridine (Ig, 4.6 mmole) was dissolved in 10ml dry THF under argon, cooled to -78° C and treated with added 2.5 M n-Butyl lithium ( 1.9 mL, 4.8 mmole) keeping the temperature of the reaction below -65° C. After the reaction had stirred 45 min DMF ( 0.717 mL, 9.25 mmole) was added, again keeping temp below -60° C, the reaction was stirred for 15 min, then quenched with saturated bicarbonate solution. The layers were separated, the aqueous extracted with CHCI3, the organic layers dried over Na2SO4, filtered and evap carefully, and the residue chromatographed in 0-50% Ether / hexanes to give the product as an oil. LCMS (m+l) = 165.2
Step 3: 4-(cyclohexylamino)-l-(3-fluorophenyl)-8-[(6-isopropoxypyridin-2-yl)methyl]-l,3,8- triazaspiro[4.5]dec-3-en-2-one. This compound was prepare in a manner similar to that described for example (5-6) using the intermediate from scheme 13 step 2 and compound (5-2). LCMS (m+l) = 494.1
EXAMPLE 13-5
8-[(6-sec-butoxypyridin-2-yl)methyl]-4-(cyclohexylamino)-l-(3-fluorophenyl)-l,3,8-triazaspiro[4.5]dec- 3-en-2-one
Figure imgf000116_0001
8-[(6-sec-butoxypyridin-2-yl)methyl]-4-(cyclohexylamino)-l-(3-fluorophenyl)-l,3,8-triazaspiro[4.5]dec- 3-en-2-one was prepared in a manner similar to that described for Example 13-4 except that dichloroethane was used in the final step. LCMS (m+l) = 508.1
Scheme 14A depicts a method for preparing 8-Benzyl-l-phenyl-4-thioxo-l,3,8-triaza- spiro[4.5]decan-2-one 14A-5 intermediates useful for making compounds of the invention. The commercially available 14A-1 may be alkylated with an appropriate alkyl halide like benzyl chloride using a suitable base like potassium carbonate in a suitable solvent like acetonitrile to afford 14A-2. A similar method is described by M. E. Kopach et. al. J. Org .Chem. 2003 68 5739-5741. A modified Strecker reaction of A-2 yields 14A-3; and followed by the treatment of chlorosulfonyl isocyanate in methylene chloride to afford 14A-4. A similar method is described by P.L. Feldman and M. F. Brackeen J. Org. Chem. 1990, 55, 4207-4209 at reference therein. 14A-5 is obtained by the thiolation of 14A-4 by Na2S. The treatment of the intermediates 14A-5 with various amines in a suitable solvent like in DMSO or DMF with heat yields the invention compounds 14A-6.
Scheme 14A
Figure imgf000117_0003
Figure imgf000117_0001
Figure imgf000117_0002
14A-1 14A-2 14A-3
Figure imgf000117_0004
Figure imgf000118_0001
14-4 14-5 14-6
Figure imgf000118_0002
14-7 14-8
EXAMPLE 14 l-(3-Fluorophenyl)-4-isobutylamino-8-(3-isopropoxy-benzyl)-l,3,8-triaza-spiro[4.5]dec-3-en-2-one (14- 8).
Figure imgf000118_0003
Step 1: 3-Isopropoxy-benzylbromide (14-3)
To a solution of 3-Isopropoxy-benzaldehyde 14-1 (20 g, 122 mmol) in methanol (400 mL), sodium borohydride (5g) is added in several portions at 0° C. The resulting mixture is then stirred at rt for 3 h. The reaction is quenched by addition of saturated NH4OH. Extracted (EtOAc), concentrated, a colorless oil 14-2 (MH+, 166) is obtained and use without purification. Re- dissolve (3-Isopropoxy-phenyl)- methanol 14-2 in ether (244 mL) PBr3 (11.5 mL, 122 mmol) is added dropwise at 0 0C. The reaction mixture is stirred at 0 0C then rt for 3 h, quenched (MeOH), extracted (EtOAc), concentrated, a colorless oil 14-3 is obtained. (MH+, 288)
Step 2: l-(3-Isopropoxy-benzyl)-piperidin-4-one monohydrate (14-4)
A mixture of 4-piperidone hydrochloride monohydrate (19.52g, 127.12 mmol), l-Bromomethyl-3- isopropoxy-benzene (19.41g, 84.76 mmol) and K2CO3 in DMF (150 mL) is stirred at rt for 16 hr. Solvent is removed in vacco, the residue is extract (EtOAc/ Brine), dried (Na2SO4), concentrated, and purified by chromatography (silica gel, EtoAc / hexanes, 2/3) to afford 14-4. (MH+, 266)
Step 3: 4-(3-Fluoro-phenyl)-l-(3-isopropoxy-benzyl)-piperidine-4-carbomtrile (14-5) To a solution of l-(3-Isopropoxy-benzyl)-piperidin~4-one monohydrate 14-4 (7.98g, 30 mmol) and aniline (3.67g, 33mmol) in glacial acetic acid (30 mL) is added TMSCN (2.98g, 30 mmol) dropwise over a 10 min period, maintaining the temperature below 40 0C. The reaction mixture is stirred an additional 30 min and than poured into a cold NH4OH mixture (30 mL NH4OH and 30 g of ice). Additional of NH4OH is slowly added until pH =10 is reach. Extracted (CHCl3), Dried (Na2SO4), Concentrated, and Purified by silica gel to afford 14-5. LCMS (MH+ 368.3)
Step 4: l-(3-Fluoro-phenyl)-8-(3-isopropoxy-benzyl)-4-thioxo-l,3,8-triaza-spiro[4.5]decan-2-one (14-7) The 4-(3-Fluoro-phenyl)-l-(3-isopropoxy-benzyl)-piperidine-4-carbonitrile 14-5 (5.28 g, 15.0 mmole) was dissolved into chloroform (15 mL). The solution was stirred and cooled to 0° C, at which point chlorosulfonyl isocyanate (Acros, 1.75 mL, 20.1 mmole, 1.25 eq) was added dropwise, causing formation of a large amount of white precipitate. The ice bath was removed, and the slurry was stirred hard with a magnetic stirrer for 10 min. LCMS (MH+ 411.2) indicated consumption of the nitrile at this point. Water (15 mL) was added, and the heterogeneous mixture was stirred hard at rt for 1 hr. In a 500 mL Erlenmeyer flask (used to accommodate a large stir bar), sodium sulfide (anhydrous, Aldrich, 22.5 g, 288 mmole) was dissolved into water (200 mL) and cooled to an internal temperature below 0° C with an ice/isopropanol bath. Acetic acid (approx 28 mL) was added dropwise to the stirred solution, over a period of about 10 min, ensuring that the internal temperature stayed close to 0° C. (During the addition, there is a formation of a large amount of light-colored precipitate and the mixture becomes thick. The thickness diminishes as the addition of acetic acid nears completion.) The addition was stopped when pH paper indicated that the pH was ~ 6, and the solution had assumed a slight greenish color. At this point, the above slurry of imine was added to the sulfide solution, using dichloromethane (~ 30 mL) to assist the transfer. Isopropanol (50 mL) was added, and the flask was sealed with a balloon, removed from the ice bath, and stirred hard for 16 hr. The reaction was then diluted with dichloromethane, and washed with water plus sufficient saturated sodium bicarbonate solution to ensure basic pH. The organic layer was then removed, and the aqueous layer was extracted with 2X dichloromethane. The combined organic layers were dried (MgSO4), filtered, and concentrated to a yellow solid. The solid was resuspended into dichloromethane, and deposited onto silica gel for chromatography. The sample was purified by flash chromatography over silica gel using a Combiflash system (80 g column), with 50% ethyl acetate/hexanes as the eluent (product Rf- 0.25), providing the product 14-7. LCMS (MH+ 428.2).
Step 6: l-(3-Fluorophenyl)-4-isobutylamino-8-(3-isopropoxy-benzyl)-l,3,8-triaza-spiro[4.5]dec-3-en-2- one (14-8). To a solution of l-(3-Fluoro-phenyl)-8-(3-isopropoxy-benzyl)-4-thioxo-l,3,8-triaza-spiro[4.5]decan-2- one SNS-I (21.4 mg, 0.05mmol) in DMSO (1 mL) was added isobutyl amine (36.5 mg, 0.5 mmol). The reaction mixture was heated at 1100C for 12 hr. The crude was purified by preparative HPLC to provide
(14-8).
1H NMR (CD3OD): δ 7.29 (br s, IH), 7.18 (m, IH), 7.05 (m, 3H), 6.90 (d, J = 8.31Hz, IH), 6.76 (br m, 2H), 4.50 (m, IH), 4.06 (br s, 2H), 3.00-3.20 (br, 2H), 2.2-2.8 (br, 4H), 1.92 ( br, IH), 1.19 (d, J =
5.87Hz), 0.86 (m, 6H). EI-MS m/z: 467.25 (MH+).
Table 6: The following compounds (or salts thereof) of table 6 were prepared in a manner similar to that described for scheme 14.
Figure imgf000120_0001
Figure imgf000121_0001
Figure imgf000122_0001
Figure imgf000123_0001
Figure imgf000124_0001
Figure imgf000125_0001
Figure imgf000126_0001
Figure imgf000127_0001
R2 elaboration can be prepared by the methods described in Scheme 3, Scheme 14-A with various substituted aniline or by Suzuki coupling of 15-1 with a various of boronic acid or boronate ester. A representative procedure for elaboration of the R.2 substituent, as depicted in Scheme 15 below, can be used in the synthesis of various compounds of the invention, including Examples (15-2) - (15-42) below. The boronate ester can be prepared as describe in Scheme 15-A. Examples (15-2) - (15-42) are depicted below in enamine form, but may also exist in tautomeric imine form, as described above.
Figure imgf000128_0001
Scheme 15-A: General Procedure for Synthesis of Boronate Esters from Aryl Halides
Figure imgf000128_0002
15-A-1 15-A-2
This procedure is based on conditions developed by Miyaura et. al.(J. Org. Chem. 1995, 60, 7508-7510). The aryl halide 15-A-l (0.20 mmol, leq), potassium acetate (O.όOmmol, 3 eq.), bis(pinacolato)diboron (0.18 mmol, 0.9 eq.) and PdCl2(dppf) (0.020mmol, 0.1 eq.) were added to a round bottom flask. Dry DMF (3 ml) was added, and the flask was flushed with nitrogen, then capped. The resultant mixture was stirred and placed into an 800C oil bath. The reaction was followed by LCMS. Upon consumption of aryl bromide (several hours), the reaction mixture was extracted with ethyl acetate / water 3-4 times, then washed with brine twice. The resultant organic solution was dried over MgSO4 and concentrated to afford crude boronate ester 15-A-2, which was used directly for the subsequent Suzuki coupling reactions. A series of representative Procedure for Synthesis of Boronate Esters from Aryl Halides is described in Scheme 15 -B-E Scheme 15-B
Figure imgf000129_0001
Compound 15-B-l ( 0.23Og 0.90mmol) was added to a stirred solution of methylamine hydrochloride ( 0.091g 1.35mmol) and pyridine ( 0.364ml 4.50 mmol) in dichloromethane (10 ml) at O0C. The reaction mixture was allowed to warm to room temperature and the reaction was followed by LCMS. Upon consumption of starting material (about 3hrs), the mixture was extracted twice with diethyl ether / saturated sodium bicarbonate solution. The organic solution was washed twice with an aqueous sodium dihydrogen phosphate (pH=3-4) solution, twice with brine, and then the organic solution was dried over MgSO4 and concentrated to afford the crude sulfonamide 15-B-2.
The crude 15-B-2 (0.05Og, 0.20 mmol ), potassium acetate (0.059g O.όOmmol), bis(pinacolato)diboron (0.046g, 0.18 mmol) and PdCl2(dppf) (0.016g 0.020mmol) were added to a round bottom flask. Dry DMF (3 ml) was then added, and the flask was flushed with nitrogen, then capped. The resultant mixture was stirred and placed into an 8O0C oil bath. The reaction was followed by LCMS. Upon consumption of starting material, the reaction mixture was extracted with ethyl acetate / water 3-4 times, then washed with brine twice. The resultant organic solution was dried over MgSO4 and concentrated to afford crude boronate ester 15-B-3 which was used directly for the Suzuki coupling without further purification, to provide Example 15-35. The Suzuki coupling was carried out using the standard conditions already described with the Boykin catalyst.
Scheme 15-C
Figure imgf000129_0002
DCM / Pyridine
Figure imgf000129_0003
3-Chloropropylsulfonyl chloride (1.20Og, 0.00678mol) was added dropwise to a stirred solution of p-bromoaniline ( 1.032g 0.00600mol) and pyridine ( 5ml) in dichloromethane (90ml) at O0C under nitrogen. The mixture was allowed to warm to rt and stirred overnight. The resultant mixture was concentrated and extracted with Et2O / aqueous sodium dihydrogen phosphate (pH=3-4) solution. The organic solution was then washed twice with saturated sodium bicarbonate solution, twice with brine, then dried with MgSO4 and concentrated to afford crude 15-C-l (1.63Og 87%).
Crude 15-C-l (1.63Og, 0.0052mol) was dissolved in 10ml DMF. The resultant solution was added dropwise to a stirred mixture of NaH 60% dispersion in mineral oil (0.48Og, 0.0104mol) and DMF (30ml) at O0C. The reaction mixture was allowed to warm up to rt and stirred overnight. Upon completion, the reaction was quenched with saturated NH4Cl aqueous solution and extracted twice with diethyl ether. The resultant ethereal solution was washed twice with an aqueous sodium dihydrogen phosphate (pH=3-4) solution, then twice with a saturated NaHCO3 aqueous solution, then twice with brine. The organic solution was dried over MgSO4 and concentrated to afford crude 15-C-2 (1.295g,
Crude 15-C-2 (0.156g, 0.566 mmol ), potassium acetate (0.167g, 1.698mmol), bis(pinacolato)diboron (0.144g, 0.509 mmol), and PdCl2(dppf) (0.046g, 0.0566mmol) were added to a round bottom flask. Dry DMF (10 ml) was then added and the flask was flushed with nitrogen. The resultant mixture was stirred and placed into an 8O0C oil bath. The reaction was followed by LCMS. Upon consumption of starting material (l-2hr), the reaction mixture was diluted with ethyl acetate, washed twice with water and twice with brine. The resultant organic solution was then dried over MgSO4 and concentrated to afford the crude boronate ester 15-C-3, which was used directly for the next step without further purification. The Suzuki coupling was carried out using the standard conditions already described with the Boykin catalyst. See example 15-36 as product.
Scheme 15-D
Figure imgf000130_0001
15-D-2 To a solution of 4-bromobenzoic acid (402.0mg, 2mmol) in DMF (10 mL), was added HATU
(836.5mg, 2.2 mmol) and DIEA (697.0μL, 4mmol). After stirring for 5 minutes at room temperature, methylamine hydrochloride salt (135.0mg, 2mmol) was added. The solution was stirred at rt overnight. The reaction mixture was diluted with water and extracted two times with ethyl acetate. The combined extract was washed with saturated sodium bicarbonate, IM HCl and brine, dried over magnesium sulfate, filtered and concentrated to dryness to provide 15-D-l (181. lmg, 42.0%) as white crystals.
A solution of 15-D-l (107.0mg, 0.5mmol), bis(pinacolato)diboron (139.7mg, 0.55mmol) and potassium acetate (245.4mg, 2.5mmol) in 2.5mL DMF, was purged with nitrogen gas, then PdCl2(dppf) (1 l.Omg, 0.015mmol) was added. The solution was heated at 800C for two hr, then cooled to rt. The reaction was quenched with water, then extracted twice with ethyl acetate. The organic solution was washed with water, then with saturated sodium bicarbonate, then with brine. The organic solution was then dried over magnesium sulfate, filtered and concentrated to dryness to provide boronate ester 15-D-2 (91.1 mg, 61.0%). The final compound, example 15-14, was prepared from the boronate ester 15-D-2 using the representative Suzuki coupling conditions and the Boykin catalyst.
Scheme 15 -E
Figure imgf000131_0001
4-Bromophenylsulfonyl chloride (3.33 g, 13.0 mmol, 1.0 eq.) and dimethylamine hydrochloride (1.58g, 19.4 mmol, 1.49 eq.) were weighed into a flask. THF (25 mL) was added, followed by DIEA (5.2 mL, 29.9 mmol, 2.3 eq.). The reaction was stirred hard at rt for 5.5 h, then diluted with diethyl ether, washed with IN hydrochloric acid, then with saturated sodium bicarbonate solution. The resulting solution was dried over magnesium sulfate, filtered and concentrated to provide the crude product. The crude material was purified by recrystallization from methylene chloride:hexanes to provide the sulfonamide 15-E-l (1.1788 g, 34%).
The N,N-dimethyl-4-bromophenyl sulfonamide above (0.486 g, 1.84 mmol, 1.0 eq.), the bis(pinacolato)diboron (538.5 mg, 2.12 mmol, 1.15 eq.), potassium acetate (881.2 mg, 8.98 mmol, 4.88 eq.), and the PdC^dppf) (1 l.Omg, 0.015mmol) were weighed into a 20 mL scintillation vial. DMF (6 mL) was added, the vial was flushed with nitrogen, capped, and placed to stir in an 80 deg C aluminum block. After 2 hr, the reaction was cooled to rt, diluted with diethyl ether, and washed with water. The organic solution was dried over magnesium sulfate, filtered, and concentrated. The crude product was purified by flash chromatography over silica gel (20% ethyl acetate/ hexanes) to provide the desired boronate ester 15-E-2 (256.2 mg, 45%), which was used in preparation of example 15-2 describe in below.
EXAMPLE 15
2'-[4-Cyclohexylammo-8-(3-isopropoxy-benzyl)-2-oxo-l,3,8-triaza-spiro[4.5]dec-3-en-l-yl]-4'-fluoro- biphenyl-4-sulfonic acid dimethylamide (15-2)
Figure imgf000132_0001
Step 1: Step 2: 2'-[4-Cyclohexylamino-8-(3-isopropoxy-benzyl)-2-oxo-l,3,8-triaza-spiro[4.5]dec-3-en-l-yl]-4'- fluoro-biphenyl-4-sulfonic acid dimethylamide (15-2)
The bromide (15-1, prepared in a manner similar to that described for Example 14) (60.4 mg, 0.106 mmol, 1.0 eq.), the boronic acid (51.8 mg, 0.166 mmol, 1.57 eq.), the palladium catalyst (26.7 mg, 0.045 mmol, 0.43 eq. For catalyst preparation, see Boykin et. al, J. Org. Chem. 2004, 69, 13, 4330-4335), and the tribasic potassium phosphate (70.6 mg, 0.333 mmol, 3.1 eq.) were weighed into a 1 dram vial. A magnetic stir bar was added, followed by absolute ethanol (1 mL). The vial was capped, and placed to stir in a 90° C aluminum block over a hot plate. When the reaction showed black palladium precipitate (approximately 3 hr), the reaction was cooled to rt. The reaction was then filtered through celite, and the resulting solution was purified directly by reverse phase HPLC in acetonitrile: water with 0.1% TFA, to provide the desired diaryl product as the TFA salt. 1H NMR (400 MHz, MeOH-^4): δ 7.83 (d, J = 8.3 Hz, 2H), 7.59 (m, 2H), 7.33 (m, 4H), 7.11 (br s, IH), 6.84 (m, 2H), 4.75-4.50 (m, IH), 4.14 (s, 2H), 2.68 (s, 6H), 2.50-2.00 (m, 2H), 2.00-1.60 (m, 6H), 1.50-1.20 (m, 10H). EI-MS tn/z: 676 (M + H)+. Table 7 : The compounds (or salts thereof) in table 7 were prepared in a manner similar to that described for Schemes 14 and 15.
Figure imgf000133_0001
Figure imgf000134_0001
Figure imgf000135_0001
Figure imgf000136_0001
Figure imgf000137_0001
Figure imgf000138_0001
Figure imgf000139_0001
Figure imgf000140_0001
Figure imgf000141_0001
Figure imgf000142_0001
Figure imgf000143_0001
Figure imgf000144_0001
Figure imgf000145_0001
Figure imgf000146_0001
Figure imgf000147_0002
EXAMPLE 15-46
4-Cyclohexylamino-8-cyclopropylmethyl-l-(4'-dimethylsulfamoyl-4-fluoro-biphenyl-2-yl)-2-oxo-l,3- diaza-8-azonia-spiro[4.5]dec-3-ene trifluoroacetate
Figure imgf000147_0001
Figure imgf000148_0001
Figure imgf000148_0003
Figure imgf000148_0002
The N-(t-butyloxycarbonyl)-4-piperidone (10.13 g, 50.8 mmol, 1.0 eq) and the 2-bromo-5-fluoroaniline (11.6Og, 61.0 mmol, 1.2 eq.) were weighed into a flask. Acetic acid (75 mL) was added, followed by trimethylsilyl cyanide (7.75 mL, 58.1 mmol, 1.14 eq.). The mixture was stirred at rt for 24 hr, and was then added to a mixture of 200 mL ice and 200 mL saturated ammonium hydroxide solution. The resulting mixture was extracted twice with methylene chloride, and the organic solution was dried over magnesium sulfate, filtered, and concentrated to provide 22.57g of crude product. This amino nitrile was converted to the thiohydantoin via the standard procedure already described. Crude thiol from the standard thiolation conditions (8.47g, 17.5 mmol, 1.0 eq.) and cyclohexylamine (8.OmL, 70 mmol, 4.0 eq.) were dissolved into DMSO (32 mL). The solution was stirred and heated to 115° C in an oil bath for 24 hr, then cooled to rt. The resulting solution was diluted with diethyl ether, and washed with 1 N hydrochloric acid, then dried over magnesium sulfate, filtered and concentrated. The crude aminohydantoin was purified by filtration through a 600 mL silica plug in 2 L fritted funnel, using 70% ethyl acetate in hexanes, followed by 100% ethyl acetate, as the elution solvents. This procedure yielded (2.0971g, 23%)of the desired product as a dark green semi-solid.
A portion of the aminohydantoin (528.6mg) was dissolved into dioxane (4 mL). A 4N solution of hydrogen chloride in dioxane (5 mL) was added, and the reaction was left to sit for 3 hr, then concentrated. The crude product was treated with dichloromethane, and washed with saturated sodium bicarbonate solution. The organic solution was dried over magnesium sulfate, filtered and concentrated. The crude free base was then purified by flash chromatography over silica gel using 5% of 2N ammonia(methanol) : 95% dichloromethane to provide the desired, deprotected piperidine (241mg, 56%).
To the deprotected piperidine (127.0mg, 0.3mmol) in DMF (3 mL) was added potassium carbonate (45.6mg, O.33mmol), followed by cyclopropane methyl bromide (32.3μL, O.33mmol). The solution was heated at 800C for 15 hours, cooled to rt and then quenched with water. The product was extracted three times with ethyl acetate, washed with water, then with aqueous IM HCl, and then with brine. The organic solution was dried over magnesium sulfate, filtered, and concentrated to dryness. The product was purified using prep-TLC (elution with 1% methanol/99% ethyl acetate) to provide the cyclopropylmethyl piperidine aryl bromide (52.6mg, 36.8%).
The final compound example 15-43 MS (MH+) 582.3 was prepared from the above aryl bromide via the standard Suzuki coupling conditions already described, using the Boykin catalyst.
EXAMPLE 15-47
4-Cyclohexylamino-8-(3-isopropoxy-benzyl)-l-[3-(5-methyl-[l,2,4]oxadiazol-3-yl)-phenyl]-2-oxo-l,3- diaza-8-azonia-spiro[4.5]dec-3-ene trifluoroacetate
Figure imgf000149_0001
To a solution of 3-amino-benzonitrile (4.7g, 40.0 mmol) in 20OmL THF, was added triethylamine (5.6mL, 40.0 mmol), followed by di-tert-butyl dicarbonate (8.7g, 40.0 mmol). After two days of heating at reflux, the solution was cooled, then partitioned between water and and ethyl acetate. The product was extracted three times with ethyl acetate, washed with aqueous IM HCl and brine, dried over magnesium sulfate, filtered, and concentrated to dryness. The product was purified using silica gel chromatography (elution with 10% hexane/90% ethyl acetate) to provide A (8.3 Ig, 93.2%).
A combined solution of A (6.54g, 30mmol), 50% w/w aqueous hydroxylamine (3.6mL, όOmmol), and 6OmL ethanol was refluxed for three hours. Ethanol was removed under high vacuum to yield B (7.3g, 96.9%) as a brittle foam.
A solution of B (1.7g, 7.0mmol), acetyl chloride (746.5μL, 10.5mmol) in 35.OmL pyridine was refluxed for one day. Pyridine was removed under high vacuum. The crude material was partitioned between ethyl acetate and water. The product was extracted three times with ethyl acetate, washed with aqueous IM HCl, then with brine, and then dried over magnesium sulfate, filtered, and concentrated to dryness. The product was purified using silica gel chromatography (elution with 15% hexane/85% ethyl acetate) to provide C. Removal of the Boc protecting group was accomplished by stirring a solution of C in 5OmL of 4M HCl/dioxane for 30 minutes at rt. Dioxane was evaporated in vacuo to yield the aniline hydrochloric salt D (944.8mg, 64.3%) as an off-white solid. The aniline was converted to the desired product Example 15-47 MS (MH+) 577.25 using the standard Ugi reaction conditions as described in Scheme 3.
EXAMPLE 15-48 l-[2-(4-Acetylamino-piperidin-l-yl)-5-fluoro-phenyl]-4-cyclohexylamino-8-(3-isopropoxy-benzyl)-2- oxo-1 ,3-diaza-8-azonia-spiro[4.5]dec-3-ene trifluoroacetate
Figure imgf000150_0001
4-t-butoxycarbonylamino-piperidine (804.4 mg, 4.02 mmol, 1.0 eq.) and 2,5- difluoronitrobenzene (679.5 mg, 4.27 mmol, 1.06 eq.) were dissolved into DMSO (4mL) in a 20 mL scintillation vial with a stir bar. Diisopropylethylamine (DIEA, ImL, 7.75 mmol, 1.93 eq.) was added, and the vial was capped and placed to stir in a 70° C aluminum block for 3.5h. The solution was then cooled to rt, diluted with diethyl ether, and washed with IN hydrochloric acid. The organic solution was dried over MgSO4, filtered, and concentrated to provide the aryl piperidine A (1.5261 g, 112%), which was carried on directly to the next step.
To a solution of A (339.36mg, 1.0 mmol) in 2.5mL methanol and 2.5 mL water, was added ammonium chloride (266.5mg, 5mmol), followed by zinc dust (327mg, 5mmol). The reaction mixture was stirred at room temperature for one hour, then filtered through a celite plug. Hydrochloric acid (1 mmol) was added to the free amine to obtain the amine hydrochloride salt. The filtrate was concentrated to yield B (307.5 mg, 89.0%) as a white solid.
To an ice-cold solution of l-(3-Isopropoxy-benzyl)-piperidine-4,4-diol (132.5mg, 0.5mmol) and B (169.9mg, 0.55mmol) in glacial acetic acid (0.5mL), was added slowly trimethylsilyl cyanide (73.4μL, 0.55mmol). The reaction mixture was kept at O0C for 5 min then allowed to warm to rt over 30 min. The resulting mixture was quenched with a saturated ammonium hydroxiderice mixture until the pH reached 10, and was then extracted twice with dichloromethane. The combined dichloromethane extracts were washed with brine, dried over magnesium sulfate and concentrated. The crude material was purified by preparative TLC (20% ethyl acetate/60% hexanes) to provide C (234.5mg, 83.0%) as an oily residue. To an ice cold solution of C (234.5mg, 0.415mmol) in 1.5mL chloroform, was added dropwise chlorosulfonyl isocyanate (39.7μL, 0.46mmol). The reaction was stirred at rt for 30 min, then quenched by addition of 830μL of water. The reaction mixture was stirred for another one hr at rt, then added to a 0° C aqueous solution Of H2S (622.5mg Na2S + 313.OmL H2O + 622.5-650.0μL acetic acid), which was prepared immediately before use. The resulting mixture was stirred at room temperature for 24 hr, then made alkaline with saturated sodium bicarbonate solution until pH>7, then extracted two times with ethyl acetate. The combined extracts was washed with brine, dried over magnesium sulfate and concentrated. The crude material was purified by preparative TLC (40% ethylacetate/60% hexane) to provide D (98.8mg, 38.0%) as an oil residue.
To a solution of D (98.8mg, 0.158mmol) in 2mL DMSO was added cyclohexyl amine (200μL, 1.58mmol). The reaction mixture was heated at 1100C for two days. The crude product was purified by preparative reverse phase HPLC to provide E (59.7mg, 54.7%) as the TFA salt, a fine yellow powder after being lyophilized.
Boc removal of E (30mg, 0.43mmol) was carried out using 0.5 ml 25%TFA/DCM at rt for 10 min. The TFA amine salt was dried in vacuo and redissolved in 0.5mL tetrahydrofuran. Triethylamine (0.09mmol, 12.5μL) was added to the reaction solution, followed by acetyl chloride (~4.0μL, 0.052mmol), and the reaction was then stirred at rt for 15 min. The crude reaction was purified by preparative reverse phase HPLC and lyophilized to provide 15-45 (6.4mg, 23.6%) MS (MH+) 633.3, as a fine yellow powder.
While the invention has been described and illustrated with reference to certain particular embodiments thereof, those skilled in the art will appreciate that various adaptations, changes, modifications, substitutions, deletions, or additions of procedures and protocols may be made without departing from the spirit and scope of the invention. It is intended, therefore, that the invention be defined by the scope of the claims that follow and that such claims be interpreted as broadly as is reasonable.

Claims

WHAT IS CLAIMED IS:
1. A compound of formula (I):
Figure imgf000153_0001
or its tautomer (V)
Figure imgf000153_0002
(I1)
wherein:
XisCRSorN;
X'isCR5HorNH;
Z is O or S;
Rl is selected from the group consisting of
(1) hydrogen,
(2)-Ci-6alkyl,
(3)-Co-6alkyl-C6-lOaryl,
(4) -Cθ-6alkyl-C5-12heteroaryl, (5) - Co-6 alkyl-C3_i2 carbocyclic, wherein the carbocyclic group optionally has from one to three ring heteroatoms selected from the group consisting of S, N and O,
(6) - O-R6 , and (7) - C0-6 alkyl-Ql-R6 ,
wherein said Rl alkyl moiety is optionally substituted with one or more
(a) -OR4,
(b) halogen,
(c) cyano, and
(d) -NR4R4\
said Rl carbocyclic moiety is optionally substituted with one or more (a) -OR4 (b) =O, (c) halogen, (d) cyano,
(e) -C(=O)-NR4R4',
(f) -C 1-6 alkyl, wherein said alkyl is optionally substituted with one or more
(I) halogen, (π) -OH, and
(III) -C6-IO aryl, (g) -NR4-SO2-R4',
Figure imgf000154_0001
(i) -NR4-C(=O)-R4', (J) -C(=O)-OR4,
(k) -NR4R4',
(1) -C(=O)-R4, and (m) -SO2-NR4R4',
and said Rl aryl and heteroaryl moieties are optionally substituted with one or more
(a) halogen,
(b) -C 1-6 alkyl,
(c) -C2-6 alkenyl, (d) -C2-6 alkynyl,
(e) -Co-3 alkyl-C6-10 aryl,
(f) cyano, (g) -O-Co-3 alkyl-C6-10 aryl, (h) -O-R4, (i) -C(=O)-NR4R4', G) -NR4R4', (k) -Q2.R.7, and
(1) -Co-3 alkyl-C5-i2 heteroaryl,
Ql and Q2 are selected from the group consisting of
(a)-C(=O)-, (b)-C(=O)-O-,
(c) -C(=O)-NR8-,
(d) -NR8-C(=O)-, (e) -S(=O)n- , (f) -Si(R8R9)., (g) -S(=O)2-R8-
(h) -R8-S(=O)2-, (i) -O-C(=O)-, (j) -NR8-C(=O)-O-,
Figure imgf000155_0001
(m) -NR4-
wherein n is 0, 1 or 2;
R2 is selected from the group consisting of
(1) hydrogen, (2) -Ci.6 alkyl,
(3) - Cθ-6 alkyl-C3-i2 carbocyclic, wherein the carbocyclic group optionally has from one to three ring heteroatoms selected from the group consisting of S, N and O,
(4) -Co-6 alkyl-C6-10 aryl, (5) -C0-6 alkyl-Q3-Cl-6 alkyl,
(6) -Cθ-6 alkyl-C5-i2 heteroaryl, wherein said R2 alkyl moiety is optionally substituted with one or more
(a) halogen
(b) cyano (c ) -C3-8 cycloalkyl
(d) -O-Cl-6 alkyl,
(e) OH,
and said R.2 cycloalkyl moiety is optionally substituted with one or more -C 1-6 alkyl,
and said R.2 aryl or heteroaryl moiety is optionally substituted with one or more (a) -ORlO,
(b) halogen,
(c) -cyano, Cd) -NO2, (e) -Q4-Ci-6 alkyl, (f) - C 1 -6 alkyl, wherein said alkyl is optionally subsitituted with one or more
(I) halogen, and
(II) cyano,
(g) -Cθ-3 alkyl -Cg.10 aryl, wherein said aryl is optionally substituted with one or more
(I) halogen,
(U) -C 1-6 alkyl,
(m) -C2-6 alkenyl,
(IV) -C2-6 alkynyl, (V) ^O-Ci-O alkyl,
(VI) -SO2 -C 1.6 alkyl,
(Vn) cyano,
(Vm) -C3-8 cycloalkyl,
(IX) -NO2, (X) -SO2-NR4R4'
(h) -SO2 -Ci-6 alkyl,
(i) -SO2 -NR4R4',
0) -NR4R4',
(k) -C3-8 cycloalkyl, (1) -C2-6 alkenyl,
(m) -NHC(=O)-Ci-6 alkyl wherein said alkyl is optionally substituted with one or more (I) -NR4R4'
(U) OH
(ffl) -SO2R4, and (IV) -NHSO2R4, (n) -NHC(=0)-Cθ-3 alkyl-C6-10 aryl> wherein said aryl is optionally substituted with one or more (I) NR4R4',
(U) OH,
Figure imgf000157_0001
(IV)-NHSO2R4,
(o) -Co-3 alkyl-C5_i2 heteroaryl, wherein said heteroaryl is optionally substituted with one or more
(I) halogen,
(II) -Ci.6 alkyl, and (IH) =O,
(p) -S(=0)m--Co-6 alkyl-C6-10 aryl,
(q) -CO2-R4,
(r) -C(=O)-NR4R4';
(s) -Co-6 alkyl-NR4 SO2-R4, (t) -O-C2-6 alkenyl, and m is 0, 1 or 2;
and Q3 and Q4 are selected from the same group as Ql and Q2;
R3 is selected from the group consisting of (1) hydrogen, (2) -C0-3 alkyl-C6-10 aryl,
(3) -CO-3 alkyl-C5-i2 heteroaryl,
(4) - Co-3 alkyl-C3-io carbocyclic, wherein the carbocyclic group optionally has from one to three ring heteroatoms selected from the group consisting of S, N and O,
wherein said R^ alkyl moiety is optionally substituted with one or more (a) -ORl I, (b) halogen, (c) cyano,
(d) -C(=O)-NR4R4', (e) -Q5-Ci-6 alkyl, (f) -Q5-H;
and said R3 cycloalkyl moiety is optionally substituted with one or more
(a) -Ci.6 alkyl, (b) -Co-3 alkyl-C6-10 aryl,
and said R3 aryl and heteroaryl moiety is optionally substituted with one or more (a) -ORl2, (b) -NR4R4') (c) halogen,
(d) cyano, (f) -NO2, (g) _Q6_R4 and (h) -C 1-6 alkyl, wherein said alkyl is optionally substituted with one or more (I) halogen,
(II) cyano, (IH) -Ci.6 alkyl,
(IV) -O-C 1-6 alkyl,
(V) -C3-8 cycloalkyl, (VI) -C(=O)-C 1 _6 alkyl,
(i) -C2-6 alkenyl, (D -C2-6 alkynyl, (k) -Co-3 alkyl-C5-i2 heteroaryl, (1) -O-C2-6 alkenyl, (m) -Co-3 alkyl -C6- 10 aryh wherein said aryl moiety is optionally substituted with one or more (I) -C 1-6 alkyl, (II) -C2-6 alkenyl, (IH) -C2-6 alkynyl, (IV) halogen,
(V) cyano,
(VI) -C3-8 cycloalkyl, and
(VII) NO2,
and Rl 2 is selected from the group consisting of
(I) hydrogen, (π) -C 1-6 alkyl, (IB) -C2-6 alkenyl,
(IV) -C2-6 alkynyl,
(V) -C3-8 cycloalkyl, and
(VI)-Co-3 alkyl-C6-lO aryl,
and said Rl 2 alkyl, alkenyl and alkynyl moiety is optionally substituted with one or more
(A) halogen,
(B) hydroxyl, (C) cyano,
(D) -O-Ci-6 alkyl, wherein said alkyl is optionally substituted with one or more halogen,
(E) -NR4R4',
(F) -NR4-S(=O)2-R4', (G) -NR4-C(=O)-R4',
(H) -NR4-C(=O)-OR4',
Figure imgf000159_0001
and said RlO cycloalkyl moiety is optionally substituted with one or more
(A) halogen,
(B) hydroxyl,
(C) -cyano,
(D) -O-Ci-6 alkyl, and (E) -C 1-6 alkyl, wherein said alkyl is optionally substituted one or more halogen;
and said Rl 2 aryl moiety is optionally substituted with one or more (A) halogen,
(B) cyano,
(C) -O-Ci-6 alkyl, and
(D) -C 1-6 alkyl, wherein said alkyl is optionally substituted one or more halogen;
Q5 and Q6 are selected from the same group as Ql and Q2; R.4 and R.4' are selected from the group consisting of
(1) hydrogen,
(2) -C 1-8 alkyl, wherein said alkyl is optionally substituted with
(a) halogen, (b) -C3-8 cycloalkyl
(c) -CO2C1-6 alkyl
(d) -OC 1-6 alkyl, wherein said alkyl is optionally substituted with one or more
(I) halogen, or
(II) cyano, (3) -C2-8 alkenyl, and
(^ -Co-S alkyl-Cό-lOaryl;
R.5 is selected from the group csoonsisting of
(1) hydrogen, (2) -C 1-6 alkyl,
(3) halogen, and (4) -CO2-R4,
R6, R7; R8; R9; RIO and Rl 1 are independently selected from the group consisting of: (1) hydrogen,
(2) -C 1.6 alkyl,
(3) -C3-8 cycloalkyl,
(4) -Co-3 alkyl-C6-lo aryl, wherein said alkyl is optionally substituted with one or more (A) halogen,
(B) hydroxyl,
(C) cyano,
(D) -O-Ci-6 alkyl, wherein said alkyl is optionally substituted with one or more halogen, and said cycloalkyl and aryl are optionally substituted with one or more
(A) halogen,
(B) hydroxyl,
(C) cyano,
(D) -O-Ci-6 alkyl, and (E) -C 1-6 alkyl, wherein said alkyl is optionally substituted one or more halogen; provided that when X is N; Z is O; Rl is unsubstituted cyclohexyl; and R2 is unsubstituted phenyl, then
R3 is not unsubstituted benzyl; and pharmaceutically acceptable salts thereof, and individual enantiomers and diastereomers thereof.
2. The compound of Claim 1 wherein X is N or X' is NH.
3. The compound of Claim 1 or 2 wherein Z is O.
4. The compound of Claim 1 or 2 wherein Rl -Cl-6 alkyl or -Q)-3 alkyl-C3_i2 carbocyclic, wherein said alkyl or carbocyclic is optionally substituted as in Claim 1.
5. The compound of Claim 1 or 2 wherein Rl is -Cθ-3 alkyl-C6-10 aryl> ar>d said aryl moiety is optionally substituted with one or more (a) halogen, or
(b) -C 1-6 alkyl.
6. The compound of Claim 1 or 2 wherein Rl is -Cθ-3 alkyl-C5_i2 heteroaryl, and said heteroaryl is optionally substituted withone or more (a) halogen, or
(b) -C 1-6 alkyl.
7. The compound of any of Claims 1 to 6 wherein R2 is selected from the group consisting of (l) -Ci-6 alkyl,
(2) -Cθ-6 alkyl-C3_8 carbocyclic, and (3) -Co-3 alkyl-C6-lO aryl, wherein said alky, carbocyclic or aryl moieties are optionally substituted as in claim 1.
8. The compound of claim 7, wherein R2 is phenyl or benzyl, and said phenyl or benzyl are optionally substituted as in claim 1.
9. The compound of Claim 1 which is a compound of formula (II)
Figure imgf000162_0001
(H)
or its tautomer (II')
Figure imgf000162_0002
(H1)
and pharmaceutically acceptable salts thereof, and individual enantiomers and diasteromers thereof, wherein X, X1, Z, Rl and R.3 are as defined in claim 1, and Rl 5 is selected from the group consisting of
(a) -ORlO,
(b) halogen,
(c) -cyano, (d) -Q4-Ci_6 alkyl, (e) - C 1-6 alkyl, wherein said alkyl is optionally substituted with one or more
(I) halogen, and
(II) cyano,
(f) -Cθ-3 alkyl-C6_io aryl, wherein said aryl is optionally substituted with one or more
(I) halogen, (U) -C 1.6 alkyl, (V) -O-Ci-6 alkyl, (VI) -SO2 -C 1-6 alkyl, (Vn) cyano,
(Vm) -C3-8 cycloalkyl,
Figure imgf000162_0003
(g) -SO2 -Cl-6 alkyl,
(h) -Sθ2 -NR4R4',
(i) -C3-8 cycloalkyl,
(j) -NHC(=O)-Ci_6 alkyl, wherein said alkyl is optionally substituted with one or more
(I) -NR4R4'
(1I) OH
(IH) -SO2R4, and
Figure imgf000163_0001
(k) -Cθ-3 alkyl-C5_i2 heteroaryl, wherein said heteroaryl is optionally substituted with one or more (I) halogen, (IT) -Ci -6 alkyl, and (BO) =O,
(1) -S(=0)m~Co-6 alkyl-C6-10 aryl,
Figure imgf000163_0002
(n) -C(=O)-NR4R4\
(o) -Co-6 alkyl-NR4 SO2-R4.
10. The compound of Claim 9 wherein X is N or X' is NH.
11. The compound of Claim 9 or 10 wherein Z is O.
12. The compound of any of Claims 9, 10 and 11, wherein R3 is selected from the group consisting of
(1) -Co-3 alkyl-C6-10 aryl, or
(2) -Cθ-3 alkyl-C5-i2 heteroaryl, and said aryl and heteroaryl are optionally substituted with one or more (a) -ORl 2,
(b) -NR4R4',
(c) halogen,
(d) cyano,
(e) -NO2, (f) -Q6- R4, and
(g) -C 1-6 alkyl, wherein said alkyl is optionally substituted with one or more
(I) halogen, (II) cyano, (ffl) -Ci.6 alkyl,
(IV) -O-Ci-6 alkyl,
(V) -C3.8 cycloalkyl, (VI) -C(=O) -C μ6 alkyl,
(h) -C2-6 alkenyl, (i) -C2-6 alkynyl, (j) -Q)-3 alkyl-C5_i2 heteroaryl, (k) -Cθ-3 alkyl-Cβ-lO aryl, a°d said aryl moiety is optionally substituted with one or more
(I) -Ci_6 alkyl,
(II) -C2-6 alkenyl,
(m) -C2-6 alkynyl,
(IV) halogen, (V) cyano,
(VI) -C3-8 cycloalkyl, and (Vn) NO2.
13. The compound of Claim 12 wherein R.3 is benzyl, which is optionally substituted with one or more
(a) -ORl2, (b) NR4R4',
(c) halogen,
(d) cyano, (f) -NO2,
(g) -Q6. R4; and
(h) -C 1-6 alkyl, wherein said alkyl is optionally substituted with one or more
(I) halogen, (H) cyano, (IH) -Ci.6 alkyl,
(IV) -O-Ci-6 alkyl,
(V) -C3-8 cycloalkyl,
(VI) -C(=O) -Cl-6 alkyl, (i) -C2-6 alkenyl, (j) -C2-6 alkynyl,
(k) -CQ-3 alkyl-C5-i2 heteroaryl, (1) -Co-3 alkyl-C6-10 aryl wherein p is 0 or 1, and said aryl moiety is optionally substituted with one or more (I) -Ci_6 alkyl, (II) -C2-6 alkenyl, (IH) -C2-6 alkynyl,
(IV) halogen,
(V) cyano,
(VI) -C3-8 cycloalkyl, and
(Vn) NO2.
14. The compound of Claim 1 which is a compound of formula (III)
Figure imgf000165_0001
(III)
or its tautomer (IQ')
Figure imgf000165_0002
(Hl1)
and pharmaceutically acceptable salts thereof, and individual enantiomers and diastereomers thereof, wherein X, X1, Z, Rl, and R.2 are as defined in claim 1, and R.16 is selected from the group consisting of (a) -ORl2
(b) NR4R4',
(c) halogen, (d) cyano, (f) -NO2,
(g) -Q6. R4 and
(h) -C 1-6 alkyl, wherein said alkyl is optionally substituted with one or more
(I) halogen,
(II) cyano, (m) -C 1-6 alkyl,
(IV) -O-C 1-6 alkyl,
(V) -C3-8 cycloalkyl,
(VI) -C(=O)-Ci_6 alkyl, (i) -C2-6 alkenyl, G) -C2-6 alkynyl,
(k) -Cθ-3 alkyl-C5_i2 heteroaryl,
(1) -Cθ-3 alkyl-C6-lO aryl, wherein said aryl moiety is optionally substituted with one or more
(I) -C 1-6 alkyl, (π) -C2-6 alkenyl,
(m) -C2-6 alkynyl,
(IV) halogen,
(V) cyano,
(VI) -C3-8 cycloalkyl, and (VII) NO2.
15. The compound of Claim 14 wherein X is N or X' is NH.
16. The compound selected from the group consisting of and tautomers thereof; and pharmaceutically acceptable salts thereof.
17. A method for the manufacture of a medicament or a composition for inhibiting β- secretase enzyme activity in humans and animals comprising combining a compound of claim 1, or a pharmaceutically acceptable salt thereof, with a pharmaceutical carrier or diluent.
18. A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I)
Figure imgf000167_0001
or its tautomer (F)
Figure imgf000167_0002
(I1)
wherein: X is CR5 or N;
X'isCRSHorNH;
Z is O or S;
Rl is selected from the group consisting of (1) hydrogen, (2)-Ci_6alkyl, (3) -Cθ-6 alkyl-C6-10 aryl, (4) -Co-6alkyl-£5-12neteroaryl>
(5) - Co-6 alkyl-C3_i2 carbocyclic, wherein the carbocyclic group optionally has from one to three ring heteroatoms selected from the group consisting of S, N and O,
(6) - O-R6 , and (7)-C0-6alkyl-Ql-R6, wherein said Rl alkyl moiety is optionally substituted with one or more
(a) -OR4
(b) halogen, (c) cyano, and
(d) -NR4R4\
said Rl carbocyclic moiety is optionally substituted with one or more (a) -OR4, (b) =0,
(c) halogen, (d) cyano,
(e) -C(=O)-NR4R4',
(f) -C 1-6 alkyl, wherein said alkyl is optionally substituted with one or more
(I) halogen,
(II) -OH, and (ffl) -C6-IO aryl,
(g) -NR4-SO2-R4', (h) -SO2-R4,
(i) -NR4-C(=O)-R4', (J) -C(=O)-OR4, 00 -NR4R4',
(1) -C(=O)-R4, and
Figure imgf000168_0001
and said Rl aryl and heteroaryl moieties are optionally substituted with one or more (a) halogen, (b) -C 1-6 alkyl,
(c) -C2-6 alkenyl,
(d) -C2-6 alkynyl,
(e) -Co-3 alkyl-C6-10 aryl
(f) cyano, (g) -O-Co-3 alkyl-C6-lO aryl,
(h) -O-R4, (i) -C(=O)-NR4R4'; G) -NR4R4',
(k) -Q2-R.7, and
(1) -CQ-3 alkyl-C5-i2 heteroaryl,
Ql and Q2 are selected from the group consisting of
(a)-C(=O)-, (b)_C(=O)-O-,
Figure imgf000169_0001
(d) -NR8-C(=O)-, (e) -SC=O)n- ,
(f) -Si(R8R9)-,
Figure imgf000169_0002
(h) -R8-S(=O)2-, (i) -O-C(O)-, (j) -NR8-C(=O)-O-,
Figure imgf000169_0003
(m) -NR4-
wherein n is 0, 1 or 2;
R2 is selected from the group consisting of (1) hydrogen, (2) -Ci-6 alkyl, (3) - Co-6 alkyl-C3-i2 carbocyclic, wherein the carbocyclic group optionally has from one to three ring heteroatoms selected from the group consisting of S, N and O,
(4) -Co-6 alkyl-C6-10 aryl (5) -C0-6 alkyl-Q3-Ci-6 alkyl, (6) -Co-6 alkyl-C5_i2 heteroaryl, wherein said R2 alkyl moiety is optionally substituted with one or more
(a) halogen (b) cyano (c ) -C3-8 cycloalkyl
(d) -O-C1.6 alkyl,
(e) OH, and said R.2 cycloalkyl moiety is optionally substituted with one or more -C 1-6 alkyl,
and said R.2 aryl or heteroaryl moiety is optionally substituted with one or more
(a) -ORlO;
(b) halogen,
(c) -cyano, (d) -NO2,
(e) -Q4_Cl_6 alkyl,
(f) - C 1-6 alkyl, wherein said alkyl is optionally substituted with one or more
(I) halogen, and (H) cyano,
(g) -Cθ-3 alkyl -C6- 10 aτyh wherein said aryl is optionally substituted with one or more
(I) halogen, (π) -Ci-6 alkyl, (IH) -C2-6 alkenyl,
(IV) -C2-6 alkynyl,
(V) -O-Ci-6 alkyl,
(VI) -SO2 -C 1-6 alkyl,
(Vn) cyano, (Vm) -C3-8 cycloalkyl,
(IX) -NO2, (X) -SO2-NR4R4'
(h) -SO2 -C 1.6 alkyl,
(i) -SO2 -NR4R4', (J) -NR4R4',
(k) -C3-8 cycloalkyl,
(1) -C2.6 alkenyl,
(m) -NHC(=O)-Ci-6 alkyl, wherein said alkyl is optionally substituted with one or more (I) -NR4R4'
(II) OH
(IE) -SO2R4, and (IV) -NHSO2R4,
(n) -NHC(=0)-Cθ-3 alkyl-C6-10 aryl> wherein said aryl is optionally substituted with one or more
(I) NR4R4', (II) OH,
(m) -SO2R4, and
(IV)-NHSO2R4,
(o) -Co-3 alkyl-C5-i2 heteroaryl, wherein said heteroaryl is optionally substituted with one or more (I) halogen,
(II) -Ci-6 alkyl, and
(m) =o,
(p) -S(=0)m-Co-6 alkyl-C6-lO aryl, (q) -CO2-R4 (r) -C(=O)-NR4R4',
(s) -Co-6 alkyl-NR4 SO2-R4, (t) -O-C2-6 alkenyl, and m is 0, 1 or 2;
and Q3 and Q4 are selected from the same group as Ql and Q2;
lected from the group consisting of
(1) hydrogen, (2) -Co-3 alkyl-C6-lO aryl, (3) -Co-3 alkyl-C5-i2 heteroaryl,
(4) - Co-3 alkyl-C3_io carbocyclic, wherein the carbocyclic group optionally has from one to three ring heteroatoms selected from the group consisting of S, N and O,
wherein said R^ alkyl moiety is optionally substituted with one or more (a) -ORl I,
(b) halogen,
(c) cyano,
(d) -C(=O)-NR4R4', (e) -Q5-Ci_6 alkyl, (f) -Q5-H;
and said R3 cycloalkyl moiety is optionally substituted with one or more (a) -Ci-6 alkyl,
(b) -Co-3 alkyl-Cό-10 aryl,
and said R.3 aryl and heteroaryl moiety is optionally substituted with one or more (a) -ORl 2,
(b) -NR4R4';
(c) halogen,
(d) cyano, (f) -NO2, (g) -Q6-R4, and
(h) -C 1-6 alkyl, wherein said alkyl is optionally substituted with one or more
(I) halogen, (H) cyano, (HI) -C 1-6 alkyl, (IV) -O-C 1-6 alkyl,
(V) -C3-8 cycloalkyl, (VI) -C(=O)-Ci-6 alkyl,
(i) -C2-6 alkenyl, (j) -C2-6 alkynyl, (k) -Co-3 alkyl-C5.12 heteroaryl,
(1) -O-C2-6 alkenyl, (m) -Co-3 alkyl-Cβ-lO aryl, wherein said aryl moiety is optionally substituted with one or more
(I) -C 1-6 alkyl, (H) -C2-6 alkenyl,
(III) -C2-6 alkynyl,
(IV) halogen, (V) cyano,
(VI) -C3-8 cycloalkyl, and (VII) NO2,
and Rl2 is selected from the group consisting of (I) hydrogen, (π) -Ci.6 alkyl, (III) -C2-6 alkenyl,
(IV) -C2-6 alkynyl,
(V) -C3-8 cycloalkyl, and (VI)-Co-3 alkyl-C6-iO aryl,
and said Rl 2 alkyl, alkenyl and alkynyl moiety is optionally substituted with one or more (A) halogen,
(B) hydroxyl,
(C) cyano,
(D) -O-Ci-6 alkyl, wherein said alkyl is optionally substituted with one or more halogen, (E) -NR4R4',
Figure imgf000173_0001
(G) -NR4-C(=O)-R4', (H) -NR4-C(=O)-OR4',
Figure imgf000173_0002
and said RlO cycloalkyl moiety is optionally substituted with one or more
(A) halogen,
(B) hydroxyl, (C) -cyano,
(D) -O-Ci-6 alkyl, and
(E) -C 1-6 alkyl, wherein said alkyl is optionally substituted one or more halogen;
and said Rl 2 aryl moiety is optionally substituted with one or more
(A) halogen,
(B) cyano,
(C) -O-Ci-6 alkyl, and (D) -C 1-6 alkyl, wherein said alkyl is optionally substituted one or more halogen;
Q5 and Q6 are selected from the same group as Ql and Q2;
4' are selected from the group consisting of
(1) hydrogen,
(2) -C 1-8 alkyl, wherein said alkyl is optionally substituted with (a) halogen,
(b) -C3-8 cycloalkyl (c) -CO2Ci-6 alkyl
(d) -OC 1 -6 alkyl, wherein said alkyl is optionally substituted with one or more (I) halogen, or
(II) cyano,
(3) -C2-8 alkenyl, and (4) -Co-3 alkyl-C6-lOaryl;
R5 is selected from the group csoonsisting of
(1) hydrogen,
(2) -C 1-6 alkyl,
(3) halogen, and (4) -CO2-R4,
R6, R7, R8; R9; RIO and Rl 1 are independently selected from the group consisting of:
(1) hydrogen,
(2) -Ci_6 alkyl,
(3) -C3-8 cycloalkyl, (4) -Co-3 alkyl-C6-lo aryl, wherein said alkyl is optionally substituted with one or more
(A) halogen,
(B) hydroxyl,
(C) cyano, (D) -O-Ci-6 alkyl, wherein said alkyl is optionally substituted with one or more halogen, and said cycloalkyl and aryl are optionally substituted with one or more
(A) halogen,
(B) hydroxyl, (C) cyano,
(D) -O-Ci-6 alkyl, and
(E) -C 1-6 alkyl, wherein said alkyl is optionally substituted one or more halogen; and pharmaceutically acceptable salts thereof, and individual enantiomers and diastereomers thereof,
19. A method of treating Alzheimer's disease in a patient in need thereof comprising administering to the patient a therapeutically effective amount of a compound of formula (I):
Figure imgf000175_0001
or its tautomer (F)
Figure imgf000175_0002
(I1)
wherein:
XisCRSorN;
X'isCR5HorNH;
Z is O or S;
Rl is selected from the group consisting of (1) hydrogen, (2)-Ci_6alkyl, (3) -Co-6 alkyl-C6-10 aryl,
(4) -Cθ-6 alkyl-C5-i2 heteroaryl,
(5) - Co-6 alkyl-C3-l2 carbocyclic, wherein the carbocyclic group optionally has from one to three ring heteroatoms selected from the group consisting of S, N and O, (6) - O-R6 , and
(7)-C0-6alkyl-Ql-R6, wherein said Rl alkyl moiety is optionally substituted with one or more
(a) -OR4,
(b) halogen, (c) cyano, and
(d) -NR4R4\
said Rl carbocyclic moiety is optionally substituted with one or more (a) -OR4 (b) =0,
(c) halogen,
(d) cyano,
(e) -C(=O)-NR4R4',
(f) -C 1-6 alkyl, wherein said alkyl is optionally substituted with one or more
(I) halogen,
(II) -OH, and (m) -C6-IO aryl,
Figure imgf000176_0001
(h) -SO2-R4,
(i) -NR4-C(=O)-R4', (]) -C(=O)-OR4, (k) -NR4R4';
(1) -C(=O)-R4, and
Figure imgf000176_0002
and said Rl aryl and heteroaryl moieties are optionally substituted with one or more (a) halogen, (b) -Ci-6 alkyl,
(c) -C2-6 alkenyl,
(d) -C2-6 alkynyl,
(e) -Co-3 alkyl-C6-lO aryl,
(f) cyano, (g) -O-Co-3 alkyl-C6-10 aryl,
(h) -O-R4, (i) -C(=O)-NR4R4'; (J) -NR4R4\
(k) -Q2_R7; and
(1) -Cθ-3 alkyl-C5_i2 heteroaryl,
Ql and Q2 are selected from the group consisting of
(a)-C(=O)-, (b>-C(=O)-O-,
(c) -C(=O)-NR8-,
(d) -NR8-C(=O)-, (e) -SC=O)n- ,
(f) -Si(R8R9)-, (g) -S(=O)2-R8-,
(h) -R8-S(=O)2-, (i) -O-C(=O)-, (j) -NR8-C(=0)-0-,
Figure imgf000177_0001
(m) -NR4-
wherein n is 0, 1 or 2;
R2 is selected from the group consisting of (1) hydrogen, (2) -Ci-6 alkyl, (3) - Co-6 alkyl-C3-i2 carbocyclic, wherein the carbocyclic group optionally has from one to three ring heteroatoms selected from the group consisting of S, N and O,
(4) -Co-6 alkyl-C6-lO ∞yh
(5) -Co-6 alkyl-Q3-Ci_6 alkyl, (6) -Co-6 alkyl-C5-i2 heteroaryl, wherein said R2 alkyl moiety is optionally substituted with one or more
(a) halogen
(b) cyano (c ) -C3-8 cycloalkyl
(d) -O-C1.6 alkyl,
(e) OH, and said R.2 cycloalkyl moiety is optionally substituted with one or more -C 1-6 alkyl,
and said R2 aryl or heteroaryl moiety is optionally substituted with one or more
(a) -ORlO,
(b) halogen,
(c) -cyano, (d) -NO2,
(e) -Q4-C 1-6 alkyl,
(f) - Ci_6 alkyl, wherein said alkyl is optionally subs ituted with one or more
(I) halogen, and (II) cyano,
(g) -Cθ-3 alkyl-Cg-io aryl, wherein said aryl is optionally substituted with one or more
(I) halogen, (H) -C 1-6 alkyl, (HI) -C2-6 alkenyl,
(IV) -C2-6 alkynyl, (V) -O-C 1-6 alkyl, (VI) -SO2 -Ci-O aIlCyI,
(Vπ) cyano, (VIII) -C3-8 cycloalkyl,
(DC) -NO2,
(X) -SO2-NR4R4' (h) -SO2 -C 1-6 alkyl, (i) -SO2 -NR4R4', (j) -NR4R4',
(k) -C3-8 cycloalkyl,
(1) -C2-6 alkenyl,
(m) -NHC(=0)-Ci-6 alkyl, wherein said alkyl is optionally substituted with one or more (I) -NR4R4'
(1I) OH
(III) -SO2R4, and (IV) -NHSO2R4,
(n) -NHC(=0)-Cθ-3 alkyl-C6-10 aτyh wherein said aryl is optionally substituted with one or more
(I) NR4R4', (H) OH,
(HI) -SO2R4, and (IV)-NHSO2R4,
(0) -Co-3 alkyl-C5_i2 heteroaryl, wherein said heteroaryl is optionally substituted with one or more (I) halogen,
(II) -Ci_6 alkyl, and
(DD =0,
(P) -S(=0)m-Co-6 alkyl-C6-l0 aryl,
Figure imgf000179_0001
(Γ) -C(=O)-NR4R4',
(s) -Co-6 alkyl-NR4 SO2-R4, (t) -O-C2-6 alkenyl, and m is 0, 1 or 2;
and Q^ and Q4 are selected from the same group as Ql and Q2;
R3 is selected from the group consisting of
(1) hydrogen, (2) -Co-3 alkyl-C6-lO aryl, (3) -Co-3 alkyl-C5_i2 heteroaryl,
(4) - Co-3 alkyl-C3-io carbocyclic, wherein the carbocyclic group optionally has from one to three ring heteroatoms selected from the group consisting of S, N and O,
wherein said R^ alkyl moiety is optionally substituted with one or more (a) -ORl I,
(b) halogen,
(c) cyano,
(d) -C(=O)-NR4R4', (e) -Q5-Ci_6 alkyl, (f) -Q5-H;
and said R^ cycloalkyl moiety is optionally substituted with one or more (a) -Ci-6 alkyl,
(b) -Co-3 alkyl-C6-lO aryl
and said R.3 aryl and heteroaryl moiety is optionally substituted with one or more (a) -ORl 2,
(b) -NR4R4',
(c) halogen,
(d) cyano, (f> -NO2, (g) -Q6-R4, and
(h) -C 1-6 alkyl, wherein said alkyl is optionally substituted with one or more
(I) halogen, (H) cyano, (ffl) -C 1-6 alkyl, (IV) -O-Ci-6 alkyl,
(V) -C3-8 cycloalkyl, (VI) -C(=O)-C 1-6 alkyl,
(i) -C2-6 alkenyl, 0) -C2-6 alkynyl, (k) -Co-3 alkyl-C5_i2 heteroaryl,
(1) -O-C2-6 alkenyl, (m) -Co-3 alkyl-C6-10 aryl, wherein said aryl moiety is optionally substituted with one or more
(I) -C 1-6 alkyl, (II) -C2-6 alkenyl,
(m) -C2-6 alkynyl,
(IV) halogen, (V) cyano,
(VI) -C3-8 cycloalkyl, and (Vn) NO2,
and Rl2 is selected from the group consisting of (I) hydrogen, (U) -C 1-6 alkyl, (HI) -C2-6 alkenyl,
(IV) -C2-O alkynyl,
(V) -C3-8 cycloalkyl, and (VI)-Co-3 alkyl-C6-10 aryl,
and said Rl2 alkyl, alkenyl and alkynyl moiety is optionally substituted with one or more (A) halogen,
(B) hydroxyl,
(C) cyano,
(D) -O-Ci-6 alkyl, wherein said alkyl is optionally substituted with one or more halogen, (E) -NR4R4',
Figure imgf000181_0001
(G) -NR4-C(=O)-R4',
(H) -NR4-C(=O)-OR4',
Figure imgf000181_0002
and said RlO cycloalkyl moiety is optionally substituted with one or more
(A) halogen,
(B) hydroxyl, (C) -cyano,
(D) -O-Ci-6 alkyl, and
(E) -Ci_6 alkyl, wherein said alkyl is optionally substituted one or more halogen;
and said Rl 2 aryl moiety is optionally substituted with one or more
(A) halogen,
(B) cyano,
(C) -0-C].6 alkyl, and (D) -C 1-6 alkyl, wherein said alkyl is optionally substituted one or more halogen;
Q5 and Q6 are selected from the same group as Ql and Q2;
R4 and R4' are selected from the group consisting of
(1) hydrogen,
(2) -C 1-8 alkyl, wherein said alkyl is optionally substituted with (a) halogen,
(b) -C3_8 cycloalkyl (c) -CO2Ci^ allcyl
(d) -OC 1-6 alkyl, wherein said alkyl is optionally substituted with one or more (I) halogen, or
(II) cyano,
(3) -C2-8 alkenyl, and
(4) -Cθ-3 alkyl-C6-lθaryl;
R5 is selected from the group csoonsisting of
(1) hydrogen,
(2) -Cl-6 alkyl,
(3) halogen, and (4) -C02-R4
R6, R.7, R85 R95 RlO and Rl 1 are independently selected from the group consisting of:
(1) hydrogen,
(2) -Ci_6 alkyl,
(3) -C3-8 cycloalkyl, (4) -Co-3 alkyl-C6-l 0 aiyl, wherein said alkyl is optionally substituted with one or more
(A) halogen,
(B) hydroxyl,
(C) cyano, (D) -O-Ci-6 alkyl, wherein said alkyl is optionally substituted with one or more halogen, and said cycloalkyl and aryl are optionally substituted with one or more
(A) halogen,
(B) hydroxyl, (C) cyano,
(D) -O-Ci-6 alkyl, and
(E) -C 1-6 alkyl, wherein said alkyl is optionally substituted one or more halogen; and pharmaceutically acceptable salts thereof, and individual enantiomers and diastereomers thereof.
PCT/US2005/036752 2004-10-13 2005-10-12 Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzhermer’s disease WO2006044497A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2007536860A JP2008515989A (en) 2004-10-13 2005-10-12 Spiropiperidine compounds useful as β-secretase inhibitors for the treatment of Alzheimer's disease
EP05812233.4A EP1804794B1 (en) 2004-10-13 2005-10-12 Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzhermer s disease
AU2005295814A AU2005295814A1 (en) 2004-10-13 2005-10-12 Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of Alzhermer's disease
CA002583342A CA2583342A1 (en) 2004-10-13 2005-10-12 Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzhermer's disease
US11/663,388 US8114887B2 (en) 2004-10-13 2005-10-12 Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61842004P 2004-10-13 2004-10-13
US60/618,420 2004-10-13

Publications (2)

Publication Number Publication Date
WO2006044497A2 true WO2006044497A2 (en) 2006-04-27
WO2006044497A3 WO2006044497A3 (en) 2006-09-08

Family

ID=36203499

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/036752 WO2006044497A2 (en) 2004-10-13 2005-10-12 Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzhermer’s disease

Country Status (7)

Country Link
US (1) US8114887B2 (en)
EP (1) EP1804794B1 (en)
JP (1) JP2008515989A (en)
CN (1) CN101068545A (en)
AU (1) AU2005295814A1 (en)
CA (1) CA2583342A1 (en)
WO (1) WO2006044497A2 (en)

Cited By (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007011810A1 (en) * 2005-07-18 2007-01-25 Merck & Co., Inc. Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
WO2007130383A2 (en) * 2006-04-28 2007-11-15 Northwestern University Compositions and treatments using pyridazine compounds and secretases
WO2008045250A1 (en) * 2006-10-06 2008-04-17 Merck & Co., Inc. Macrocyclic spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
WO2008055945A1 (en) 2006-11-09 2008-05-15 Probiodrug Ag 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
WO2008055947A1 (en) * 2006-11-09 2008-05-15 Probiodrug Ag Novel inhibitors of glutaminyl cyclase
WO2008065141A1 (en) 2006-11-30 2008-06-05 Probiodrug Ag Novel inhibitors of glutaminyl cyclase
WO2008054698A3 (en) * 2006-10-30 2008-06-19 Merck & Co Inc Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
WO2008085509A1 (en) * 2007-01-04 2008-07-17 Merck & Co., Inc. Bicyclic spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
WO2008104580A1 (en) 2007-03-01 2008-09-04 Probiodrug Ag New use of glutaminyl cyclase inhibitors
US7592348B2 (en) 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
WO2009136350A1 (en) * 2008-05-05 2009-11-12 Pfizer Inc. Novel class of spiro piperidines for the treatment of neurodegenerative diseases
JP2010502705A (en) * 2006-09-07 2010-01-28 メルク エンド カムパニー インコーポレーテッド Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's disease
US7700603B2 (en) 2003-12-15 2010-04-20 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7759353B2 (en) 2005-06-14 2010-07-20 Schering Corporation Substituted spiro iminopyrimidinones as aspartyl protease inhibitors, compositions, and methods of treatment
US7759354B2 (en) 2005-06-14 2010-07-20 Schering Corporation Bicyclic guanidine derivatives as asparyl protease inhibitors, compositions, and uses thereof
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
WO2011029920A1 (en) 2009-09-11 2011-03-17 Probiodrug Ag Heterocylcic derivatives as inhibitors of glutaminyl cyclase
WO2011107530A2 (en) 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
WO2011110613A1 (en) 2010-03-10 2011-09-15 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
WO2011125006A3 (en) * 2010-04-09 2011-12-29 Pfizer Inc. Sultam compounds
US8093254B2 (en) 2006-12-12 2012-01-10 Schering Corporation Aspartyl protease inhibitors
US8110682B2 (en) 2005-06-14 2012-02-07 Schering Corporation Preparation and use of compounds as aspartyl protease inhibitors
US20120041039A1 (en) * 2007-11-01 2012-02-16 Acucela Inc. Amine derivative compounds for treating ophthalmic diseases and disorders
WO2012123563A1 (en) 2011-03-16 2012-09-20 Probiodrug Ag Benz imidazole derivatives as inhibitors of glutaminyl cyclase
WO2014071298A1 (en) 2012-11-05 2014-05-08 Nant Holdings Ip, Llc Cyclic sulfonamide containing derivatives as inhibitors of hedgehog signaling pathway
US8722708B2 (en) 2005-06-14 2014-05-13 Merck Sharp & Dohme Inc. Substituted isoindolines as aspartyl protease inhibitors
US8729071B2 (en) 2009-10-08 2014-05-20 Merck Sharp & Dohme Corp. Iminothiadiazine dioxide compounds as BACE inhibitors, compositions and their use
US9018391B2 (en) 2012-08-27 2015-04-28 Boehringer Ingelheim International Gmbh Inhibitors of beta-secretase
EP2865670A1 (en) 2007-04-18 2015-04-29 Probiodrug AG Thiourea derivatives as glutaminyl cyclase inhibitors
EP2776437A4 (en) * 2011-11-07 2015-06-24 Sunovion Pharmaceuticals Inc Modulators of opioid receptors and methods of use thereof
US9145426B2 (en) 2011-04-07 2015-09-29 Merck Sharp & Dohme Corp. Pyrrolidine-fused thiadiazine dioxide compounds as BACE inhibitors, compositions, and their use
US9181236B2 (en) 2011-08-22 2015-11-10 Merck Sharp & Dohme Corp. 2-spiro-substituted iminothiazines and their mono-and dioxides as bace inhibitors, compositions and their use
US9212153B2 (en) 2009-03-13 2015-12-15 Vitae Pharmaceuticals, Inc. Inhibitors of beta-secretase
US9221839B2 (en) 2011-04-07 2015-12-29 Merck Sharp & Dohme Corp. C5-C6 oxacyclic-fused thiadiazine dioxide compounds as BACE inhibitors, compositions, and their use
US9259319B2 (en) 2005-08-19 2016-02-16 Bioventrix, Inc. Method and device for treating dysfunctional cardiac tissue
US9290477B2 (en) 2012-09-28 2016-03-22 Vitae Pharmaceuticals, Inc. Inhibitors of β-secretase
EP3461819A1 (en) 2017-09-29 2019-04-03 Probiodrug AG Inhibitors of glutaminyl cyclase

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102317289A (en) * 2008-11-23 2012-01-11 辉瑞大药厂 Lactams as beta secretase inhibitors
JP5828848B2 (en) 2010-02-24 2015-12-09 ヴァイティー ファーマシューティカルズ，インコーポレイテッド Beta-secretase inhibitor
TWI557112B (en) 2012-03-05 2016-11-11 百靈佳殷格翰國際股份有限公司 Inhibitors of beta-secretase

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3639409A (en) 1967-06-22 1972-02-01 Sankyo Co 1 3 8-triaza-2-oxo- or thioxo-3-substituted-4-oxo or imin 7 9 9-tetraalkyl spiro(4 o-75)decanes
US3542729A (en) 1968-03-19 1970-11-24 Sankyo Co Stabilization of synthetic polymers
JPS4920973B1 (en) 1970-05-28 1974-05-29
US4066615A (en) 1971-06-05 1978-01-03 Sankyo Company Limited Polymer compositions containing piperidine derivatives as stabilizers
DE3643890A1 (en) 1986-12-22 1988-06-30 Basf Ag NEW POLYALKYLPIPERIDE INDEXIVES WITH ALKYLENE BRIDGES, THEIR USE AS A STABILIZER AND INTERMEDIATE PRODUCTS
US5221675A (en) * 1989-12-15 1993-06-22 Abbott Laboratories Aza-spirocyclic compounds that enhance cholinergic neurotransmission
JP2893097B2 (en) 1989-12-20 1999-05-17 富士写真フイルム株式会社 Silver halide color photographic materials
US5852029A (en) 1990-04-10 1998-12-22 Israel Institute For Biological Research Aza spiro compounds acting on the cholinergic system with muscarinic agonist activity
US5534520A (en) * 1990-04-10 1996-07-09 Fisher; Abraham Spiro compounds containing five-membered rings
EP1087770A4 (en) 1998-06-15 2001-11-14 Merck & Co Inc Inhibitors of prenyl-protein transferase
US20040067950A1 (en) 1998-07-27 2004-04-08 Schering-Plough Corporation High affinity ligands for nociceptin receptor ORL-1
DE10012859A1 (en) 1999-03-19 2000-09-21 Ciba Sc Holding Ag New (poly)ethers prepared by reacting hydroxy-2,2,6,6-tetramethyl-piperidine or -piperazine hindered amine light stabilizer with methylene halide are used for stabilizing organic material, e.g. polymer or lacquer
KR100974901B1 (en) 2001-12-28 2010-08-10 아카디아 파마슈티칼스 인코포레이티드 Spiroazacyclic compounds as monoamine receptor modulators
AU2003223093B2 (en) 2002-05-03 2010-02-04 Israel Institute For Biological Research Methods and compositions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor
AU2003274053A1 (en) 2002-10-22 2004-05-13 Glaxo Group Limited Aryloxyalkylamine derivates as h3 receptor ligands

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of EP1804794A4 *

Cited By (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8937093B2 (en) 2003-12-15 2015-01-20 Merck Sharp & Dohme Corp. Heterocyclic aspartyl protease inhibitors
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7700603B2 (en) 2003-12-15 2010-04-20 Schering Corporation Heterocyclic aspartyl protease inhibitors
US8178513B2 (en) 2003-12-15 2012-05-15 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7592348B2 (en) 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
US9416108B2 (en) 2003-12-15 2016-08-16 Merck Sharp & Dohme Corp. Heterocyclic aspartyl protease inhibitors
US8722708B2 (en) 2005-06-14 2014-05-13 Merck Sharp & Dohme Inc. Substituted isoindolines as aspartyl protease inhibitors
US9382242B2 (en) 2005-06-14 2016-07-05 Merck Sharp & Dohme Corp. Preparation and use of compounds as protease inhibitors
US8110682B2 (en) 2005-06-14 2012-02-07 Schering Corporation Preparation and use of compounds as aspartyl protease inhibitors
US7759353B2 (en) 2005-06-14 2010-07-20 Schering Corporation Substituted spiro iminopyrimidinones as aspartyl protease inhibitors, compositions, and methods of treatment
US7759354B2 (en) 2005-06-14 2010-07-20 Schering Corporation Bicyclic guanidine derivatives as asparyl protease inhibitors, compositions, and uses thereof
AU2006270084B2 (en) * 2005-07-18 2011-08-25 Merck Sharp & Dohme Corp. Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's disease
WO2007011810A1 (en) * 2005-07-18 2007-01-25 Merck & Co., Inc. Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
JP2009502786A (en) * 2005-07-18 2009-01-29 メルク エンド カムパニー インコーポレーテッド Spiropiperidine β-secretase inhibitors for treating Alzheimer's disease
US8211904B2 (en) 2005-07-18 2012-07-03 Merck, Sharp & Dohme Corp. Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
WO2007011833A3 (en) * 2005-07-18 2007-03-29 Merck & Co Inc Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
US9259319B2 (en) 2005-08-19 2016-02-16 Bioventrix, Inc. Method and device for treating dysfunctional cardiac tissue
WO2007130383A3 (en) * 2006-04-28 2008-06-19 Neuromedix Inc Compositions and treatments using pyridazine compounds and secretases
WO2007130383A2 (en) * 2006-04-28 2007-11-15 Northwestern University Compositions and treatments using pyridazine compounds and secretases
JP2010502705A (en) * 2006-09-07 2010-01-28 メルク エンド カムパニー インコーポレーテッド Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's disease
US8399473B2 (en) 2006-10-06 2013-03-19 Merck, Sharp & Dohme, Corp. Macrocyclic spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's disease
WO2008045250A1 (en) * 2006-10-06 2008-04-17 Merck & Co., Inc. Macrocyclic spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
WO2008054698A3 (en) * 2006-10-30 2008-06-19 Merck & Co Inc Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
US8293759B2 (en) 2006-10-30 2012-10-23 Merck, Sharp & Dohme, Corp. Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
WO2008055947A1 (en) * 2006-11-09 2008-05-15 Probiodrug Ag Novel inhibitors of glutaminyl cyclase
WO2008055945A1 (en) 2006-11-09 2008-05-15 Probiodrug Ag 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
WO2008065141A1 (en) 2006-11-30 2008-06-05 Probiodrug Ag Novel inhibitors of glutaminyl cyclase
US8093254B2 (en) 2006-12-12 2012-01-10 Schering Corporation Aspartyl protease inhibitors
US8377954B2 (en) 2007-01-04 2013-02-19 Merck, Sharp & Dohme, Corp Bicyclic spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's disease
WO2008085509A1 (en) * 2007-01-04 2008-07-17 Merck & Co., Inc. Bicyclic spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
WO2008104580A1 (en) 2007-03-01 2008-09-04 Probiodrug Ag New use of glutaminyl cyclase inhibitors
EP2481408A2 (en) 2007-03-01 2012-08-01 Probiodrug AG New use of glutaminyl cyclase inhibitors
EP2865670A1 (en) 2007-04-18 2015-04-29 Probiodrug AG Thiourea derivatives as glutaminyl cyclase inhibitors
US8716529B2 (en) * 2007-11-01 2014-05-06 Acucela Inc. Amine derivative compounds for treating ophthalmic diseases and disorders
US9056849B2 (en) 2007-11-01 2015-06-16 Acucela Inc. Amine derivative compounds for treating ophthalmic diseases and disorders
JP2013216665A (en) * 2007-11-01 2013-10-24 Acucela Inc Amine derivative compound for treating ophthalmic disease and disorder
US20120041039A1 (en) * 2007-11-01 2012-02-16 Acucela Inc. Amine derivative compounds for treating ophthalmic diseases and disorders
US9452153B2 (en) 2007-11-01 2016-09-27 Acucela Inc. Amine derivative compounds for treating ophthalmic diseases and disorders
AU2009245322B2 (en) * 2008-05-05 2011-07-14 Pfizer Inc. Novel class of spiro piperidines for the treatment of neurodegenerative diseases
CN102083841A (en) * 2008-05-05 2011-06-01 美国辉瑞有限公司 Novel class of spiro piperidines for the treatment of neurodegenerative diseases
WO2009136350A1 (en) * 2008-05-05 2009-11-12 Pfizer Inc. Novel class of spiro piperidines for the treatment of neurodegenerative diseases
US10336717B2 (en) 2009-03-13 2019-07-02 Vitae Pharmaceuticals, Llc Inhibitors of beta-secretase
US9212153B2 (en) 2009-03-13 2015-12-15 Vitae Pharmaceuticals, Inc. Inhibitors of beta-secretase
WO2011029920A1 (en) 2009-09-11 2011-03-17 Probiodrug Ag Heterocylcic derivatives as inhibitors of glutaminyl cyclase
US8729071B2 (en) 2009-10-08 2014-05-20 Merck Sharp & Dohme Corp. Iminothiadiazine dioxide compounds as BACE inhibitors, compositions and their use
US9029362B2 (en) 2009-10-08 2015-05-12 Merck Sharp & Dohme Corp. Iminothiadiazine dioxide compounds as brace inhibitors, compositions, and their use
US8940748B2 (en) 2009-10-08 2015-01-27 Merck Sharp & Dohme Corp. Iminothiadiazine dioxide compounds as BACE inhibitors, compositions, and their use
US9687494B2 (en) 2009-10-08 2017-06-27 Merck Sharp & Dohme Corp. Iminothiadiazine dioxide compounds as BACE inhibitors, compositions, and their use
US9475785B2 (en) 2009-10-08 2016-10-25 Merck Sharp & Dohme Corp. Iminothiadiazine dioxide compounds as BACE inhibitors, compositions and their use
US9428475B2 (en) 2009-10-08 2016-08-30 Merck Sharp & Dohme Corp. Iminothiadiazine dioxide compounds as BACE inhibitors, compositions, and their use
WO2011107530A2 (en) 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
WO2011110613A1 (en) 2010-03-10 2011-09-15 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
WO2011125006A3 (en) * 2010-04-09 2011-12-29 Pfizer Inc. Sultam compounds
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
WO2012123563A1 (en) 2011-03-16 2012-09-20 Probiodrug Ag Benz imidazole derivatives as inhibitors of glutaminyl cyclase
US9145426B2 (en) 2011-04-07 2015-09-29 Merck Sharp & Dohme Corp. Pyrrolidine-fused thiadiazine dioxide compounds as BACE inhibitors, compositions, and their use
US9221839B2 (en) 2011-04-07 2015-12-29 Merck Sharp & Dohme Corp. C5-C6 oxacyclic-fused thiadiazine dioxide compounds as BACE inhibitors, compositions, and their use
US9181236B2 (en) 2011-08-22 2015-11-10 Merck Sharp & Dohme Corp. 2-spiro-substituted iminothiazines and their mono-and dioxides as bace inhibitors, compositions and their use
EP2776437A4 (en) * 2011-11-07 2015-06-24 Sunovion Pharmaceuticals Inc Modulators of opioid receptors and methods of use thereof
US9580409B2 (en) 2011-11-07 2017-02-28 Sunovion Pharmaceuticals, Inc. Modulators of opioid receptors and methods of use thereof
AU2012335980B2 (en) * 2011-11-07 2017-08-17 Sunovion Pharmaceuticals Inc. Modulators of opioid receptors and methods of use thereof
AU2012335980C1 (en) * 2011-11-07 2017-12-14 Sunovion Pharmaceuticals Inc. Modulators of opioid receptors and methods of use thereof
US9018391B2 (en) 2012-08-27 2015-04-28 Boehringer Ingelheim International Gmbh Inhibitors of beta-secretase
US9290477B2 (en) 2012-09-28 2016-03-22 Vitae Pharmaceuticals, Inc. Inhibitors of β-secretase
WO2014071298A1 (en) 2012-11-05 2014-05-08 Nant Holdings Ip, Llc Cyclic sulfonamide containing derivatives as inhibitors of hedgehog signaling pathway
US9499539B2 (en) 2012-11-05 2016-11-22 Nantbioscience, Inc. Cyclic sulfonamide containing derivatives as inhibitors of hedgehog signaling pathway
US10183013B2 (en) 2012-11-05 2019-01-22 Nant Holdings Ip, Llc Cyclic sulfonamide containing derivatives as inhibitors of hedgehog signaling pathway
EP3461819A1 (en) 2017-09-29 2019-04-03 Probiodrug AG Inhibitors of glutaminyl cyclase

Also Published As

Publication number Publication date
JP2008515989A (en) 2008-05-15
EP1804794A2 (en) 2007-07-11
WO2006044497A3 (en) 2006-09-08
EP1804794A4 (en) 2010-03-31
CN101068545A (en) 2007-11-07
AU2005295814A1 (en) 2006-04-27
CA2583342A1 (en) 2006-04-27
US20070197571A1 (en) 2007-08-23
US8114887B2 (en) 2012-02-14
EP1804794B1 (en) 2013-07-31

Similar Documents

Publication Publication Date Title
EP1804794B1 (en) Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzhermer s disease
EP1910364B1 (en) Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
EP2091328B1 (en) Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
WO2008030412A2 (en) Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
EP1817312B1 (en) Macrocyclic aminopyridyl beta-secretase inhibitors for the treatment of alzheimer's disease
WO2010094242A1 (en) Spiropyrrolidine beta-secretase inhibitors for the treatment of alzheimer's disease
WO2007019078A2 (en) Tricyclic beta-secretase inhibitors for the treatment of alzheimer's disease
AU2009330234A1 (en) Gamma secretase modulators
CN108148060B (en) Substituted heterocyclic compound and derivative thereof, pharmaceutical composition, preparation method and application thereof
EP2117309B1 (en) Bicyclic spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
WO2008045250A1 (en) Macrocyclic spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
EP2443119A1 (en) Gamma secretase modulators
EP1912963B1 (en) Cyclic ketal beta-secretase inhibitors for the treatment of alzheimer's disease
NZ621092B2 (en) COMPOUNDS AND COMPOSITIONS AS c-KIT KINASE INHIBITORS

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 11663388

Country of ref document: US

Ref document number: 2007197571

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 1217/CHENP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2005295814

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200580034396.0

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2005812233

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2583342

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007536860

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2005295814

Country of ref document: AU

Date of ref document: 20051012

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005295814

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2005812233

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 11663388

Country of ref document: US